CLINICAL STUDY PROTOCOL  
NCT Number:  
Study  Title:  
Study  Number: [STUDY_ID_REMOVED]  
A Phase 2, Randomized, Placebo -Controlled Study to Evaluate Safety, 
Tolerability, and Efficacy of TAK -079 in Patients With Generalized 
Myasthenia Gravis  
TAK-079-1005
Protocol Version and Date: 
Version 4.0: 03-Feb-2021 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
PROTOCOL
A Phase 2, Randomized, Placebo -Controlled Study to Evaluate Safety, Tolerability, and 
Efficacy of TAK -079 in Patients With Generalized Myasthenia Gravis
Safety, Tolerabili ty, and Efficacy  of TAK -079 in Pati ents Wi th Generalized Myasthenia Gravis
Sponsor: Millennium Pharmaceuticals, Inc.*
[ADDRESS_3718]
Cambridge, MA [ZIP_CODE]
[LOCATION_003]
Please note: Millennium Pharmaceut icals, Inc, a who lly owned 
subsidiary  of [COMPANY_005] Pharmaceut ical Company Limi ted, m ay be 
referred to in this protocol as “Millen nium,” “sponsor,” or “[COMPANY_005]”.
Study  Number: TAK -079-[ADDRESS_3719] Number: 2019-003383-47
Com pound: TAK -079
Date: 02 February 2021 Versi on/Amendment 
Number: 4
Amendment History: 
Date Amendment Number Type Region
[ADDRESS_3720] of the study.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3721] complaints. 
[COMPANY_005] Development Center–
sponsored invest igators per individual country requirements will be 
provi ded wi themergency  medical  contact [CONTACT_4109].
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevant guidelines 
provi ded to the si te.
The names and contact [CONTACT_4110] o fficer are in 
the study  contact [CONTACT_4111].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK-[ADDRESS_3722] for the individual participants in accordance 
with the requirements of this clinical study protocol and in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Council for Harmonisation E6 Good Clinical Practice: Consolidated Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
study disclosure laws, and regulations.
SIGNATURES
The signature [CONTACT_4233] (and other signatories, as applicable) can 
be found on the signature [CONTACT_3264].
Electronic Signatures may be found on the last page of this document.
, MD, PhD
 Autoimmune DiseasesDate , PhD
, Biostatistics
Statistical and Quantitative SciencesDate
, PhD (or designee)
Quantitative Clinical PharmacologyDate[INVESTIGATOR_4012]
PI
3URSHUW\RI7DNHGD)RUQRQFRPPHUFLDOXVHRQO\DQGVXEMHFWWRWKHDSSOLFDEOH7HUPVRI8VHdance ance 
g:
dated Guated G
rivacy livacy
er signasig
s documdocu
teeO
(or desigor de
PharmacPharmQFQO\PI[INVESTIGATOR_4013] -[ADDRESS_3723] Version of the Approved Protocol
Sections Affected by [CONTACT_4112] 1.2Approval Change name [CONTACT_4234] .To update study personnel.
Section 2.0STUDY SUMMARY
Section 6.1Overview of Study
Section 9.5Study Procedures
Section 9.5.4 Medical/Surgical 
Histor y
Section 9.5.5 Concomitant 
Medications and Procedures
Section 9.5.7 Height and Weight
Appendix ASchedule of EventsIncrease the length of the screening 
period from 21 days 28 days.To lengthen the screening period by 
1 week due to COVID -19-related 
shippi[INVESTIGATOR_4014].
Section 2.0STUDY SUMMARY
Section 6.3Number of Patients Increase number of study centers 
from 40 to 50.To mitigate the delayed enrollment 
caused by [CONTACT_4113] -19.
Section 2.0STUDY SUMMARY
Section 7.2Exclusion Criteria Exclusion Criterion No 1: Changed 
from: “histo ry of thy moma or other 
thymic neoplasms ”to read: 
“Presence of a thymoma (previous 
history of a fully  encapsulated 
thymoma removed ≥12months 
before screening is allowed) or 
history  of invasive thymic 
malignancy unless deemed cured by 
[CONTACT_4114] ≥5 years before 
screening. ”To clarify that the intent is to exclude 
subjects with a current thymoma and 
not a previous history of a fully 
encapsulated thymoma (removed 
≥12 months before screening) and to 
provid e further detail regarding other 
malignancies of the thymus.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3724] Version of the Approved Protocol
Sections Affected by [CONTACT_4112] 2.0STUDY SUMMARY
Section 5.2.2 Secondary Endpoints
Section 5.2.3 Exploratory Endpoints 
Section 13.1.3 Efficacy Analysis Secondary Endpoint: The 
MG-QoL15r scale has been removed 
as one of the MG clinical impairment 
scales to assess the percenta ge of 
patients meeting minimal clinically 
important difference criteria.
Explo ratory  Endpoint: The 
MG-QoL15r scale has been removed 
as one of the MG clinical impairment 
scales to assess the duration of a 
clinically meaningful effect on MG 
disease severity.To remove the MG -QoL15r scale 
from this analysis as it does not have 
an established cutoff of clinically 
meaningful change.
Section 8.1Study Drug 
AdministrationChanged “...the Week 1 dose will be 
administered by [CONTACT_4115] 30 minutes apart ”to read: 
“the Week 1 dose will be 
administered by [CONTACT_4115] 30 minutes apart 
(±10minutes)... ”To provide a [ADDRESS_3725] dose of study drug 
from: “Considering the timing of the 
greatest pharmacologic effect of 
TAK -079, postdose medication 
should be given after the first dose 
and [ADDRESS_3726] dose of study 
drug.” to read: Considering the 
timing o f the greatest pharmacologic 
effect of TAK -079, postdose 
medication should be given 2 hours 
(±15 minutes) after the first injection 
of the first dose and [ADDRESS_3727] dose of study drug in the 
morning.”To provide more detailed guidance 
on the adm inistration of postdose 
medication.
Section 9.5.6 Physical Examination
Appendix A, footnote gThe following sentence has been 
added: “Women of childbearing 
potential should be asked about their 
menstrual history at each visit. A 
serum pregnancy test should be 
conducted for delayed menses (see 
Section 9.5.1 0).”To ensure a woman is not pregnant 
before study drug administration.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3728] Version of the Approved Protocol
Sections Affected by [CONTACT_4112] 9.5.8 Vital Signs
Appendix ASchedule of Events, 
footnote i .A window of ±[ADDRESS_3729] and second administration of 
study drug. To provide a 10 -minute window for 
obtaining vital signs after 
administration of study drug
In addition, footnote “i”in 
Appendix A was revised to remove 
unclear wording about which vital 
signs are to be taken during the 
visits.
Section 9.5.[ADDRESS_3730] 
should be completed and a negative 
result obta ined before dosing with 
the study  drug.To ensure a woman is not pregnant 
before study drug administration.
Section [IP_ADDRESS] Definition of Women 
of Childbearing PotentialRem oved: “Has not been naturally 
postmenopausal (amenorrhea after 
cancer therapy does not rule out 
childbearing potential) for at least 
24 consecutive months, ie, has had 
menses at any time in the preceding 
24 consecutive months. ”
Clarified the definition of 
postmenopausal.To remove confusing wording from 
template language that does not 
apply  to this protocol.
Section [IP_ADDRESS] MG-QoL 15r Revised total score range from “0 to 
60”to read: “0 to 30. ”
Rem oved last sentence that read: A 
reductio n by [ADDRESS_3731] the total score of the 
MG-QoL15r scale. 
Rem oved criteria for clinically 
meaningful improvement as this 
pertained to the MG -QoL15 scale, 
not the revised MG -QoL15r scale.
Section 9.12 Coronavirus Disease 
2019 -Related Procedural Changes
Appendix ASchedule of Events , 
footnote sAdded text: “The assessment of 
forced vital capacity for the QMG 
test may be omitted for 
COVID -19-related reasons. ”To allow added flexibility for sites 
with varying policies and procedures 
due to COVID -19.
Date of FDA guidance on 
COVID -[ADDRESS_3732] recent FDA 
guidance on COVID -19.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3733] read and that I understand this protocol, the investigator’s brochure (IB), 
prescribing information, and any other product information provided by [CONTACT_456]. I agree to 
conduct thi s study  in accordance wit h the requirements of this protocol and to protect the rights, 
safet y, privacy, and well -being of study  patients in accordance with the fo llowing:
The eth ical principles that have their origin in the Declaration of Helsinki.
ICH, E6 Good Clinical Pract ice: Conso lidated Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements fo r reporting serious adverse events defined in Sect ion 10.0 of this 
protocol .
Terms outlined in the clinical study  site agreement.
Responsibilit ies o fthe invest igator ( Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Eof this protocol .
Signature [CONTACT_4235] (print or ty pe)
Invest igator’s Tit le
Locati on of Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3734] ives...................................................................................... 31
5.1.3 Exploratory  Objectives .................................................................................... 31
5.2 Endpoints ................................................................................................................. 31
5.2.1 Primary Endpo int............................................................................................. 31
5.2.2 Secondary  Endpo ints....................................................................................... 31
5.2.3 Exploratory  Endpo ints..................................................................................... 32
6.0 STUDY DESIGN .......................................................................................................... 32
6.1 Overview of Study  Design ....................................................................................... 32
6.2 Safety and Disease Assessments .............................................................................. 34
6.2.1 PK and Pharmacodynamic Assessments .......................................................... 35
6.3 Number of Patients .................................................................................................. 35
6.4 Durati on of  Study .................................................................................................... 35
6.4.1 Durati on of  an Individual Pat ient’s Study  Parti cipati on.................................... 35
6.4.2 End of Study /Study  Com pletion Definit ion and Pl anned Reporting .................. 35
6.4.3 Time Frames for Primary  and Secondary  Endpoints to Support Disclosures .....35
6.4.4 Total  Study  Durati on....................................................................................... 35
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 9of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL7.0 STUDY POPULATION ................................................................................................ 36
7.1 Inclusio n Cri teria..................................................................................................... 36
7.2 Exclusio n Cri teria.................................................................................................... 37
8.0 STUDY DRUG ............................................................................................................. 38
8.1 Study  Drug Adm inistrati on...................................................................................... 38
8.1.1 Prem edicat ion.................................................................................................. 40
8.1.2 Postdose Medi cation........................................................................................ 40
8.1.3 Rescue Therapy ............................................................................................... 41
8.2 Excluded Conco mitant Medi cations and Procedures ................................................ 41
8.3 Permi tted Concomitant Medications and Procedures ................................................ 41
8.4 Study  Stoppi[INVESTIGATOR_1869] ............................................................................................... 42
8.4.1 Assessment and Criteria for Terminating Pat ient Dosing .................................. 42
8.5 Precauti ons and Restri ctions.................................................................................... 45
8.5.1 Pregnancy, Lactation, and Contraception ......................................................... 45
8.5.2 Drug Interactions ............................................................................................. 46
8.5.3 Interference wit h Serol ogical Testing ............................................................... 47
8.6 Management of Clinical Events ............................................................................... 47
8.6.1 Hypersensi tivity Reacti ons: Infusio n Reactions ................................................ 47
[IP_ADDRESS] Management Recommendat ions for Hy persensi tivity React ions.............. 48
8.6.2 Cytokine Release Syndrome ............................................................................ 49
[IP_ADDRESS] Management Recommendat ions for CRS ................................................. [ADDRESS_3735] igational Agents ...................................................................... 53
8.7.1 Study  Drug: TAK -079 ..................................................................................... 53
[IP_ADDRESS] Preparati on, Reconstitution, and Dispensat ion......................................... 53
[IP_ADDRESS] Packaging and Labeling ........................................................................... 53
[IP_ADDRESS] Storage, Handling, and Accountabilit y..................................................... 53
8.7.2 Clinical Study  Drug Blinding ........................................................................... 54
8.7.3 Randomization Code Creation and Storage ...................................................... 54
8.7.4 Clinical Study  Blind Maintenance/Unblinding Procedure .................................54
8.7.5 Destruction of Spons or-Supplied Drugs ........................................................... 55
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3736] ...................................................................................................... 56
9.1 Study  Personnel and Organizations .......................................................................... 56
9.2 Arrangements for Recruit ment of Patients ................................................................ 56
9.3 Assignment of Rando mizat ion Numbers .................................................................. 56
9.4 Treatment Group Assignments ................................................................................. 56
9.5 Study  Procedures ..................................................................................................... 57
9.5.1 Inform ed Consent ............................................................................................ 57
9.5.2 Inclusion and Exclusio n................................................................................... 57
9.5.3 Patient Dem ographi cs...................................................................................... 57
9.5.4 Medical/Surgical History ................................................................................. 57
9.5.5 Concomitant Medications and Procedures ........................................................ 57
[IP_ADDRESS] Background MG Therapy ........................................................................ [ADDRESS_3737] ................................................................................................ 59
[IP_ADDRESS] Definit ion of Women of Childbearing Potential ....................................... 59
[IP_ADDRESS] Timing of Pregnancy  Testing ................................................................... 59
9.5.11 AEs ................................................................................................................. 60
9.5.12 Clinical Laboratory  Evaluat ions....................................................................... 60
[IP_ADDRESS] Clinical Chemistry  and Hematol ogy........................................................ 60
9.5.13 Disease Assessment ......................................................................................... 60
[IP_ADDRESS] MG-ADL Score ....................................................................................... 60
[IP_ADDRESS] MGII Score .............................................................................................. 61
[IP_ADDRESS] MGC Score .............................................................................................. 61
[IP_ADDRESS] QMG Score for Disease Severit y............................................................. 61
[IP_ADDRESS] MG-QoL15r ............................................................................................ 61
[IP_ADDRESS] Patient Gl obal Impressi on of Change ....................................................... 62
[IP_ADDRESS] Patient Gl obal Impressi on of Severi ty...................................................... 62
[IP_ADDRESS] Quant ificat ion of Ig ................................................................................. 62
9.5.14 Biomarker, Pharm acodynamic, and PK Samples .............................................. 62
[IP_ADDRESS] Primary Specimen Collection ................................................................... 63
9.5.15 PK Measurements ............................................................................................ 63
9.5.16 Pharmacodynamic/Bio marker Measurements ................................................... 63
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 11of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL9.5.16.1 Autoantibodies ......................................................................................... 64
[IP_ADDRESS] Pharmacodynamics .................................................................................. 64
[IP_ADDRESS] Circulat ing Bio markers ............................................................................ 64
[IP_ADDRESS] Immunoprofiling ...................................................................................... 64
[IP_ADDRESS] Vaccine -Induced Protecti ve Ant ibodies ................................................... [ADDRESS_3738] ion.................................................................64
9.6 End of Safet y Follow-up Assessments ..................................................................... 65
9.7 Com pletion of Study  Treatm ent (f or Individual Patients) ......................................... 65
9.8 Com pletion of Study  (for Individual Pat ients).......................................................... 65
9.9 Discontinuati on of  Treatment Wi th Study  Drug ....................................................... 65
9.10 Withdrawal o f Patients From  Study ......................................................................... 66
9.11 Study  Com pliance .................................................................................................... 66
9.12 Coronavirus Disease 2019–Related Procedural Changes .......................................... [ADDRESS_3739] ics......................... 77
13.1.3 Efficacy Analysis ............................................................................................. 77
13.1.4 PK Analysis ..................................................................................................... 78
13.1.5 Immunogenici ty Analyses ................................................................................ 78
13.1.6 Safety Analysis ................................
................................................................ 78
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3740] ions................................ 80
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 80
15.1 IRB and/or IEC Approval ........................................................................................ [ADDRESS_3741] OF IN -TEXT TABLES
Table 8.a Summary  of TAK -079/Pl acebo Dose Administration ......................................... [ADDRESS_3742] .............................................. 71
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3743] igator Consent to Use of Personal Information.......................................... 97
Appendix F MG-ADL Score .................................................................................................98
Appendix G MGII Score ........................................................................................................ 99
Appendix H MGC Score ...................................................................................................... 100
Appendix I QMG Score ...................................................................................................... 101
Appendix J MG-QoL15r ..................................................................................................... 102
Appendix K PGIC................................................................................................................ 103
Appendix L PGIS ................................................................................................................ 104
Appendix M Protocol  History............................................................................................... 105
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 14of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL2.0 STUDY SUMMARY
Name [CONTACT_790]: Millennium Pharmaceuticals, Inc Compound: TAK -079
Title of Protoco l: A Phase 2, Randomized, 
Placebo -Controlled Study to Evaluate Safety, Tolerability, 
and Efficacy of TAK -[ADDRESS_3744] No. : 2019 -003383 -47
Study Number: TAK -079-1005 Phase: 2
Study Design:
This is a phase 2, randomized, double -blind, placebo -controlled study designed to assess the safety, tolerability, and 
efficacy of TAK -079 in patients with generalized myasthenia gravis (MG) in combination with standard background 
therapy . 
It is expected that approximately 36 patients will be randomized into the study. After a screening period of up to 28 
days, eligible patients will be randomized in a 1:1:1 ratio to one of the following treatment groups:
TAK -[ADDRESS_3745] background therapy .
TAK -[ADDRESS_3746] background therapy.
Matching placebo added to stable standard background therapy.
The study  will be divided into 3 sequential periods: a dosing period (8 weeks), a safety follow -up period (SFP; 8 
weeks), and a long -term follow -up period (LFP; 16 weeks). 
During the 8 -week dosing period, TAK -079/matching placebo will be administered via subcutaneous (SC) injection 
once weekly for 8 weeks. Patients will be premedicated with an antipyretic (such as acetaminophen ) and an 
antihistamine (such as diphenhydramine) [ADDRESS_3747] study drug (TAK -079/placebo) doses mo dified (eg, withheld or delayed) for safety reasons. 
After completing the 8 -week dosing period, patients will enter an 8 -week blinded SFP, completing safety and efficacy 
assessments every 2 weeks. After completion of the Week 16 visit in the SFP, patients will be unblinded before 
entering the LFP visit at Week 20. 
Patients randomized to TAK -079 will be followed ever y 4 weeks from Week 20 through to Week 32 of the LFP for 
MG clinical activity scores and autoantibody levels; the end -of-study  visit will take place at Week [ADDRESS_3748] at Week 20 of the LFP. 
Adverse events ( AEs)ongoing at the Week 16 visit of the SFP (including unresolved clinical/laboratory parameters) 
should be mo nitored through the LFP until they are resolved, return to baseline, or are clearly determined to be due to 
a patient’s stable or chronic condition or intercurrent illness(es). Study drug –related AEs/ serious adverse events 
(SAEs )with onset after the SFP w ill be collected through the LFP. Overall, the maximum follow -up period is 
approximately [ADDRESS_3749] dose of study drug. 
Patients will be permitted to receive rescue medication, as determined by [CONTACT_093], eg, intravenous 
immunoglobulin (IVIg), high dose corticosteroids, or plasmapheresis/plasma exchange. If the patient receives rescue 
therapy  during the dosing period, they will automatically enter the SFP.
Primary Objective:
To evaluate the safety and tolerability of TAK -079 in patient s with generalized MG who are receiving stable 
background therapy for MG.
Secondary Objective:
To assess the effects of TAK -079 on MG disease activity using clinical rating scales and autoantibody levels.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 15of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALPatient Population: Generalized MG positive anti –acetylcholine receptor (AChR) or anti –muscle -specific tyrosine 
kinase (MuSK) antibodies, class II to IV disease according to the Myasthenia Gravis Foundation of America (MGFA), 
and a Myasthenia Gravis -Activities of Daily Livin g (MG -ADL) score of 6 or higher.
Number of Patients : 36 patients Number of Sites : Approximately 50sites
Dose Level : TAK -079 300 mg, 600 mg, or matching 
placebo administered once weekly for 8 weeks.Route of Administration : TAK -079/matching 
placebo: SC injection
Duration of Treatment: 
Dosing period: maximum of 8 weeks.Period of Evaluation: From first dose of TAK -[ADDRESS_3750] LFP visit.
Main Criteria for Inclusion:
Each patient must meet all the following inclusion criteria to be randomized to treat ment:
1.Aged [ADDRESS_3751] 4 points of this score attributed to nonocular items.
5.If receiving immunosuppressive drugs (ie, mycophenolate mofetil, methotrexate, cyclosporine, tacrolimus, 
cyclophosphamide), therapy must be ongoing for at least [ADDRESS_3752] be expected to remain stable throughout the study 
unless dose reduction is required due to toxicities. Allowed background therapy is defined as no more than a 
cholinesterase inhibitor ± c orticosteroid ± 1 steroid -sparing immunosuppressive drug (limited to azathioprine, 
mycophenolate mofetil, methotrexate, cyclosporine, tacrolimus, or cyclophosphamide). Patients must be on at 
least [ADDRESS_3753] be able and willing to comply with study procedures.
Main Criteria for Exclusion:
Patients meeting any of the following exclusion criteria are not to be randomized to treatment:
1.Presence of a thymoma (previous history of a fully encapsulated thymoma removed ≥12 months before screening 
is allowed) or history of invasive thymic malignancy unless deemed cured by [CONTACT_4116] ≥5 years before screening. 
2.Histor y of thy mectomy  within 1 2 months before screening.
3.MGFA class I or V.
4.Received IVIg, SCIg (subcutaneous immunoglobulin), or plasmapheresis/plasma exchange within 4 weeks 
before screening, or an expectation that any therapy besides the patient’s standard background therapi[INVESTIGATOR_4015] b e 
used for treatment of MG (eg, a rescue therapy) between screening and dosing.
5.Chro nic obstructive pulmonary disease (COPD) or asthma with a pre -bronchodilatory forced expi[INVESTIGATOR_4016] 1 second (FEV 1) <50% of predicted normal.
Note: FEV 1testing is re quired for patients suspected of having COPD or asthma.
6.Received rituximab, belimumab, eculizumab, or any monoclonal antibody for immunomodulation within [ADDRESS_3754] of the study.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 16of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL8.Received a live vaccine within 4 weeks before screening or has any live vaccination planned during the study.
9.Any medical c ondition that, in the opi[INVESTIGATOR_871], might interfere with the patient’s participation in 
the study  (such as significant cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, 
renal, neurologic, malignancy, or infec tious disease), poses added risk for the patient, or could confound the 
assessment of the patient.
10.Pregnancy or lactation during the screening period or on Day [ADDRESS_3755] dose of study drug.
11.Participation in any other investigational drug study or exposure to other investigational agent within 4 weeks or 5 
half-lives, whichever is longer, before Day 1.
12.An opportunistic infection ≤12 weeks before initial study dosing or is currently receiving treatment for a chronic 
opportunistic infection, such as t uberculosis (TB), pneumocystis pneumonia, cytomegalovirus, herpes simplex 
virus, herpes zoster, or atypi[INVESTIGATOR_4017]. A mild, localized herpes simplex infection within [ADDRESS_3756] emic therapy before Day 1.
13.Inadequate organ and bone marrow function:
a)Alanine aminotransferase or aspartate aminotransferase >3 times the upper limit of normal (ULN).
b)Total bilirubin >1.[ADDRESS_3757] (Note: Patients with a confirmed and documented diagnosis of Gilbert 
syndrome are not excluded based on this criterion).
c)Platelets <75,000/mm3.
d)Absolute neutrophil count <1500/mm3.
e)Hemoglobin <8 g/dL.
f)IgG <5 g/L (500 mg/dL) .
g)Lymphocy te count <500/mm3.
14.A positive T -cell interferon -γ release assay (TIGRA) (result t hrough QuantiFERON -TB Gold test or 
T-Spot/Elispot) at the screening visit, noting the following: 
a)A purified protein derivative ([COMPANY_003]) skin test may be used if TIGRA testing is not available.
b)Patients with an indeterminate TIGRA result must meet the followi ng criteria:
i.Negative [COMPANY_003] skin test (defined as <5 mm induration).
ii.At low risk of acquiring TB (eg, avoids close contact [CONTACT_4117] -positive individual[s]) and/or chest x -ray 
≤6 mo nths before the screening visit that is consistent with no evidence of latent o r active TB.
15.Any serious medical or psychiatric illness that could, in the investigator’s opi[INVESTIGATOR_1649], potentially interfere with the 
completion of treatment according to this protocol.
16.A positive test result for hepatitis B surface antigen, or hepatitis B cor e antibody, hepatitis C antibody, or HIV 
antibody/antigen, at screening. However, an individual who has a known history of chronic hepatitis C and has 
been treated and fully cured of the disease, confirmed with a negative hepatitis C virus RNA polymerase c hain 
reaction test at screening, is not excluded on the basis of positive hepatitis C antibody alone.
17.A histo ry of severe allergic or anaphylactic reactions to recombinant proteins or excipi[INVESTIGATOR_4018]079/placebo formulation.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 17of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALMain Criteria for Evaluation and Analyses:
Primary : Percentage of patients with treatment -emergent adverse events ,including Grade 3 or higher events, SAEs, 
and AEs leading to TAK -079 discontinuation.
Secondary : 
1.Score change from baseline in the following:
a)MG Activities of Daily  Living (MG -ADL) score.
b)Quantitative Myasthenia Gravis (QMG) score.
c)Myasthenia Gravis Composite (MGC) score.
d)Revised 15 -item My asthenia Gravis Quality of Life scale (MG -QoL15r).
2.Change f rom baseline in anti -AChR antibody or anti -MuSK antibody levels
3.Percentage of patients meeting minimal clinically important difference criteria in the respective MG clinical 
impairment scales (MG -ADL, QMG, MGC).
Explo ratory :
1.Serum concentration -time profile of TAK -079 PK parameters will include, but are not limited to, observed 
concentration at the end of a dosing interval (Ctrough) over time.
2.Change in serum immunoglobulin levels.
3.Pharmacodynamic analysis of the presence and changes of immune cells in peripheral bl ood before and during 
therapy .
4.Score change from baseline in the Myasthenia Gravis Impairment Index (MGII) score.
5.Duration of a clinically meaningful effect on MG disease severity (in all clinical disease impairment scales: 
MG-ADL, QMG, MGC, MGII).
6.Percent age of patients meeting minimal clinically important difference criteria in the MGII scale.
7.Frequency and proportion of patients requiring rescue therapy.
8.Immunogenicity assessment of TAK -079 in peripheral blood, including antidrug antibody (ADA).
9. Biomarke rs of disease activity such as complement levels (C3, C4, complement split products); specific markers 
of CD38 pathway modulation may also be evaluated.
10.Change in levels of the following vaccine -protective antibodies: measles, mumps, rubella, diphtheria, and tetanus.
Statistical Considerations:
Safety Analysis
The safety analysis set will include all patients who have received at least 1 dose of study drug. 
Safety will be evaluated by [CONTACT_4118], severity and types of AEs, and by [CONTACT_4119]’ 
vital signs, weight, and clinical laboratory results using the safety analysis set. Exposure to study drug and reasons for 
discontinuatio n will be tabulated. 
TEAEs that occur after administration of the first dose of study drug and through to the end of the SFP period will be 
tabulated. 
AEs will be tabulated according to the Medical Dictionary for Regulatory Activities, and data will be s ummarized 
using Preferred Term and primary  System Organ Class. All safety analyses will be performed using the safety analysis 
populatio n 
Efficacy Endpoint Analyses: The analy sis of the efficacy endpoints will be performed on the full analysis set, define d 
as all randomized patients w ho had baseline and at least 1 postbaseline efficacy assessment. Efficacy endpoints will be 
summarized by [CONTACT_4120]. Where appropriate, efficacy endpoints may be 
analy zed with the following methods:
Binary  endpoints will be analyzed using a Fisher’s exact test. 
Changes from baseline endpoints measured repeatedly over time will be analyzed using a mixed -model 
repeated- measures analysis, which includes treatment, visit, and (treatme nt × visit) interaction terms as the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 18of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALfactors, with baseline values as covariates.
All tests of treatment effects will be conducted at a 2 -sided α level of 0.05, and 95% CIs for the differences in 
proportions and least square means will be provided. No infe rential hy pothesis was tested in these endpoints, so CIs 
and p-values are not adjusted for multiplicity. 
Sample Size Justification: 
Approximately 36 patients are planned to be randomized to treatment in a ratio of 1:1:1 (TAK -079 300 mg, TAK -079 
600 mg, or placebo). This study is exploratory and not powered to address any predefined hypothesis. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3758] in the study manual/binder. The ident ified vendors will perform specific study -related 
activit ies eit her in full or in partnership with the sponsor.
3.[ADDRESS_3759] of clinical 
research, and study  participation. The signatory  coordinating investigator [INVESTIGATOR_4019] .
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3760]
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
FcRn neonatal Fc receptor
FDA Food and Drug Administration (US)
FEV 1 forced expi[INVESTIGATOR_3741] 1 second
GCP Good Clinical Practice
GLP Good Laboratory Practice
hCG human chorionic gonadotropin
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC independent ethics committee
Ig immunoglobulin
IRB institutional review board
IRR infusion -related reaction
ISR injection site reaction
IV intravenous(ly)
IVIg intravenous immunoglobulin
IXRS interactive voice/web response system
LFP long-term follow -up period
MedDRA Medical Dictionary for Regulatory Activities
MG myasthenia gravis
MG-ADL Myasthenia Gravis Activities of Daily Living
MGC Myasthenia Gravis Composite
MGFA Myasthenia Gravis Foundation of America
MGII Myasthenia Gravis Impairme nt Index
MG-QoL15r revised 15 -item Myasthenia Gravis Quality of Life scale
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3761] level
PGIC Patient Global Impression of Change
PGIS Patient Global Impression of Severity
PK pharmacokinetic(s)
PMDA Pharmaceuticals and Medical Devices Agency
[COMPANY_003] purified protein derivative
PTE pretreatment event
QMG Quantitative Myasthenia Gravis
RBC red blood cell
RRMM relapsed and/or refractory multiple myeloma
SAE serious adverse event
SC subcutaneous(ly)
SFP safety follow -up period
SLE systemic lupus erythematosus
SOE schedule of events
S[LOCATION_003]R suspected unexpected serious adverse reaction
TB tuberculosis
TEAE treatment -emergent adverse event
TIGRA T-cell interferon -γ release assay
TNF -α tumor necrosis factor alpha
[LOCATION_006] [LOCATION_008]
ULN upper limit of the normal range
US [LOCATION_002]
WHO World Health Organization
3.4 Corporate Identification 
Millennium Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of [COMPANY_005] Pharmaceutical 
Company Limited
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 22of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL4.0 INTRODUCTION
4.1 Disease Background
Myasthenia gravis (MG) is a rare autoimmune disorder in which autoantibodies target the 
neuro muscular junction (NMJ) and postsynapt ic membrane and interfere with neuromuscular 
transmissio n, which leads to progressive weakness of skeletal muscles. The est imated annual 
incidence of MG in the [LOCATION_002] (US) is 5.3 per millio n, wi th a prevalence of approximately  
77.7 per millio n [1-4] . 
Characteristically  for MG, the skeletal  muscle weakness and fat igabilit y worsens wi th physical  
activit y and improves wit h rest [5]. In some cases, muscle weakness can lead to respi[INVESTIGATOR_4020] [6]. The disease remains life -threatening; in a myasthenic crisis, the muscles 
that control breathing beco me too weak, which can result in death due to paralysis of the 
respi [INVESTIGATOR_4021]. 
MG i s caused by [CONTACT_4121]. Most patients 
(80% -90%) with MG produce immunoglobulin (Ig)G1 and IgG3 autoantibodies against the 
acetylcho line receptor (AChR), while the remaining patients either produce IgG4 autoantibodies
against muscle specific t yrosine kinase (MuSK; ~5% of patients), IgG1 -[ADDRESS_3762] the 
low-densit y lipoprotein receptor
-related protein 4 (~1% of patients), or produce no detectable 
autoantibodies [7]. The binding of autoantibodies to proteins in the NMJ ultimately leads to 
damage of  the postsynaptic membrane [
5].
Reducing the levels of pathogen ic autoantibodies is challenging. The autoantibody -producing 
plasma cells are resistant to many convent ional pharmaco logic strategi es because they  are not 
actively cycling and express relat ively few surface ant igens. 
The current standard of care for MG co nsists of a combinat ion of symptomatic therapy  
(acetylcho linesterase inhibitors, to increase the levels on acetylcho line in the synapse) and 
immunosuppressio n. Immunosuppressive or immuno modulatory  therapi[INVESTIGATOR_014] (such as 
corticosteroi ds, azathi oprine, m ethotre xate, cyclosporine, tacrolimus, cyclophosphamide, 
plasmapheresis/plasma exchange, and intravenous immunoglobulin [IVIg]) are given to patients 
who do not have satisfactory result s with symptomatic therapy alone. Nevertheless, approximately 
10% of patients have treatm ent-refractory  disease, and up to 80% of patients fail to reach a 
complete stabl e remissio n [8]. Imm unosuppressive medicat ions have several drawbacks, 
including limited efficacy and severe dose -limit ing toxicit ies. Furthermore, these drugs do not 
directly affect auto antibody production. 
Autoantibody  levels can be lowered by [CONTACT_4122] B -cell progenitors of plasma cells. Rituximab 
(an anti -CD20 ant ibody ) targets these plasma cell progenitors, thereby  [CONTACT_4123] r eplenishment of autoreactive plasma cells. However, 
rituximab’s efficacy  in MG has been limited, likely  because the l ong-lived plasma cells that are 
thought to be primarily responsible for ant i-AChR ant ibody  producti on do not express CD20 and 
are therefore not targeted by  [CONTACT_4124] [
5]. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 23of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALThere are some therapeutic options available to lower the ant ibody  levels by  [CONTACT_4125], eg, plasmapheresis/plasma exchange, administration of 
IVIg, or n eonatal Fc receptor (FcRn) antagonists. Plasmapheresis and IVIg are mostly used until 
other m edicati ons take effect, before surgery , or f or myasthenic crisis because of their fast but 
short -lived impact. An alternative approach to increase the clearance of autoantibodies may  be 
achieved by [CONTACT_4126], and several FcRn antagonists are currently in clinical development. 
These drugs decrease pathogenic IgG by [CONTACT_4127] -mediated 
IgG recy cling. None of these [ADDRESS_3763] is relat ively short; consequent ly, most likely chronic administration would be required to 
maintain low levels o f pathogenic autoantibodies [9]. 
Another therapeutic strategy  in MG that does not eliminate the root cause of the disease is to 
reduce the complement -mediated dam age of the postsynapt ic membrane at the NMJ. This can be 
achieved with eculizumab, a monoclonal ant ibody  against complement protein C5. While showing 
moderate efficacy, eculizumab therapy  is related to increased risks of meningococcal infect ions 
and thereb y is restri cted by  [CONTACT_4128] [10]. 
In conclusio n, there is a need for novel therapi[INVESTIGATOR_4022] h a favorable safet y profile, to help decrease use of corticost eroids and to improve 
patients’ qualit y of life. Targeting CD38, a cell surface mo lecule whose expression is restricted to 
subsets of hematopoiet ic cells and that is highly expressed on plasmablasts, short -lived plasma 
cells, and long- lived plasma cells, i s an attractive therapeut ic strategy  in MG. TAK -[ADDRESS_3764] CD38, an ant igen 
that is highly expressed on plasma cells, plasmablasts, and natural killer (NK) cells and is induced 
on activated T cells and B cells. TAK -079 adminis tration resul ts in depleti on of  cells expressing 
high l evels of CD38 through a mechanism that involves apoptosis, ant ibody -dependent 
cell-mediated cy totoxici ty, and com plement -dependent cy totoxici ty 
[11]. TAK -[ADDRESS_3765] etes the 
cells that produce the pathogenic autoantibodies (plasmablasts, plasma cells, and especially  
long-lived plasma cells). A reduct ion in plasmablasts and long -lived plasma cells by [CONTACT_4129] -[ADDRESS_3766] also been shown in human clinical studies. In an in vitro study , TAK -079 reduced 
both short -and long -lived plasma cells iso lated from bone marrow aspi[INVESTIGATOR_4023] (SLE) (TKD -BCS -[ZIP_CODE]- R1). 
TAK -079 al so reduced the number of cells producing autoantibodies, including VH4 -34 (9G4) 
(reduced in 71% of samples) and ant i-Ro (reduced in 58% of samples) in SLE patien t sam ples. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 24of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALThese effects on autoantibodies corresponded to comparable reductions in total IgG -producing 
cells, indicat ing that total IgG could be used as a surrogate bio marker for autoantibodies, in the 
absence of autoantibody  data.
An in vivo study  in a m onkey collagen -induced arthrit is model of autoimmune disease 
demonstrated the therapeutic efficacy  of TAK -079 (TAK -079- [ZIP_CODE]). Treatment of arthrit ic 
monkeys wit h TAK -079 (3 m g/kg intravenously  [IV] weekly ) was well tolerated and reduced 
disease progressi on. Arthrit is scores and jo int swelling were significant ly lower than wi th the 
vehicle control and were accompanied by [CONTACT_4130] C -reactive protein, alkaline 
phosphatase, and NK, B, and T cells. Histopathology , morphometry , and radi ology revealed 
significant ly less jo int dam age in animals treated with TAK -079 or dexamethasone (0.1 mg/kg 
oral gavage daily) co mpared with vehicle control animals, illustrating potential disease -modifying 
activit y of TAK -079. These data indicate that depletion of CD38
-expressing cells could be a 
therapeuti c mechanism for treating autoimmune diseases.
In a study  in healt hy subjects (TAK -079_101), a single subcutaneous (SC) injection of 0.6 mg/kg 
TAK -079 l ed to >90% reduction in peripheral blood plasmablasts. The cells reverted to 
pretreatm ent levels wit hin 50 days. The levels o f immunoglobulins (IgM, IgA and IgG) were 
reduced by  15% to 60% and di d not f ully return to prestudy  baseline by  [CONTACT_2054]  
(78days). These data indicate that TAK -079 m ay reduce a utoantibody  levels for a comparable 
durati on, which is unique amo ng therapeutics in clinical development for MG. 
Preliminary data from the ongoing clinical study  in pati ents wi th relapsed and/or refractory  
multiple myelo ma (RRMM; TAK -079- 1501) confirm  theexpected pharmacodynamic profile of 
TAK -079. Peripheral blood samples and bone marrow biopsies fro m pat ients dosed at 45, 135, 300, 
and 600 mg demo nstrated target occupancy  and reducti on of  target cells (ie, pl asmablasts, short -
and long -lived plasma cell s) in the target organ, ie, bone marrow. Reductions in IgA, IgG, and IgM 
levels were also observed. Maximal pharmacodynamic effects were observed in the bone marrow 
of patients dosed at ≥[ADDRESS_3767] ing doses and a regimen of TAK -079 for treating patients with MG was based 
upon identifying safe and well -tolerated doses that demonstrate pertinent pharmacodynamic 
activit y.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 25of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALThe clinical experience to date has demonstrated that TAK -079 is safe and well -tolerated in 
3different populat ions (ie, healt hy subjects, patients with RRMM, and patients with SLE) and 
across a broad range of doses ( ≤600 mg), vascular concentrations, and exposures. 
In healthy subjects, single doses of TAK -079 up to 0.06 mg/kg IV and 0.6 mg/kg SC were well 
tolerated: adverse events (AEs) were mild to moderate in intensit y, with most of  the AEs being 
mild. There were no serious adverse events (SAEs) or deaths reported in the study, and no AEs led 
to either st udy or visit discont inuat ion. No remarkable findings for laboratory  tests, 
electrocardi ogram s (ECGs), vi tal signs, or phy sical examinat ions were reported that were related 
to TAK -079 treatm ent (see TAK -079 Investi gator’s Brochure [IB]). 
As of June 2019, [ADDRESS_3768] been enrolled in the ongoing RRMM study across 4 dose 
escalat ion cohorts (4 patients in 45 mg; 3 patients in 135 mg; 12 patients in 300 mg; and 
12patients in 600 mg). The maximum durat ion of exposure is [ADDRESS_3769] ively. The maximum tolerated dose has not been 
ident ified. At the IB data cutoff date (20 March 2019), the safet y profile was comparable for all 
tested doses (45 mg [n = 4], 135 mg [n = 3], 300 mg [n = 6], and 600 mg [n = 6]). No patients have 
experienced dose -limit ing toxicit y, inject ion site reactions, or systemic infusio n react ions. 
Drug -related SAEs, AEs that led to study  discont inuation, or on- study  deaths have not been 
reported. The most commonly reported ( ≥20% of all pat ients) treatm ent-emergent adverse events 
(TEAEs) by  [CONTACT_4131] (MedDRA) Preferred Term regardless 
of causalit y at doses up to [ADDRESS_3770] been Grade 1 or 2 other than 2 events reported as 
drug-related Grade 3 events (decreased neutrophil count and anaemia [in 1 patient each]), both of 
which were transient (see current TAK -079 IB for further details). 
As of June 2019, [ADDRESS_3771] acebo (in a 
blinded manner) in the ongoing study  in SLE. Data are still blinded, but 1 patient has reported 
2TEAEs: nausea and headache (both events Grade 1). No infusio n reactions, cy tokine release 
syndro me (CRS), or inject ion site reactions have been reported (see current TAK- 079 IB [cutoff 
20 March 2019] for further details).
There were 3 adverse effects observed in nonclinical 3 -month, Good Laboratory  Practi ce 
(GLP) -compliant toxi cology studies in pharmaco logically responsive mo nkeys. These adverse 
effects were dose -dependent thrombocy topeni a, anemia, and/or leukopenia (associated with 
infect ion only at nontolerated doses). Thrombocytopenia set the nonclinical 
no-observed -adverse -effect l evel (NOAEL) at a dose of 0.3 mg/kg, which corresponded to a 
maximum observed concentration (C max) of 8.1 µg/m L and an area under the concentration -time 
curve (AUC) of 28,875 day *ng/mL.
To further invest igate the potential for anemia and thrombocytopenia in h umans, a seri es of  in 
vitro studies was perform ed. TAK -079 bound to CD38 on 11% to 17% of human platelets in 
platelet-rich plasma (1:8 platelet -rich plasma dilution, n = 2 healt hy donors) with intensit y 57% to 
70% that of isoty pe control  antibody  at concentrations of 20 µg/mL (TKD -BCS -[ZIP_CODE]- R1 
Amendment 1) (monkey platelets were not assessed because of technical limitat ions). Also, 
TAK -079 bound to CD38 on healthy human red blood cells (RBCs) (~10% -51%, n = 5) and 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 26of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALmonkey RBCs (up to 19%, n = 1) with low int ensit y at concentrations 0.1 to 100 µg/mL in vitro 
(TKD- BCS -[ZIP_CODE]- R1-Report and TKD -BCS -[ZIP_CODE] -R1 Amendment 1) and did not induce 
hemo lysis at ≤20 µg/mL, or hemagglut ination at ≤1000 µg/mL, the highest concentrations tested 
(TKD- BCS -
[ZIP_CODE]- R1 Amendment 1). T AK-[ADDRESS_3772] cy totoxi city in these cells 
(TKD- BCS -
[ZIP_CODE]- R1 and TKD- BCS - [ZIP_CODE]- R1). Last ly, TAK -[ADDRESS_3773] eted cells that express high densit ies of CD38, eg, plasma cells, 
plasmablasts, and NK cells (TAK -079- [ZIP_CODE], TAK -079- [ZIP_CODE], and TAK - 079-1501). Importantly, 
despi[INVESTIGATOR_4024], drug -related anemia or thrombocy topeni a has not been 
observed in cl inical  studi es to date, despi [INVESTIGATOR_4025], concentrations, and exposures up to a maximum clinical dose of 600 mg 
(maximum individual concentration of 235 µg/mL and exposure of 698,070 day *ng/mL).
Two pharmacodynamic effects of TAK -[ADDRESS_3774] pertinent to treating patients with 
MG. Changes in the level of serum Ig are used as a surrogate bio marker of ant i-AChR and 
anti
-MuSK ant ibodies because these autoantibodies are of the same IgG an tibody  class and are not 
present in healthy subjects, patients with RRMM, or patients with SLE. A single SC dose of 
TAK -079 at 0.1, 0.3, or 0.6 mg/kg to healthy subjects reduced serum mean IgA levels by 20% to 
30%; IgG levels by 40% to 60%; and IgM by  10% to 25% ( Figure 4.a). Similarly , weekly  dosing 
of patients with RRMM with 45, 135, 300, or 600 mg generally reduced serum IgA to 30% to 95%, 
IgG to 5% to 60%, and IgM to 0% to 50% of baseline levels 
(Figure 4.b). 
The second pharmacodynamic effect is a reduction in the level o f plasma cells in bone marrow 
aspi[INVESTIGATOR_4026]. The eliminat ion of nonmalignant plasma cells in the bone marrow aspi[INVESTIGATOR_4027] a surrogate for the eliminat ion of pathogenic 
autoantibody -secret ing plasma cells, as the bone marrow is a known site for aut oantibody  
producti on in MG [
12]. The desi red 80% reducti on in nonmalignant bone marrow plasma cells 
requi red dosing at 300 and 600 mg of TAK -079 ( Figure 4.
c). Reductions in nonmalignant bone 
marrow pl asma cells generally appeared similar with exposure to 300 and 600 mg of TAK -079. 
Considering the small sample size, variabilit y in pharmacokinet ics (PK), and comparable safet y 
profiles, selecting both doses for assessing potential efficacy is warra nted.
The dosing schedule was est imated based on the desired effect of achieving autoantibody 
reducti ons that are correlated with clinical improvement in MG. While there is no accepted 
consensus for such an autoantibody reduct ion thresho ld, group -level cli nical  improvements in MG 
patients have been reported with reductions in the >50% range with rituximab [13]and 
efgartigimod [
14]. In the absence of data characterizing TAK -079 activit y on autoantibody  levels 
in MG patients, changes in serum IgG were used as a surrogate. In patients with RRMM, a ~50% 
reducti on in IgG was observed only after 8 weekly doses of TAK -079 (in the 300 m g and 600 mg 
cohorts, Figure 4.b). Based on these data, a schedule of 8 weekly doses was selected for the present 
study , with weekly m onitoringof clinical  laboratory  values (CBC, immunogl obulin levels, see 
Secti on
 8.4.1 ) to ensure the safet y of this approach. Following the 8 -week dosing peri od, a 
6-month follow-up is planned for the continued monitoring of safet y laboratory parameters and for 
evaluat ing the durabilit y of any clinical benefit. Addit ionally , informat ion will be obtained on the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3775] ion in patients with 
MG because of similarit ies in target cell le vels between these 2 populat ions. The mean levels o f 
target cells in the target organ (bone marrow) are similar between pat ients with MG and the 
patients wi th RRMM studi ed in the 300 mg and 600 m g dose cohorts. In patients with MG, the 
mean level o f plasma cells was reported to be 2.6% ± 1.9% of total mononuclear cells [15], while 
the mean levels of myelo ma cells in the 300 and 600 mg cohorts were 2.3 ± 1.8% and 2.1% ± 2.6%, 
respectively . As we have selected the 300 and 600 mg doses bas ed on safet y, tolerabili ty, and 
pharmacodynamic analyses (discussio ns above), the similarit y in target cell levels between these 
patient groups provides reassurance that these analyses are translatable across the MG and RRMM 
indicat ions. 
Case reports exis t of successfully treating ant ibody -driven diseases with ant i-CD38 therapy  using 
the same dose and schedule as in patients with mult iple myelo ma (daratumumab 16 mg/mL for ≥6 
weekly doses), despi[INVESTIGATOR_4028] o f overall elevations in target plasma cells. F or exam ple, 
daratum umab was used to treat a patient with pure red cell aplasia (and otherwise normal bone 
marrow) from persistent anti –
red bl ood cell ant ibodies after an ABO -mismatched allogenic bone 
marrow transplant for myelodysplast ic syndro me [16]. Similarly, daratumumab was used 
successfully in a pediatric patient with ant i–
red bl ood cell ant ibodies after bone marrow 
transpl antati on [17]. Lastly , a case of ant ibody -medi ated reject ion after renal transplantation for 
postinfect ious m embranoproliferat ive glo merulo nephrit is was treated successfully wit h 
daratum umab after failur e of bortezomib and rituximab therapy  in a pati ent wi th normal  bone 
marrow (less than 1% plasma cells) and concurrently treated with tacrolimus and predniso ne [18]. 
No specific safet y concerns of daratumumab therapy  were reported. Together, these case reports 
indicate that the myelo ma dose of ant i-CD38 therapy  was safe and effect ive in nonmyelo ma 
patients who di d not have any plasma cell tumor burden, had normal if not hy pocellular bone 
marrow, and who had a crit ical need for rem oval of plasma cells secret ing path ogenic ant ibodies. 
In conclusio n, the collective safety , tolerabili ty and pharm acodynamic profiles of TAK -[ADDRESS_3776] of 8 weekly doses of 
300 or 600 mg.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 28of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALFigure 4.a Change in Serum Baseline Levels of Total IgA, IgG, and IgM in Healthy 
Subjects
Ig: immunoglobulin; IV: intravenous; SC: subcutaneous; SEM: standard error mean.
Serum samples obtained after a single administration of TAK -079 or placebo, administered either as IV dosed 0.003 to 
0.06 mg/kg or SC injection dosed 0.03 to 0.6 mg/kg. 
Symbols represent the mean change for the coho rt, and error bars represent the SEM.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 29of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALFigure 4.b Serum Levels of Total IgA, IgG, and IgM in Patients With RRMM 
Ig: immunoglobulin; LLD: lower limit of detection; RRMM: relapsed and/or refractory multi ple myeloma. 
Serum Ig levels (represented as percentage of baseline value for IgA, IgG, or IgM) for each subject obtained after 
TAK -079 subcutaneous dosing (45, 135, 300, or 600 mg) 1 week after the indicated number of doses. The 
myeloma -associated Ig is not shown. Ig profiles whose baseline values were already low (within 10% of the LLD of 
the assay ) and subsequently dropped below the LLD are not shown.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 30of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALFigure 4.c Pharmacodynamic Effects of TAK -079 on Plasma Cells in Bone Marrow 
Aspi[INVESTIGATOR_4029]: receptor occupancy (target occupancy); RRMM: relapsed and/or refractory multiple myeloma. 
Target occupancy (blue lines, percentage of CD38 bound by [CONTACT_4129] -079) and levels of plasma c ells (red line, percent 
change from baseline level) in bone marrow aspi[INVESTIGATOR_4030] (screen) and then after 4 doses 
(Cycle 2), 12 doses (Cycle 4), and 14 doses (Cycle 6) of TAK -079 at 45, 135, 300, or 600 mg (dosed weekly for 8 
week s, followed by [CONTACT_4132] 8 weeks, then every 4 weeks until disease progression). Target occupancy and 
plasma cell levels were quantified by [CONTACT_4133], and the data represent individual patients.
4.[ADDRESS_3777] not been fully determined.
Potenti al benefi ts of TAK -079 in patients with MG are based on nonclinical and clinical data 
presented in Secti on 4.2. TAK -079 has been shown to reduce autoantibodies in an in vitro study o f 
long-lived plasma cells fro m lupus pat ients, reduce inflammat ion in a monkey co llagen -induced 
arthri tis model, and reduce total immunoglobulin levels (a surrogate marker for autoantibodies) in 
a clinical study  of heal thy subjects and a clinical study  of patients wi th RRMM. It i s therefore 
hypothesized that TAK -[ADDRESS_3778] ion 4.3and the 
intrinsic pharmaco logy of TAK -079 di scussed in Section 8.6.
 Risks may  include, but are not 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3779] ion site reactions (ISRs), CRS, hypersensit ivity react ions, changes in hematologic 
param eters and infect ions. Patients will be monitored closely for these AEs in clinical studies wit h 
TAK -079.
5.0 STUDY OBJECTIVES AND ENDPO INTS
5.1 Objectives
5.1.1 Primary Objective
To evaluate the safet y and tol erabili ty of TAK -079 in pat ients with generalized MG who are 
receiving stable background therapy  for MG. 
5.1.2 Secondary Objectives
To assess the effects of TAK -079 on MG disease activit y using clinical rating scales and 
autoantibody  levels. 
5.1.3 Exploratory Objectives
1.To determine the pharmacokinet ics (PK) of TAK -079.
2.To determine the pharmacodynamic profile of TAK -079.
3.To expl ore the eff ects of repeated administration of TAK -[ADDRESS_3780] on MG disease severit y (using at least 
1 MG clinical rat ing scale).
5.To expl ore the frequency and proportion of pat ients requi ring rescue therapy .
6.To expl ore vaccine -induced protective ant ibodies.
7.To expl ore the effects of repeated administration of TAK -[ADDRESS_3781] ivity.
5.2 Endpoints
5.2.1 Primary Endpoint
Percentage of patients with TEAEs, including Grade 3 or higher events, SAEs, and AEs leading to 
TAK -079 di scont inuat ion. 
5.2.2 Secondary Endpoints
1.Score change fro m baseline in the fo llowing:
a)MG Act ivities o f Daily Living (MG -ADL) score. 
b)Quant itative Myastheni a Gravis (QMG) score.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 32of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALc)Myasthenia Gravis Co mposite (MGC) score. 
d)Revised 15- item Myasthenia Gravis Qualit y of Life scale (MG- QoL15r).
2.Change from baseline in ant i-AChR antibody  or anti -MuSK ant ibody  levels.
3. The percentage of patients meeting minimal clinica lly important difference criteria in the 
respective MG clinical impairment scales (MG -ADL, QMG, MGC).
5.2.3 Exploratory Endpoints
1.Serum  concentrati on-time profile of TAK -079 PK parameters will include, but are not limited 
to observed concentration at the end of a dosing interval (C trough) over time.
2.Change in serum immunoglobulin levels.
3.Pharmacodynamic analysis o f the presence and changes of immune cells in peripheral blood 
before and during therapy .
4.Score change fro m baseline in Myasthenia Gravis Impairment Ind ex (MGII) scores. 
5.Durati on of a clinically meaningful effect on MG disease severit y (in all o f the clinical disease 
impairment scales: MG -ADL, QMG, MGC, MGII).
6.Percentage of patients meet ing minimal clinically important difference criteria in the MGII 
scale.
7.Frequency and proportion of pat ients requi ring rescue therapy .
8.Immunogenicit y assessment of TAK -079 in peripheral  blood, including ant idrug ant ibody  
(ADA). 
9.Biomarkers o f disease activit y such as co mplement levels (C3, C4, complement split products); 
specific markers of CD38 pathway  modulati on may  also be evaluated. 
10.Change in levels of the fo llowing vaccine- protective ant ibodies: measles, mumps, rubella, 
diphtheria, and tetanus.
6.[ADDRESS_3782] background therapy . 
It is expected that approximately 3 6 pati ents will  be randomized into the study . After a screening 
period of up to 28 days, eligible pat ients will be randomized in a 1:1:1 ratio to one of the fo llowing 
treatm ent groups:
TAK -[ADDRESS_3783] background therapy .
TAK -[ADDRESS_3784] background therapy.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 33of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALMatching placebo added to stable standard background therapy.
Evaluat ion of intermediate doses and expansio n of an exist ing dose level are all permissible after 
discussio ns between the sponsor and the invest igators, if such measures are needed for patient 
safet y or for a better understanding of the dose -related toxicit y, clinical  activity, exposure, or 
pharmacodynamics of TAK-079.
The study  will be divided into 3 sequent ial periods: a dosing period (8 weeks), a safet y follow-up 
period (SFP; 8 weeks), and a long -term follow-up peri od (LFP; 16 weeks). 
During the 8- week dosing period, TAK -079/m atching pl acebo will be administered via SC 
inject ion once weekly  for 8 weeks (see Secti on 8.1for details on study  drug administrati on). 
Safety assessment, including safet y laboratory  tests (as listed in Appendix A), will be performed 
each week before subsequent dosing. Patients may have study  drug (TAK -079/pl acebo) doses 
modified (eg, wi thheld or delayed) for safet y reasons (see further details on dose modificat ion/ 
stoppi[INVESTIGATOR_4031] 8.d). 
After complet ing the [ADDRESS_3785] ivity scores and autoant ibody  levels; the end -of-study  visit will take 
place at Week [ADDRESS_3786] at Week 20 of the LFP. The study  schemat ic diagram is outlined in Figure 6.
a.
AEs ongo ing at the Week 16 visit of the SFP (including unreso lved clinical/laboratory parameters 
[see Section 9.6]) should be monitored through the LFP unt il they are reso lved, return to baseline, 
or are cl early  determined to be due to a patient’s stable or chronic condit ion or inte rcurrent 
illness(es). Study  drug –related AEs/SAEs wi th onset after the SFP will be collected through the 
LFP. 
Overall, the maximum fo llow-up peri od is approximately [ADDRESS_3787] dose of study  
drug.
Patients will  be permitted to receive rescue m edicati on (eg, IVIg, high dose corticosteroids, or 
plasmapheresis/plasma exchange) as determined by [CONTACT_4134]8.1.[ADDRESS_3788] ices 
or the physician’s best medical judgment to con trol and manag e underlying MG condit ions.
Study  procedures and assessments, with associated time po ints, are presented in the schedule o f 
events (SOE) table in Appendix A. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 34of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALFigure 6.a Study Schematic
AE: adverse event; LFP: SAE: serious adverse event; W: week.
* Unresolved AEs as of Week 16 and related AEs/SAEs with onset after SFP will be collected through the LFP.
6.2 Safety and Disease Assessments
Safety evaluations will include m onitoring of  TEAEs per National Cancer Institute Commo n 
Termino logy Cri teria for Adverse Events (NCI CTCAE) Version 4.03. Changes in clinical 
laboratory  parameters (standard hematology and chemistry ), vital signs, and ECGs that are judged 
by [CONTACT_4135] (eCRF) as an AE.
Safety stoppi [INVESTIGATOR_4032] 8.4.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 35of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALEfficacy evaluat ions will include measurements of changes in MG disease activit y using clinical 
rating scales and autoantibody  levels. 
Autoantibody  levels will be measu red at every  visit, and MG clinical activit y scores will be 
assessed throughout the study  as shown in the SOE in Appendix A. 
6.2.1 PK and Pharmacodynamic Assessments
Samples for PK, pharmacodynamic, and immunogenicit y testing will be obtained at prespecified 
time points as described in the SOE in Appendix A.
6.3 Number of Patients
Approximately  36 pati ents wi th moderate to severe MG will be randomized from approximately  
50study  sites in the US, Canada, and Europe. 
6.4 Duration of Study
6.4.1 Duration of an Individual Patient’s Study Participation
Study  treatm ent durati on will be a m aximum  of [ADDRESS_3789] ivity scores and autoantibody levels. Pat ients rando mized 
to placebo will attend an end -of-study  visit at Week 20 of the LFP.
The total duration of an individual pat ient’s study  parti cipat ion will be approximately  9 months.
6.4.2 End of Study/Study Completion Definition and Planned Reporting
The analyses for the clinical study report will be conducted after all pat ients rando mized in the 
study  have co mpleted the end
-of-study  visit (ie, Week 20 for placebo pa tients or Week 32 for 
TAK -079 pati ents), as shown in Appendix A.
6.4.[ADDRESS_3790] attended the 
end-of-study  visit in the LFP (ie, Week 20 for placebo patients or Week 32 for TAK -079 pat ients) 
as shown in Appendix A. It is expected that the study  will last for approximately 18 months 
(including enro llment, dosing period, SFP, and LFP).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3791] meet all the fo llowing inclusio n criteria to be rando mized to treatment:
1.Thepatient understands and agrees to study  parti cipati on by [CONTACT_4136] a signed and dated 
written inform ed consent form  (ICF) and any required privacy authorization before the 
initiation of any st udy procedures (as applicable, the patient’s legally acceptable representative 
may provide written informed consent in accordance with local and regional regulatory  
requi rements) and, in the opi[INVESTIGATOR_3078] n of the invest igator, is capable of co mplying with protocol 
requi rements.
2.Aged [ADDRESS_3792] for anti -AChR or anti -MuSK 
antibodies at screening.
4.Myasthenia Gravis Foundat ion of America (MGFA) clinical classificat ion II to IV at 
screening.
5.MG-ADL total score of [ADDRESS_3793] 4 points attrib uted to nonocular 
items.
6.If receiving immunosuppressive drugs (ie, mycopheno late mo fetil, methotrexate, cyclosporine, 
tacrolimus, cy clophosphamide), therapy  must be ongo ing for at least [ADDRESS_3794] be expected to remain stable 
throughout the study  unless dose reduction is required due to toxicit ies. Allowed background 
therapy  is defined as no more than a cho linesterase inhibitor ± corticosteroid 
± 1steroi d-sparing im munosuppressive drug (limit ed to azathioprine, mycopheno late mofetil, 
methotrexate, cyclosporine, tacrolimus, or cyclophosphamide). Patients must be on at least one 
allowed background medication.
10.Female pat ients of childbearing potential are required to ha ve a negative pregnancy test. Both 
male and female pat ients must practice an effect ive, reliable, and approved contraceptive 
regimen during the study  and f or up to 90 day s or 5 half -lives, whichever is lo nger, after 
discontinuat ion of treatm ent (see Sectio n 8.5.1 )
. 
11.Patients m ust be able and willing to comply wit h study  procedures.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 37of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL7.2 Exclusion Criteria
Patients m eeting any o f the following exclusio n crite ria are not to be randomized to treatment:
1.Presence of a thymo ma (previous history  of a fully encapsulated thymo ma rem oved 
≥12months before screening is allowed ) or history of invasive thymic malignancy unless 
deem ed cured by [CONTACT_4137] o f recurrence for ≥5 years before 
screening.
2.History  of thymectomy  within 12 mo nths before screening.
3.MGFA class I or V.
4.Received IVIg, SCIg (subcutaneous immunoglobulin), or plasmapheresis/plasma exchange 
within 4 weeks before screening, or an expectation that any  therapy  besides the pati ent’s 
standard background therapi[INVESTIGATOR_4033] (eg, a rescue therapy) 
between screening and dosing.
5.Chronic obstructive pulmo nary disease (COPD) or asthm a with a pre -bronchodilatory  forced 
expi[INVESTIGATOR_4034] 1 second (FEV 1) <50% of predicted normal.
Note: FEV 1testing is required for patients suspected of having COPD or asthma.
6.Received rituximab, belimumab, eculizumab, or any  monoclonal antibody  for 
immuno modulation wit hin [ADDRESS_3795] of 
the study .
8.Received a live vaccine wit hin 4 week s before screening or has any live vaccination planned 
during the study .
9.Any medical condit ion that, in the opi[INVESTIGATOR_3078] n of the investigator, might interfere with the patient’s 
participat ion in the study (such as significant cardiovascular, pulmo nary, hematolog ic, 
gastrointestinal, endocrino logic, hepat ic, renal, neurologic, malignancy, or infect ious disease), 
poses added risk for the patient, or could confound the assessment of the patient.
10.Pregnancy or lactation during the screening period or on Day [ADDRESS_3796] ion ≤[ADDRESS_3797] ion, such as tuberculosis (TB), pneumocystis 
pneumo nia, cytomegalo virus, herpes simplex virus, herpes zoster, or atypi[INVESTIGATOR_4017]. A 
mild, localized herpes simplex infect ion within 12 w eeks of study dosing is allowed, as long as 
the lesio n has reso lved without systemic therapy prior to Day 1.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3798] ion:
a)Alanine aminotransferase or aspartate aminotransferase >3 times the upper limit of normal 
(ULN).
b)Total  bilirubin >1.[ADDRESS_3799] (Note: Patients with a confirmed and documented 
diagnosis of Gilbert syndrome are not excluded based on this criterion).
c)Platelets <75,000/mm3.
d)Absolute neutrophil count <1500/mm3.
e)Hem oglobin <8 g/dL.
f)IgG < 5 g/L (500 mg/dL) .
g)Lymphocy te count <500/mm3.
14.A posi tive T-cell interferon -γ release assay (TIGRA) (result through Quant iFERON -TB Gol d 
test or T -Spot/Elispot) at the screening visit, noting the fo llowing: 
a)A purified protein derivat ive ([COMPANY_003]) skin test may be used if TIGRA te sting is not available.
b)Patients wi th an indeterminate TIGRA result must meet the following criteria:
i. Negative [COMPANY_003] skin test (defined as <5 mm indurat ion).
ii. At low ri sk of acquiring TB (eg, avoids close contact [CONTACT_4117] -positive individual[s]) 
and/or chest x -ray ≤[ADDRESS_3800] igator’s opi[INVESTIGATOR_3078] n, potenti ally 
interfere wi th the com pletion of treatment according to this protocol .
16.A posit ive test result for hepatit is B sur face ant igen, or hepatit is B core ant ibody , or hepatitis C 
antibody , or HIV antibody /antigen, at screening. However, an individual who has a known 
history  of chroni c hepat itis C and has been treated and fully cured of the disease, confirmed 
with a negat ive hepat itis C virus RNA polymerase chain react ion test at screening, is not 
excluded on the basis of the positive hepat itis C antibody  alone.
17.A history  of severe allergic or anaphylact ic react ions to recombinant proteins or excipi[INVESTIGATOR_4035] -079/pl acebo form ulation.
8.[ADDRESS_3801] igator or ident ified subinvestigator(s). 
After complet ion of all screening assessments and procedures and confirmat ion of eligibilit y, 
patients will  report to the study  site on Week 1 of the dosing period and be dosed with TAK -079 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 39of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL300 mg, TAK -079 600 mg, or matching placebo in accordance with their assigned treatment. Both 
the pati ent and physician will be blinded to treatment. Before TAK- 079/placebo administration, 
patients will  receive premedicat ion as listed in Section 8.1.[ADDRESS_3802] for 8 weeks. As dose levels (300 and 600 mg) will 
requi re mult iple SC inject ions to administer the full dose, the Week [ADDRESS_3803] ion 30 minutes apart (±10 minutes) until the full scheduled dose has been 
administered. On all other drug administration days if the pat ient did not have a clinically 
significant infusi on react ion per the invest igator, the SC inject ions can be given at the same time 
without a wai ting period.
Investigators will evaluate patients before each dose for the parameters outlined in Table 8.d. For 
the first dose, laboratory  assessments in Table 8.
dmay be evaluated using results obtained at 
screening. Otherwise, laboratory results should be obtained on the day before or the day of dosing. 
In instances where clinical parameters do not meet criteria for con tinued dosing, the study  drug 
must be temporarily  withheld until parameters meet dosing levels, or discont inued, as outlined in 
Table 8.dor in accordance with the principal investigator’s judgment. Dosing o f 
TAK -079/pl acebo m ay not otherwi se be reduced or escalated for any  given pat ient.
Note: If study  dosing i s held for [ADDRESS_3804] background therapy (as listed in Table 8.
c),
throughout the study  unless dose reduction is required due to toxicit ies. Allowed background 
therapy  is defined as no more than a cho linesterase inhibitor ± corticosteroid ± 1steroi d-sparing 
immunosuppressive drug (limited to azathioprine, mycopheno late mofetil, methotrexate, 
cyclosporine, tacrolimus, or cy clophosphamide). Pati ents m ust be on at least one allowed 
background medicat ion.
Excluded and permitted medicat ions are summarized in
 Table 8.band Table 8. c, respecti vely. 
Rescue therapy  information is outlined in Section
 8.1.3 .
Table 8.a Summary of TAK -079/Placebo Dose Administration
Treatment Arm Treatment aDose Number of Patients
Arm 1 TAK -079 300 mg 12
Arm 2 TAK -079 600 mg 12
Arm 3 Matching placebo Not applicable 12
a Patients will receive TAK -079 or matching placebo via subcutaneous administration once weekly over the course of 
8 weeks, for 8 total doses.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 40of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL8.1.1 Premedication
On each dosing day , 1 to 3 hours before TAK -079/pl acebo administrati on, pati ents are to be 
prem edicated wi th an ant ipyretic (such as acetaminophen) and an ant ihistamine (such as 
diphenhydramine). The premedicat ion regimen should be consistent with, but not limited to, the 
following:
Antipyretic: oral acetaminophen (650 -1000 mg).
Antihistamine: oral or IV diphenhydramine (25 -50 m g, or equivalent).
8.1.[ADDRESS_3805] and second 
TAK -079/pl acebo dose; before discharge from the clinic, the possible signs and symptoms of 
anaphylactic reactions and CRS should be reviewed with pat ients.
After the first dose of study drug, patients will receive low -dose m ethylpredniso lone (≤20 mg), or 
an equivalent, for the prevent ion of delayed inject ion-related reaction. Considering the timing of 
the greatest pharmaco logic effect of TAK -079, postdose medicat ion should be given 2 hours (±15 
minutes) after the first inject ion of the first dose and [ADDRESS_3806] dose of study  drug in the 
morning.
Postdose low-dose m ethylpredniso lone (≤20 m g) is not m andated after subsequent doses of 
TAK -079/pl acebo (Weeks 2 -8); however, it may  be given if clinically indicated and under the 
discreti on of  the principal invest igator.
NOTE: Pati ents wi th a higher risk of respi[INVESTIGATOR_4036] (eg, patients with a history  of 
COPD and patients with asthma) may be administered the fo llowing, after each study  dose (at the 
investigator’s discret ion):
a)An ant ihistamine (diphenhydramine or equivalent) on the first and second days after study 
dosing.
b)A short -acting β2 -adrenergic receptor agonist, such as salbutamol (albuterol) aerosol.
c)Control  medicati ons f or lung disease, such as the following: 
–Inhaled corticosteroids wi th or wi thout long-acting β2 adrenergic receptor agonists for 
patients wi th asthma. 
–Long -acting bronchodilators, such as tiotropi[INVESTIGATOR_4037], with or without inhaled 
corticosteroi ds, for pati ents wi th COPD.
The clinical site is responsible for sourci ng treatments administered pre -or post –
TAK -079/pl acebo administrati on.
On the basis of emerging data, the [COMPANY_005] physician/designee may enhance treatments 
administered pre -or post –TAK -079/placebo injectio n to ensure patient safet y.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3807] ices or the physician’s best medical judgment to control and manage underlying 
MG condit ions. Rescue medicat ions may include, but are not limited to, h igh-dose corticosteroids, 
IVIg, and plasmapheresis/plasma exchange. Protocol -restri cted and permitted concomitant 
medicat ions are outlined in Table 8.band Table 8. c, respectively .
Patients shoul d remain on their stable dose of immunosuppressive and corticosteroid therapi[INVESTIGATOR_4038]  (as align ed wi th protocol  requi rements in
 Table 8.band Table 8. c). If the 
patient receives rescue therapy , they  will autom atically enter the SFP.
Increasing, adding, or changing background immunosuppressive therapi[INVESTIGATOR_014], or adding a 
medicat ion not otherwise wit hin protocol limits, as deemed necessary by [CONTACT_1961] [INVESTIGATOR_4039], should result in discontinuation of the patient from 
study  dosing and advancement to SFP.
8.2 Excluded Concomitant Medications and Procedures
Excluded conco mitant m edicat ions are provided in
 Table 8.b. If patients receive excluded 
medicat ion, they  will be discont inued fro m the dosing period and automat ically enter the SFP.
Table 8.
b Excluded Concomitant Medications
Category or AgentExclusion Criteria
(Exclusion Criteria Must Be Upheld Throughout Study Participation, 
in Addition to the Time Points Indicated Below) a
Intravenous immunoglobulinbRestricted from ≤4 weeks before the screening visit.
Plasmapheresis/plasma exchange bRestricted from ≤4 wee ks before the screening visit.
Subcutaneous immunoglobulinbRestricted from ≤4 weeks before the screening visit.
Rituximab, belimumab, eculizumab, 
or any monoclonal antibody for 
immunomodulation Restricted from ≤[ADDRESS_3808] dosing.
Live vaccinations Restricted from ≤4 weeks before the screening visit. 
AE: adverse event; MG: myasthenia gravis.
aExceptions to excluded medications may be allowed for treatment of AEs, after discussion and agreement between 
the sponsor and principal investigator.
bPatients for whom any therapy (besides the allowed standard background therapi[INVESTIGATOR_4040]) is reasonably expected 
between screening and dosing are excluded from study participation.
8.3 Permitted Concomitant Medications and Procedures
Permitted concomi tant medicat ions are summarized in Table 8.c.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 42of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALTable 8.c Permitted Concomitant Medications
MedicationsCriteria
(Criteria Are to Be Maintained From Screening to Completion of Study 
Dosing Phase)
Immunosuppressants
Azathioprine aTherapy  must be ongoing for at least [ADDRESS_3809] 3 
months before the screening visit.Mycophenolate mofetil
Methotrexate
Cyclosporine
Tacrolimus
Cyclophosphamide
Oral corticosteroids Therapy  must be ongoing for at least [ADDRESS_3810] 6 months before screening visit.
8.4 Study Stoppi[INVESTIGATOR_4041]/designee will provide ongo ing safet y oversight and surveillance throughout the 
study  dosing period, SFP, and LFP. As such, TAK -079 clinicians/designee are to receive and trend 
all reported SAEs and conduct a review o f all safety data periodically throughout the study. On the 
basis of outcomes of the [COMPANY_005] safety  reviews and in accordance with predefined criteria, 
decisio ns about the dosing regimen are to be made and implemented.
8.4.[ADDRESS_3811] be temporarily  withheld until parameters meet dosing levels, or discont inued. 
Patients whose clinical parameters meet dose discont inuat ion criteria, as outl ined in Table 8.
d, are 
to be perm anent ly discont inued fro m study  dosing and will advance to the SFP, completing all 
associ ated assessments listed in the SO E tabl e in Appendix A
.
In addit ion, pat ients should be permanent ly discontinued fro m study dosing if any of the fo llowing 
is experienced:
An AE or other medical condit ion in which the principal investigator [INVESTIGATOR_4042].
The patient receives rescue medication as described in Sect ion 8.1.3 .
If study  dosing is held for 2 consecut ive doses because of safet y concerns or conditions 
outlined in Table 8.
d.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 43of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALThe patient chooses to withdraw from study  dosing.
The patient has a confirmed pregnancy .
NOTE: Safet y reviews of all AEs will be conducted in an ongoing manner (see details in 
Secti on13.1.6 ). If the stoppi[INVESTIGATOR_4043], an invest igation of the 
safet y profile will be conducted and a decision regarding accrual will be made. Further, if 2 or 
more pati ents discont inue study  drug dosing on the basis of the dose discont inuat ion criteria in 
Table 8.d, the [COMPANY_005] clinician/designee will review available safet y data to determine if 
adjustm ents to the treatm ent plan should be made. 
Immunoglobulin levels may be reduced with TAK -079; therefore, quantitative Ig levels (IgG, IgA, 
and IgM) will be evaluated during the treatment period at a central laboratory . If any of these 
are >50% below the lower limit of normal , the investigator should manage as clinically appropriate 
on the basis of signs and symptoms the patient is experiencing. If IgG levels are below the lower 
limit of normal and the patient is experiencing a se
vere infect ion, IVIg may be administered, as per 
physician discretion according to standard practice. If IVIg is given as a rescue treatment, as 
described in Section 8.1.3 , the patient will be discont inued from the dosing period of the study and 
enter the SFP.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 44of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALTable 8.d Summary of Subsequent Dosing Criteria
Safety ParameterDosing Criteria
Continue Dosing Dose Hold aDose Discontinuation b
Laboratory Investigations
Neutrophils ANC ≥1500/mm3Total neutrophils ≥Grade 2 c
ANC <1500/mm3
Platelets Thrombocytopenia ≤Grade 2 c
Platelets ≥50,000/mm3Thrombocytopenia ≥Grade 3c
Platelets <50,000/mm3
Total lymphocyte count ≥500/mm3or ≥90% of the baseline 
level<500/mm3 and <90% of the baseline level
Hgb ≥8 g/dL <8 g/dL
Events of Clinical Interest
Hypersensitivity (IRR, allergic reaction, or 
anaphy laxis) (See Section 8.6.1 ).
NOTE: IRR, allergic reaction or anaphylaxis are 
each classified according to CTCAE v4.03. 
Anaphylaxis is diagnosed according to Sampson 
et al [19].≤Grade 2 c≥Grade 3c
orany signs or symptoms of an 
anaphy lactic reaction [19]
CRS (See Section 8.6.2 )
NOTE: CRS dis classified according to Lee et al 
[20].Grade 1 with symptomatic treatment 
allowed in accordance with Lee et al 
[20].≥Grade 2
Systemic infection Grade 2 c
Hold dosing until the infection is resolved. ≥Grade 3 c orinfections requiring 
hospi[INVESTIGATOR_4044]: absol ute neutrophil count; CRS: cytokine release syndrome; CTCAE: Common Terminology Criteria for Adverse Events; Hgb: hemoglobin; IRR: infusion -related reaction; 
MG: myasthenia gravis; NCI: National Cancer Institute; SFP: safety follow -up period.
aPatients wh ose clinical parameters meet dose -hold criteria will not receive the scheduled dose of TAK -079; patients instead return for reassessment and evaluation at next planned 
visit.
bPatients whose clinical parameters meet dose discontinuation criteria are to be permanently discontinued from study dosing; patients will advance to the SFP, completing all 
associated assessments. Standard background therapy for MG will be managed according to the principal investigator’s discreti on.
cLaboratory, IRR, allergic react ions, anaphylaxis and infection grading arebased on CTCAE v4.03.
d Afull cytokine panel is to be obtained for any suspected events, at any grade, of CRS; further information and suggested manag ement of CRS is provided in the protocol. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 45of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL8.5 Precautions and Restrictions
Patients will  be closely m onitored before all TAK -079/pl acebo administrati ons and for at l east 
2hours after the administration of the first and second dose of TAK -079/pl acebo, wi th addi tional 
assessment and observat ions as necessary based on the principal invest igator’s best medical 
judgment, and as warranted by  [CONTACT_4138]. 
Postdose m onitoring shoul d include vital sign assessments as outlined in Sect ion 9.5.[ADDRESS_3812] been performed for TAK -
079 to date; hence, the effects of 
TAK -079 on fert ility and the developi[INVESTIGATOR_4045]. There were no 
TAK -079–
related findings (organ weight changes or microscopic findings) noted in the 
reproducti ve tract (cervix, epi[INVESTIGATOR_4046], ovary , oviduct, testis, and vagina) of sexually  immature 
male and female mo nkeys after administration f or up to 13 weeks. Women of childbearing 
potenti al may be enrolled in clinical studies with appropriate precautions to prevent pregnancy .
The half -life of TAK -079 has not y et been determined. Based on conservat ive information in the 
literature regarding th e half -life o f IgG1 as well as other IgG1 human monoclonal ant ibodies 
[21,
22], a conservat ive time frame to con tinue contraception would be [ADDRESS_3813] m eet 1 of  the fo llowing:
Postmenopausal  for at least 1 year before the screening visit, OR
Surgically sterile, OR
If they  are of  childbearing potential, agree to practice [ADDRESS_3814] ive (barrier) method of contraception at the same time ( Table 8.
e), from the 
time of signing of the ICF through 90 day s or 5 half -lives*, whichever is longer, after 
discontinuat ion of treatm ent, OR
Agree to practice true abstinence, w hen this is in line wit h the preferred and usual lifest yle of 
the pati ent (peri odic abstinence [eg, calendar, ovulation, symptothermal, postovulat ion 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contracep tion. Female and male condoms should not be used together).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 46of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALTable 8.e Highly Effective and Other Effective Methods of Contraception for Female 
Patients
Highly Effective Methods Other Effective Methods (Barrier Methods)
IUD Latex or nonlatex condom with or without a spermicidal 
agent
Hormonal (oral contraceptives, injectable contraceptives, 
contraceptive patches, or contraceptive implants)Diaphragm with spermicide; cervical cap with a 
spermicide; sponge with a spermicide
IUD: intrauterine device.
It is recommended to combine a highly effective method with a barrier method. If one of the highly effective methods 
cannot be used, using 2 barrier methods at the same time is recommended.
Male patients, even if surgically  sterilized (ie, status post -vasectomy), must agree to 1 of the 
following:
Agree to practice effective barrier contraception ( Table 8.f) during the ent ire study  treatm ent 
period and through 90 day s or 5 half -lives*, whichever is longer, after discontinuation o f 
treatm ent, OR
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the patient. Peri odic abst inence (eg, calendar, ovulation, symptothermal, postovulat ion 
methods), withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.
Table 8.f Highly Effective and Other Effective Methods of Contraception for Male 
Patients
Highly Effective Methods Other Effective Methods (Barrier Methods)
Vasectomy Latex or nonlatex condom with or without a spermicidal 
agent
Diaphragm with spermicide; cervical cap with 
spermicide; sponge with spermicide
It is recommended to combine the highly  effective method with a barrier method. If the highly effective method cannot 
be used post -vasectomy, using 2 barrier methods at the same time is recommended.
* Note that the half -life of TAK -079 has not y et been determined. Based on conservat ive 
inform ation in the literature regarding the half -life of IgG1 as well as other IgG1 human 
monoclonal antibodies [21,22] , a conservative time frame to continue contracepti on woul d be 
[ADDRESS_3815] not been conducted with TAK -079. However, as a fully 
human IgG1 monoclonal antibody , the risk of drug -drug interactions is low.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3816] for up to 6 months. The determinat ion of a 
patient’s ABO and Rh blood ty pe are not impacted, but the RBC binding ma y mask detecti on of  
antibodies to minor ant igens in the patient’s serum [23,24] . It is possible TAK [ADDRESS_3817] the 
resul ts of these blood tests, this is being evaluated. Should a patient require a blood transfusio n, 
blood transfusio n centers should be informed of this interference with sero logical testing [24].
8.6 Management of Clinical Events
8.6.1 Hypersensitivity Reactions: Infusion Reactions
Because infusio n reactions and other antibody -medi ated hypersensit ivity reactions have been 
reported with other bio logic agents, similar AEs may  be seen wit h TAK -079. Infusio n react ions 
are poten tially dose -limit ing AEs, not uncommo nly associ ated wi th IV administrati on of  biologic 
agents, but are less frequent ly associated with SC inject ion of these therapi[INVESTIGATOR_014] [20,
25,26] .
Symptom s of hypersensit ivity may range from mild skin rash to more severe reactions , wheezing, 
hypotension, poor perfusio n, respi[INVESTIGATOR_4047], and rarely death. Nonanaphylactic clinical 
hypersensit ivity typi[INVESTIGATOR_4048]; however, delayed responses 
have been reported in literature with other bio logic ag ents [27]. Symptom s of anaphylaxis, a 
potenti ally life-threatening condit ion, range from swelling, angioedema, and bronchospasm to 
respi [INVESTIGATOR_4049] [27]. Hypersensi tivity react ions in the literature often occur within a 
few hours fo llowing drug intake [20,
27]. Based on outcomes fro m studies wit h daratumumab, 
patients who experience CRS and have preexist ing COPD or asthma may be at particular risk for 
such respi[INVESTIGATOR_4050] n reaction event occur. 
Therefore, patients whose FEV 1is <50% of predicted normal will be excluded fro m study  
participat ion (see Section 7.2)
 [28]. Eligible patients with a history  of COPD m ay requi re 
additional postdose m edicat ions to manage respi[INVESTIGATOR_4036] (see Section
 8.1.2 ) [26].
To date, subjects administered TAK -[ADDRESS_3818] ic symptoms. In the 
clinical study  of healt h
y subjects (TAK -079_101), an infusio n-related reaction (IRR) was defined 
as a TEAE occurring within 2 hours after the start of an infusion; there were no IRRs in this study, 
and no allergic or cytokine release reactions were observed wit hin this t ime perio d (TAK -079 IB).
In thi s study :
Patients wi th a history  of severe allergic or anaphylact ic react ions to recombinant proteins or 
excipi[INVESTIGATOR_4051] -079 form ulation are not eligible and therefore will not be exposed 
to TAK -079. 
Prem edicat ion before e ach study  dose, to prevent IRRs, is mandatory  for all patients (as 
described in Section
 8.1.1 ); postdose medication can be administered at the invest igator’s 
discreti on.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 48of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALPatients who are treated with TAK -079/placebo will be carefully  monitored in the clinic for [ADDRESS_3819] itutional standards of care [19,29] . 
NOTE: Addi tional blood pressure measurements should be assessed any time the pat ient 
complains of symptoms consistent with an IRR. If the patient e xperiences hypotensio n (wi th or 
without symptoms), intensive blood pressure monitoring according to local practice should be 
instituted. The patient should not be released fro m the site until bl ood pressure has returned to 
Grade [ADDRESS_3820] 1 hour.
[IP_ADDRESS] Management Recommendations for Hypersensitivity Reactions
Patients in clinical studies receiving TAK -079 are to be carefully  monitored f or signs and 
symptoms of systemic hypersensit ivity reactions (including IRRs, allergic react ions, or 
anaphylaxis ; management recommendat ions for CRS are discussed separately in Section [IP_ADDRESS] ). 
Signs and symptom s of systemic hypersensit ivity reactions include rash, urti caria, fever, and/or 
bronchospasms. Depending on the severit y of the reaction, management of hypersensit ivity 
reacti ons may include discontinuation of SC administration of TAK -079 and/or the administration 
of appropri ate m
edical  therapy .
Reco mmen dations for the m anagement of hypersensit ivity reacti ons [19] are as follows:
Grade 1
a)Study Management :
If the full dose of TAK -079 has not yet been administered, hold dosing until symptoms 
resolve, at which time the remainder of TAK -079 dose m ay be administered. 
b)Patient Support : 
Moni tor cl osely  until resol ution of symptoms.
Grade 2
a)Study Management :
If the full dose of TAK -079 has not yet been administered, hold dosing until symptoms 
resolve, at which time the remainder of TAK -079 dose m ay be administered.
b)Patient Support : 
Administer appropriate symptomat ic and prophylactic medical care; consider 
postinje ction medicat ions as outlined in Sect ion 8.1.2 .
For allergic reaction, provide symptomat ic treatment (eg, antihistamines, nonsteroidal 
anti-inflammatory  drugs, narcotics, epi[INVESTIGATOR_238]) as medically appropriate and consider 
postinject ion medicat ions.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 49of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALGrade 3 or Greater (including any  diagnosis of anaphylaxis according to Sampson et al [19]). 
a)Study Management: 
Patients are to di scont inue study  dosing and advance to the safet y follow-up peri od of  
the study .
b)Patient Support: 
Provi de symptom atic treatment, including epi[INVESTIGATOR_238], until symptoms reso lve. 
Consider hospi[INVESTIGATOR_4052].
8.6.2 Cytokine Release Syndrome
CRS represents an important infusio n reaction often associated with the use of natural and 
bispecific mo noclonal antibodi es used in ant i-inflammatory and ant itumor therapi[INVESTIGATOR_014] [20,30,31] . 
Onset of CRS may occu r early in therapy, often after the first infusio n of the drug [20
,31,32] , 
because o f a high level o f activation of the immune system and engagement and pro liferat ion of T 
cells that can result in increased cytokine release. 
An in vit ro study with human lymphocy tes dem onstrated that TAK -[ADDRESS_3821] ivation. In 
repeated -dose toxicit y studies in cyno molgus mo nkeys, there were no TAK -
079–related increases 
in cytokines at 0.1 m g/kg. At ≥0.3 mg/kg, dose -related increases (up to 29.5 -fold for any  
individual mo nkey) in tum or necrosis factor alpha (TNF -α) were observed [ADDRESS_3822] dose of TAK -079. These increases were considered small co mpared with elevat ions observed 
during a cy tokine storm event, were not accompanied by [CONTACT_4139], and did not 
transl ate into clinical manifestation of CRS. Increases in serum TNF -α may  be related to 
TAK -079– mediated lyses of CD38+ lymphocy tes.
In the first -in-human study , conducted i n healt hy subjects, rarely observed symptoms consistent 
with mild CRS were reported, particularly at higher doses; dose adjust ment or interruption was not 
requi red. No CRS has been reported in the ongoing SLE and RRMM studies (TAK -079 IB).
The CRS hallmark is fever [20]. CRS al so presents wi th rash, urti caria, headache, chills, fat igue, 
nausea, and/or vomit ing [20,
30]. Severe CRS is characterized by [CONTACT_4140], often 
accompanied by [CONTACT_4141], in addit ion to fever, chills, rigors, urticaria, and 
angioedema. The acute respi[INVESTIGATOR_4053] a chest x -ray. The syndro me frequent ly manifests within 
[ADDRESS_3823] infusio n [
20,32, 33]. Pati ents wi th a history  of pulm onary 
insufficiency or those with pulmo nary tumor infiltrati on may  be at greater risk of poor outcome 
and should be treated with increased caution. On the basis o f outcom es from studi es of  the 
anti-CD38 monoclonal ant ibody  daratumumab, patients with preexist ing COPD or asthma may be 
at particular risk for respi[INVESTIGATOR_4054], such as bronchospasm, should an infusion react ion 
or CRS event occur [
28]. Therefore, if the patient’s FEV 1is <50% of predicted normal, they will 
be excluded fro m study  parti cipat ion (see Section
 7.2). Eligible pat ients with a history  of COPD 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 50of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALmay require addit ional postinjecti on medicat ions to manage respi[INVESTIGATOR_4055] [26] (see 
Secti on 8.1.2 )
.
[IP_ADDRESS] Management Recommendations for CRS
Prem edicat ion before each study dose, to prevent infusio n react ion, is mandatory for all patients as 
described in Section 8.1.[ADDRESS_3824] igator’s 
discreti on, is described in Section
 8.1.[ADDRESS_3825] of care is recommended 
[20]. Before discharge fro m the clinic, the possible si gns and symptom s of anaphylact ic react ions 
and CRS should be reviewed wit h patients. Further, patients should receive informat ion about 
what to do if emergency care is needed (see Appendix Cfor further details on clinical signs and 
symptoms associated with CRS and the CRS grading system [20]).
If a patient is exhibit ing signs or symptoms possibly assessed as CRS by [CONTACT_3170], a blood 
draw shoul d be perform ed for central  evaluat ion that coul d include, but need not be limited to, 
immune markers and cy tokine m arkers. Addit ional guidance for study  management and pati ent 
support for CRS by  [CONTACT_4142]: 
Grade 1 (defined as fever, constitutional symptoms) 
a)Study Management: 
Hold study  dosing unt il symptom s reso lve; resume dose of TAK -079 at sam e dose 
level after symptom resolut ion.
b)Patient Support: 
Provi de vigilant supportive symptomat ic treatment, which may include ant ipyretics, 
analgesics, and ant ihistamines. 
Grade 2 (defined as hypotensio n, hypoxia, organ toxicit y) 
a)Study Management:
Discontinue study  dosing and advance to SFP.
b)Patient Support:
Provi de vigilant supportive symptomat ic treatment, which may include ant ipyretics, 
analgesics, and ant ihistamines, with or w ithout tocilizumab. 
Grade 3 (defined as hypotensio n, hypoxia, and severe organ toxicit y) 
a)Study Management:
Discontinue study  dosing and advance to SFP.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 51of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALb)Patient Support:
Provi de vigilant supportive care, including but not limited to tocilizumab, antipyret ics, 
analgesics, and ant ihistamines, as medically indicated [20].
8.6.3 Hematologic Effects
Reductions in platelets, lymphocy tes, and RBCs occurred in nonclinical studies in some animals 
administered repeated doses of TAK- 079 at ≥1mg/kg, higher than the NOAEL of 0.3 mg/kg. In 
the first -in-human study , no decreases were seen in RBCs or platelets. 
In the healt hy subjects study  (TAK -
079-101), whi ch is com pleted, and in the SLE study  
(TAK -079- 2001), whi ch is ongoing, hematol ogic param eters were m onitored cl osely . There were 
no m arkedly  abnorm al hematol ogic values in any subject or any AEs related to thrombocytopenia 
or anemia in the healt hy subjects study  or, as of the TAK -079 IB clinical data cutoff (20 March 
2019), in the SLE study . 
In the study  in RRMM (TAK -079- 1501), hem atologic parameters were 
monitored according to standard practice. At doses up to 600 mg, no decreases in platelet counts 
below the lower limit of normal related to TAK -079 were seen (note: 1 event of Grade 3 
thrombocytopenia was reported as related to progressio n of the underlying myelo ma). Two events 
of Grade [ADDRESS_3826] been reported, with one reported as related to study  drug and the other 
reported as not related to study  drug but rel ated to progression of the underlying myelo ma. No 
events of lymphocy topeni a (or decreased lymphocy te count) have been reported (TAK -079 IB).
Patients will  be monitored cl osely, including testing of hematologic parameters throughout this 
clinical study  as described in Sect ion
 9.5.[ADDRESS_3827] itutional 
guidelines.
8.6.4 Infections
In a GLP -compliant, 13 -week toxico logy study , bacteri al and/or vi ral infecti on, secondary to 
immune suppression, was observed in cyno molgus monkeys at IV doses of 3, 30, and 80 mg/kg 
administered once every  2 weeks. The NOAEL dose of 0.3 mg/kg, administered IV once every  
week, was not associated with infect ions. 
Mild infection, specifically  nasopharyngi tis, was reported across all SC dose levels in the healthy 
subject s study (TAK -079_101). As of the TAK -079 IB data cutoff (20 March 2019) in the study in 
patients wi th RRMM (TAK -079- 1501), 4 of 19 patients treated at doses up to 600 mg reported an 
event in the infections and infestations Sy stem  Organ Class; the most comm on AE reported was 
upper respi [INVESTIGATOR_2826] (n = 2); all were Grade 2, and only [ADDRESS_3828] been reported in the patients in the SLE study  (TAK -079- 2001) 
(TAK -079 IB). 
Patients will be monitored for any signs and symptoms o f infect ions throughout this clinical study 
(see
 Appendix Aand Table 8.d). In instances where clinical parameters do not meet dosing criteria, 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3829] not been observed in mo nkey and rat nonclinical studies 
after SC and/ or IV administration of TAK -079. In the clinical study  of heal thy subjects 
(TAK -079- 101), mild inject ion site AEs were reported; most were Grade [ADDRESS_3830] been reported [
34]. ISRs 
consisted of induration, ery thema, inject ion site discoloration , and hematomas (all grade 16.7%) 
[34].
Mild inject ion site AEs, reported as ery thema or tenderness with palpat ion, were mostly observed 
at the [ADDRESS_3831] ions reso lved wit hin a few days. No 
oral medicati ons, such as paracetamo l (acetaminophen) or antihistamines, were needed to treat 
these mild ISRs. In the study  in pat ients with RRMM at doses up to 600 mg (given with [ADDRESS_3832] ions), no ISRs have been reported (TAK -079 IB). Pati ents receiving TAK -[ADDRESS_3833] medical care.
8.6.6 Antidrug Antibody Interactions
Antidrug ant ibody  (ADA) responses were detected in mo st monkeys in the single -dose PK studies 
and the 4
-week (non -GLP) and 13- week (GLP) toxico logy studi es. Stronger posit ive ADA 
responses were generally associated with lower serum concentrations of TAK -079, and this was 
especial ly notable in the 13 -week repeated -dose toxicit y studi es and at l ower doses. In the 
single- dose heal thy subjects study  (TAK -079- 101), 5 of 54 TAK -079– treated subjects were 
positive for ADA (3 subjects with transient ADA and 2 subjects with persistent ADA). Of these, [ADDRESS_3834] was treated in the 0.06 mg IV cohort, and the remaining 4 subjects were treated with 0.03 
mg/kg (2 subjects), 0.1 mg/kg ([ADDRESS_3835]), or 0.6 mg/kg ([ADDRESS_3836]) SC TAK -079. Immunogenicit y 
was not associated with clinically significant AEs , even in the 2 subjects with persistent 
immunogenicit y (TAK -079 IB).
8.6.[ADDRESS_3837] (ie, patient) according to the study protocol. 
To date, there is no experience with overdose of TAK -079. If an overdose does occur, as defined in 
Secti on 10.1.2 , close m onitoring and supportive treatment, as medically required, are 
recommended. Events of overdose, with or without an associated AE, should be prompt ly reported 
to the study  medical m onitor and will  be entered into the eCRFs as an AE.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 53of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL8.7 Description of Investigational Agents
8.7.1 Study Drug: TAK -[ADDRESS_3838] for SC use in this study  is 100 m g TAK -079 in 1 mL 
(100 m g/mL). TAK -[ADDRESS_3839] and matching placebo are supplied in asept ically filled, 
single- use, cl ear, ty pe I, borosilicate glass vials wit h fluoropolymer -coated butyl rubber stoppers 
and aluminum crimp seals wit h flip-off caps.
[IP_ADDRESS] Preparation, Re constitution, and Dispensation
Refer to the pharmacy  manual for detailed instructions regarding the preparation of TAK -079 
study  supply.
TAK -079 i s a m onocl onal antibody  and cauti on shoul d be exercised when handling TAK -079 as 
with other bi ologics.
[IP_ADDRESS] Packagi ng and Labeling
Supplies o f TAK-079 are labeled according to the current International Council for Harmonisatio n 
(ICH) guidelines on Good Clinical Pract ice (GCP )and Good Manufacturing Practices and include 
any locally  required statem ents.
[IP_ADDRESS] Storage, Handlin g, and Accountability
During shippi[INVESTIGATOR_007], vials are to be protected from light and maintained within temperatures provided 
in the pharmacy manual. Each TAK -[ADDRESS_3840] igator’s 
essent ial docum ent file. The sponsor must be notified immediately  of any tem perature excursions 
and shippi[INVESTIGATOR_4056] .
All clinical study material must be kept in an appropriate, limited access, secure location unt il used,  
destroy ed, or returned to the sponsor or designee. TAK -[ADDRESS_3841] be stored according to the 
manufacturer’s stipulat ion, as specified on the label (see the pharmacy manual for addit ional 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 54of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALinform ation). Detailed dosage preparation instructions are provided in the Directions for Use 
section of the pharmacy manual. Co mplete receipt, inventory , accountabilit y, reconciliat ion, and 
destruction records must be ma intained for all used and unused study  drug vi als. Detailed 
instructi ons and the associated forms for these activit ies are in the pharmacy manual. Drug 
supplies will be counted and reconciled at the site before being returned to [COMPANY_005] or designee or 
being destroy ed. 
The investigator or designee must ensure that the study  medicati on is used in accordance with the 
approved protocol and is dispensed only to patients enro lled in the study. To document appropriate 
use of study medication (TAK -079), the investi gator must maintain records of all study medicat ion 
delivery  to the si te, si te inventory , use by [CONTACT_4143], and return to the sponsor or designee.
The invest igator will be notified of any expi[INVESTIGATOR_4057] n of clinical study  
materi al during the study  conduct. On expi[INVESTIGATOR_4058], the 
site must com plete all instructions outlined in the notification, including segregat ion of expi[INVESTIGATOR_4059]. 
Further gui dance and information are provided in the pharmacy  manual .
8.7.[ADDRESS_3842] ive 
voice/web response system (IXRS). All rando mizatio n informat ion will be stored in a secured area, 
accessible only by [CONTACT_4144].
8.7.4 Clinical Study Blind Maintenance/Unblinding Procedure
To maintain the integri ty of the study , all study  personnel, including the invest igators, site 
personnel, the contract research organizat ion (CRO) medical mo nitor, study  clinicians, and the 
sponsor, will be blinded to the treatment assignments during the trea tment peri od. Treatm ent 
assignments will be obtained through the IXRS according to the procedures outlined in the study  
manual or relevant training materials. Informat ion regarding the treatment assignments will be 
kept securely at [COMPANY_005] or designee, per its standard operating procedures. 
Records of the patient number, the date the study  drug was dispensed, and the treatment 
assignment will be maintained by [CONTACT_4145].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 55of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALEmergency  unblinding, if necessary, will be conducted via the IXRS. The following are key  
factors to be considered regarding breaking the study  blind: 
–If the treatment assignment must be revealed for the safet y of the patient, to treat an AE, or 
to inform decisi ons for subsequent therapy , the investigator will contact [CONTACT_4146] (in accordance to contact [CONTACT_4147] m aterials). 
–A decisio n to break the blind must be reac hed by [CONTACT_4148]. 
The invest igator, or designee, may break the blind through the IXRS independent of the 
[COMPANY_005] clinician only if the investigator considers the situation to be an emergency and 
requi res specific knowledge of the blinded study  treatm ent to properly  treat the AE/safet y 
issue. 
–If the treatment of the AE/safet y issue is ant icipated to be the same regardless of study drug 
assignment, the blind should not be broken. 
–The event requiring breaking the blind must be documented in the eCRF, including the date 
the blind was broken. 
After breaking the blind, the patient will be discontinued from further study drug administration in 
this study .
8.7.[ADDRESS_3843] itution (where applicable) is responsible 
for TAK -[ADDRESS_3844] maintain 100% accountabilit y for all study medicati on (TAK -079) received 
and dispensed during his or her ent ire parti cipat ion in the study . Proper drug accountabilit y 
includes, but is not limited to:
Continuously mo nitoring expi[INVESTIGATOR_4060]/retest date is provided to the 
investigator.
Frequent ly verifying that actual inventory  matches docum ented inventory .
Verifying that the log is completed for the drug lot used to prepare each dose.
Verifying that all containers used are documented accurately on the log.
Verifying that required fields are com pleted accurately  and legibly .
Per standard clinical pract ice, a site representative, otherwise uninvo lved with study conduct, will 
review the patient dosing log before Day  [ADDRESS_3845] maintain a 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 56of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALcurrent inventory  (drug accountabilit y log) of  all sponsor- supplied study medicat ion delivered to 
the site, inventory  at the si te, and patients’ use records . Thi s log m ust accurately  reflect the drug 
accountabilit y of the study medicat ion at all times. The fo llowing informat ion will be recorded at a 
minimum: protocol number and tit le, name [CONTACT_4236], site ident ifier and number, descript ion 
of sponsor -supplied medication, expi[INVESTIGATOR_4061]/retest date, and amount dispensed including the init ials of 
the person dispensing and the person receiving the study  medicat ion. The log should include all 
requi red inform ation as a separate entry  for each pati ent to whom  study  medicati on is dispensed.
Before site closure or at appropriate intervals, a representative fro m the sponsor or its designee will 
perform  clinical study material accountabilit y and reconciliat ion before clinical study materials are 
returned to the sponsor or its designee or destroy ed at the si te, as applicable. The invest igator will 
retain the original documentation regarding clinical study  material accountabili ty, return, and/or 
destruction, and copi[INVESTIGATOR_4062].
Further gui dance and information are provided in the pharmacy  manual .
9.[ADDRESS_3846] igator, interactive response techno logy provi der, and CRO team  may 
be found in the study  manual/binder. The list of investigators is available in the sponsor’s
investigator database.
9.2 Arrangements for Recruitment of Patients
Recrui tment and enro llment strategies for this study may include recruit ment from the 
investigator’s local practice or referrals from other physicians. If advert isements become part of 
the recruitment strategy , they  will be reviewed by  [CONTACT_4149] (IRB)/ 
independent ethics co mmittee (IEC). 
9.3 Assignment of Randomization Numbers
At the time of rando mization, after completion of all screening assessments and procedures and 
confi rmation of eligibilit y, pati ents are assigned a 4 -digit randomizat ion sequence number. 
Randomization numbers are generated by  [CONTACT_4150].
9.4 Treatment Group Assignments
Patients will  be randomly assigne d in a 1:1:1 rati o to 1 of the 3 treatment arms as outlined in 
Table 8.aat the complet ion of study  screening and before dosing on study  Day  1, in accorda nce 
with the randomizat ion schedule as generated by  [CONTACT_4150]. Randomizat ion informat ion is stored 
in a secured area, accessible only by  [CONTACT_4151], and necessary  site staff in instances of 
emergency unblinding. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 57of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL9.5 Study Procedures
Refer to the SOE (Appendix A) for timing of assessments. Addit ional details are provided as 
necessary  in the secti ons that follow.
The screening period for this study  is 28 days (Day -28 to Day -1). Assessments and procedures 
shoul d be perform ed on schedule, within the time frame and window allowance in Appendix A. 
Further time allowance for most study  procedures and assessments is acceptable in extenuat ing 
circumstances (i e, ho lidays, vacat ions, and other administrative reasons) on approval by [CONTACT_4152]; however , these time extensio ns should not deviate more than 
7days from the scheduled procedural time.
9.5.1 Informed Consent
Each patient will be asked to provide written informed consent before any study -related 
procedures are conducted, unless those procedures are p erform ed as part of the patient’s standard 
care.
9.5.[ADDRESS_3847] provide the [COMPANY_005] clinician/study medical mo nitor a summar y of key 
eligibilit y criteria for review so eligibilit y can be verified before randomizing each patient. 
9.5.[ADDRESS_3848] ics will be collected at screening and will include age, sex, race, 
and ethnicit y (opti onal depending on country ).
9.5.4 Medical/Surgical History
A complete medical history is co mpi[INVESTIGATOR_4063] (ie, ≤28days 
before study  Day 1) and inclu des assessment and documentation of prior medical history , 
comorbidi ties, and concomitant treatments. This includes assessments of current MG signs, 
symptoms, morbidit ies, as evaluated and scored by [CONTACT_4153], and previous and current 
MG thera pi[INVESTIGATOR_014].
9.5.[ADDRESS_3849] 
dose of TAK -079 through the end of the patient’s participat ion in the study will be recorded in the 
eCRF. Trade name a nd internat ional nonproprietary name (if available), indicat ion, and start and 
end dates of the administered medication are to be recorded. Medicat ions used by [CONTACT_4154] c procedures com pleted by  [CONTACT_4155] (se e Secti ons8.[ADDRESS_3850] of exclud ed and permitted concomitant medications).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3851] received MG background therapy  (Table 8.c) before screening. Once 
rando mized into the study , pati ents will remain on background therapy , as managed by [CONTACT_4156], in accordance wit h local institutional pract ices, and in alignment with the 
study  protocol, throughout study participation. Allowed back
ground therapy is defined as no more 
than a cho linesterase inhibitor ± corticosteroid ± 1 steroid -sparing immunosuppressive drug 
(limited to azathioprine, mycopheno late mo fetil, methotrexate, cyclo sporine, tacrolimus, or 
cyclophosphamide). Patients must be on at least one allowed background medicat ion. Background 
MG therapy ongoing at the time of screening will be recorded in the eCRF, as well as any changes 
to this therapy .
9.5.[ADDRESS_3852] of care at 
the times specified in the SOE ( Appendix A). Women of childbearing potential should be asked 
about thei r menstrual history  at each visi t. A serum pregnancy  test shoul d be conducted for 
delayed menses (see Sect ion 9.5.10 )
.
9.5.7 Height and Weight
Height will be measured during screening only (within [ADDRESS_3853] dose of TAK -079).
Weight will be measured during screening and at Weeks 10, 16, and 32 as ou tlined in Appendix A.
9.5.8 Vital Signs
Vital signs (body  temperature, respi[INVESTIGATOR_2842], heart rate, and blood pressure) will be evaluated at 
visits specified in
 Appendix Aand recorded both on the source documentation and in the eCRF. In 
addition, vi tal signs shoul d be assessed at any  time it is clinically  warranted, i e, pati ent exhibi ts 
signs or symptom s of ISR, CRS, or hy persensi tivity reacti ons. As indicated in Appendix A, vital 
signs are to be assessed be fore each study  dose and 2 hours (±10 minutes) postdose after the first 
and second TAK -079/pl acebo dose. 
Clinically significant values, as determined by [CONTACT_458], must be documented as 
an AE and closely monitored for fo llow-up. 
9.5.9 12-Lead ECG
A single 12 -lead ECG is to be performed at the screening visit (for assessment of eligibilit y) and at 
Weeks [ADDRESS_3854] ice. 
NOTE: Any  ECG finding that i s judged by  [CONTACT_4157] (except at the 
screening visit) is considered an AE; as such, clinically significant fi ndings are to be recorded on 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3855]
A serum pregnancy (human chorionic gonadotropin [hCG]) test will be completed for all female 
patients; this test will be performed at screening and during the SFP and must be negat ive for the 
patient to be randomized and to continue in the study . 
A urine pregnancy test will be completed for all female pat ients before the first dose of 
TAK -079/pl acebo and at Week [ADDRESS_3856] shoul d be co mpleted and a negative result obtained before dosing with the 
study  drug.
All study  pregnancy testing may  be conducted at a designated local laboratory  as determined and 
confirmed by [CONTACT_456], with appropriate laboratory  docum entati on provi ded in advance of 
study  testing.
[IP_ADDRESS] Definiti on of Women of Childbearing Potential
A wo man of childbearing potential is a sexually mature woman who: 
Has not undergone a hysterectomy or bilateral oophorectomy, or 
Is not postmenopausal. A postmenopausal state is defined as no menses for 12 months wit hout 
an alternative medical cause.
[IP_ADDRESS] Timing of Pregnancy Testing 
Women of childbearing potential must have pregnancy testing co mpleted in accordance with the 
timing outlined as fo llows: 
Before Initial Study Dosing : 
–Screening period : a negative serum pregn ancy test (hCG <5 m IU/mL).
–Baseline: (Either Day  1 pri or to init ial study  dosing, or 1 day  before study  dosing) a 
negat ive urinepregnancy test with a sensit ivity of at least 50 m IU/mL. If the urine test is 
indeterminate, a serum pregnancy test is mandator y.
During Study Enrollment :
–At Week 5, before dosing ( urine pregnancy  test).
–During SFP, and LFP as outlined in Appendix A(serum pregnancy  test).
–If a menstrual period is delayed ( serum pregnancy test). 
–Addit ional pregnancy  tests to be conducted as requested by  [CONTACT_4158]/or as required by  
[CONTACT_4159]. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 60of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL9.5.11 AEs
Moni toring of AEs, serious and nonserious, will be conducted throughout the study as specified in 
Appendix A. Refer to Section 10.0 for details regarding definit ions, documentation, and reporting 
of AEs and SAEs. 
9.5.12 Clinical Laboratory Evaluations
Hem atology, serum chemistry, and sero logy assessment s will be performed locally, wit h reference 
ranges provided in the electronic data capture (EDC) sy stem . Clinical  laboratory  evaluati ons will 
be perform ed according to the SOE in Appendix Athroughout the study . 
Instructi ons for handling and shippi[INVESTIGATOR_4064].
[IP_ADDRESS] Clinical Chemistry and Hematology
Blood sam ples f or analysis of the clinical chemistry  and hematol ogy parameters shown in 
Table 9.awill be obtained as specified in the SOE ( Appendix A) .
Table 9.a Clinical Chemistry and Hematology Tests
Hematology Serum Chemistry
Hematocrit
Hemoglobin
Leukocytes with differential
Total ly mphocy te count
Neutrophils (ANC)
Platelet (count)
Coom bs test (both direct and 
indirect)
Serum pregnancy testAlbumin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Bilirubin (total)
Blood urea nitrogen (BUN)
Calcium
Carbon dioxide (CO 2)
CreatinineChloride
Glucose
Lactate dehydrogenase (LDH)
Potassium
Sodium
ANC : absolute neutrophil count .
9.5.[ADDRESS_3857] ions and in accordance wit h the SOE in Appendix A. 
Further details for completing the disease assessment scales are provided in the rater manual and 
associ ated training materi als. 
[IP_ADDRESS] MG-ADL Score
The MG- ADL is a validated, 8 -question patient -reported outcome measure of MG symptoms 
[35,
36]. The MG -ADL assesses relevant MG symptoms and their funct ional impact on the patient. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 61of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALThe patient will assess functional disabilit y secondary  to oc ular (2 items), bulbar (3 items), 
respi [INVESTIGATOR_696]  (1 item), and gross m otor or limb impairment (2 items). Each item is individually 
graded fro m 0 (norm al) to 3 (severe). The total MG -ADL score ranges from 0 to24points, with 
higher scores indicat ing greater f unctional impairment and disabilit y.
A 2-point reduction in the MG -ADL total score is considered a clinically meaningful 
improvement. 
[IP_ADDRESS] MGII Score
The MGII is a novel and validated measure of MG severit y, with dem onstrated feasibilit y, 
reliabilit y, and cons truct validit y [37,38] . The MGII score was developed using pat ient input and 
consists of [ADDRESS_3858] 
(ie, more dynamic range at the lower end of the scale) than other commo nly used m easures and is 
therefore m ore sensit ive to detect change. The total score ranges fro m 0 to 84 ( with higher scores 
indicat ing worse MG disease act ivity), and a group -level reduct ion by 8 points reflects the minima l 
clinically important difference.
[IP_ADDRESS] MGC Score
The MGC sca le is a validated patient -and physic ian-reported 10 -item assessment tool  for 
evaluat ing the signs and symptoms of MG. Physician assessment includes assessment for ptosis 
(upward gaze), double visio n on l ateral  gaze, ey e closure, neck flexi on or extensio n,shoul der 
abduct ion, and hip flexio n; patient assessment includes self -report of tal king, chewing, 
swallowing, and breathing. Items are scored based on [ADDRESS_3859]: normal, mild, 
moderate, or severe. The total score ranges from [ADDRESS_3860] ional activities [
39-41] .
A 3-point reduction in the MGC total score is considered a clinically meaningful improvement.
[IP_ADDRESS] QMG Score for Disease Severity
The QMG score is a physician -reported, validated, 13 -item disease -severit y assessment tool . The 
QMG score evaluate s muscle strength based on quant itative testing of sent inel muscle groups: 
ocular (2 i tems), facial  (1 item), bulbar (2 i tems), gross m otor (6 i tems), axial (1 i tem), and 
respi [INVESTIGATOR_696]  (1 item). Each i tem is graded on a scale of [ADDRESS_3861] severe. The 
total score ranges from 0 to 39, with higher scores represent ing a greater disease burden [
42,43] .
A 3-point reduction in the QMG total score is considered a clinically meaningful improvement.
[IP_ADDRESS] MG-QoL15r
The MG
-QoL15r is a validated tool containing 15 patient -reported items about the patient’s 
percepti on of  impai rment and disabilit y and the degree to which the patient tolerates disease 
manifestations [44-46] . The total score ranges from [ADDRESS_3862] ivity.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 62of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL9.5.13.6 Patient Global Impression of Change
The Pati ent Gl obal Impressi on of Change (PGIC) is an anchor scale used to aid the interpretation 
of the above MG disease act ivity instrum ents (MG -ADL, MGII, MGC, QMG and MG -QoL15r). 
The PGIC m ay be used in analyses of meaningful chan ge and other psychometric properties and 
perform ance characteristics of these instruments.
[IP_ADDRESS] Patient Global Impression of Severity
The Pati ent Gl obal Impressi on of Severi ty (PGIS) is an anchor scale used to aid the interpretation 
of the above MG disease act ivity instrum ents (MG -ADL, MGII, MGC, QMG and MG -QoL15r). 
The PGIS may be used in analyses of meaningful change and other psy chometric properti es and 
perform ance characteristics of these instruments.
[IP_ADDRESS] Quantification of Ig
Serum samples for IgM, IgG, and IgA will be obtained at screening and throughout the study at the 
time points specified in Appendix A; testing will be performed at the central laboratory .
9.5.14 Biomarker, Pharmacodynamic, and PK Samples
Samples are collected by [CONTACT_4160] 
(Appendix A) for the m easurement of serum concentrations of TAK- 079 and bio marker 
assessments. Samples will be tested at a central laboratory.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 63of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL9.5.14.1 Prima ry Specimen Collection
Table 9.b Primary Specimen Collection
Specimen Name [CONTACT_4237]19+ counts Mandatory a
Blood sample for pharmacodynamics Blood Pharmacodynamic (changes in 
CD38+ cells) Mandatory
Blood sample for immunoprofiling Blood Broad immune cell changes Mandatory
Serum sample for circulating 
biomarkersSerum Biomarker measurements Mandatory
Serum sample for quantitative 
IgA/IgM/IgGSerum Ig measurements Mandatory
Serum sample for immunogenicity 
assessmentsSerum Immunogenicity assessments Mandatory
Serum sample for TAK -079 PK Serum PK measurements Mandatory
Serum sample for vaccine -induced 
protective antibodiesSerum Vaccine -induced protective 
antibodiesMandatory
Serum sample for HBV, HCV, and 
HIVSerum Study eligibility Mandatory
Blood sample for HCV RNA PCR Blood Study eligibility Mandatory b
HBV: hepatitis B virus; HCV: hepatitis C virus; Ig: immunoglobulin; PCR: polymerase chain reaction; PK: 
pharmacokinetics.
aCD19 evaluation to be performed only in patients with prior exposure to rituximab.
bTo be performed only for patients who have received curative treatment for prior chronic HCV infection.
9.5.[ADDRESS_3863] or AEs. 
Details regarding the preparation, handling, and shippi[INVESTIGATOR_4065].
9.5.16 Pharmacodynamic/Biomarker Measurements
In thi s study , several  biomarkers will be assessed to test for correlat ion with safet y, PK, and, if 
possible, with efficacy. These bio markers will be used to identify patients who have a higher 
probabilit y of response or adverse reactions to TAK -079. The bio marker sample analysis will be 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3864] igator, a blood 
draw shoul d be perform ed for central  evaluat ion that coul d include, but i s not limit ed to, immune 
markers and cytokine markers. Further details are provided in the laboratory  manual.
[IP_ADDRESS] Autoantibodies
Serum  samples will be co llected to detect anti- AChR and anti -MuSK ant ibodies as outlined in 
Appendix Aand analyzed by a central laboratory . 
[IP_ADDRESS] Pharmacodynamics
Blood sam ples will be collected to analyze CD38+ expressio n and m onitor changes in immune 
cells by [CONTACT_4161], during, and at the end of treatment. These evaluations will be 
perform ed at a central  laboratory . 
[IP_ADDRESS] Circulating Biomarkers
Serum  samples for cy tokines/chemokines will be collected before, during, and at the end of 
treatm ent to hel p identify pat ients who have a higher probabilit y of response or of experiencing 
adverse reactions to TAK -079.
[IP_ADDRESS] Immunoprofiling
Blood sam ples for immunoprofiling will be collected for profiling of immune cells before, during, 
and at the end of treatmen t. These blood samples will be analyzed for the presence and changes o f 
immune cells by [CONTACT_4162] w or m ass cy tometry. 
[IP_ADDRESS] Vaccine -Induced Protective Antibodies
Serum  samples for vaccine -induced protective ant ibodies (measles, mumps, rubella, tetanus, and 
diphtheria ) will  be collected before, during, and at the end of treatment. 
9.5.17 Immunogenicity Sample Collection
Serum  samples for the measurement of ant i–TAK -079 antibody  (anti drug ant ibody  and ADA are 
exchangeable terms in this protocol) will be co llected at mult iple time po ints as specified in the 
SOE in Appendix A
.
The samples must be taken before each dosing. Details regarding the preparation, handling, and 
shippi [INVESTIGATOR_4066] y samples are provided in the laboratory  manual . Posi tive ADA 
screening samples will be further tested for true posit ivity and titer by [CONTACT_4163].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 65of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL9.6 End of Safety Follow -up Assessments
End of SFP clinical parameters, as outlined in Table 9.c, will be assessed at Week 16 of the SFP 
(see SOE in
 Appendix A). If clinical  presentati on and parameters do not meet the end of SFP 
criteria, and are deemed by [CONTACT_458] [INVESTIGATOR_4067], the study -related parameters 
not m eeting end -of-study  criteria will  cont inue to be assessed in the LFP unt il they normalize or 
return to baseline. 
Table 9.c End of Safety Follow -Up Period Clinical Parameters
Safety Parameter Laboratory 
Investigations End-of-Study Criteria Continuation to Long -term Follow -up
Neutrophils ≥LLN or ≥study baseline levels, 
or abnormal levels that are not 
directly related to dosing of 
investigational product.<LLN and <study baseline levels that are 
directly related to dosing of investigational 
product.Platelets
Total ly mphocy te count
Hgb
IgG, IgA, and IgM levels 
Events of clinical interest
TAK -079–related 
hypersensitivity reaction (IRR, 
allergic reaction, or anaphylaxis) 
(See Section 8.6.1 ).Clinical symptoms related to 
hypersensitivity reaction 
resolved.Clinical symptoms related to hypersensitivity 
reaction o ngoing.
TAK -079-related CRS (See 
Section 8.6.2 ).Clinical symptoms related to 
CRS reaction resolved.Clinical symptoms related to CRS reaction 
ongoing.
Systemic infection Any ≥Grade 2 asystemic infection that is not 
resolved.
CRS: cytokine release syndrome; CTCAE: Common Terminology Criteria for Adverse Events; Hgb: hemoglobin; Ig: 
immunoglobulin; IRR: infusion -related reaction; LLN: lower limit of normal; NCI: National Cancer Institute. 
aLaboratory an d infection grading are based on NCI CTCAE v4.03 .
9.7 Completion of Study Treatment (for Individual Patients)
Patients will  be considered to have completed study  treatm ent once they  have com pleted the 
8-week dosing period.
9.8 Completion of Study (for Individual Patients)
A pat ient will be considered to have completed the study  once they  have co mpleted the dosing 
period and at com pletion of  the Week 20 or Week 32 end -of-study  visit of the LFP (for patients 
rando mized to placebo or TAK -079, respect ively). 
9.[ADDRESS_3865] be permanent ly discontinued for patients meet ing any o f the following criteria:
Withdrawal by [CONTACT_4164].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 66of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALPregnancy.
Treatment with study  drug m ay also be discont inued for any o f the follow ing reasons:
AE/SAE.
Protocol  deviat ion. 
Symptom atic deteri oration. 
Unsat isfactory  therapeuti c response. 
Study  terminated by  [CONTACT_3211].
Lost to follow -up.
Other.
Once study drug has been discont inued, all study procedures outlined for the end -of-treatm entvisit 
will be co mpleted as specified in the SOE in Appendix A. The primary  reason for study  drug 
discontinuat ion will  be recorded on the eCRF.
In addit ion, study  drug shoul d also be discont inued if the patient meets the criteria outlined in 
Secti on 8.4.1 .
9.10 Withdrawal of Patients From Study
A pat ient will be wi thdrawn from  the study  for any of the fo llowing reasons:
Death.
Study  terminated by  [CONTACT_3211].
Withdrawal by [CONTACT_4164].
Lost to follow -up.
Other.
The conseq uence of a patient withdrawing consent fro m further treatment and fo llow
-up is that no 
new inf ormation will be co llected fro m the withdrawn pat ient and added to the exist ing data or any 
database. However, every  effort will be m ade to foll ow all pat ients for safet y. Data collected 
during patient consent, however, must be included in the database.
9.11 Study Compliance
TAK -079/pl acebo will be administered or dispensed only to eligible patients under the supervisio n 
of the invest igator or ident ified subinvest igator(s). The appropriate study  personnel will maintain 
records of study  drug recei pt and di spensing.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 67of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL9.12 Coronavirus Disease 2019–Related Procedural Changes
The following informat ion provides guidance regarding changes to the study procedures that could 
be implemented for study  partici pants or study  sites affected by  [CONTACT_4165] 2019 
(COVID -19) public health emergency. This guidance takes references fro m the Food and Drug 
Associ ation (FDA) Guidance on Conduct of Clinical Trials of Medical Products during 
COVID -[ADDRESS_3866] itutional 
Review Boards, March 2020, updated 04 December 2020, and the European Medicines Agency 
(EMA) Gui dance on the Management of Clinical Trials During the COVID -19 (Coronavirus) 
Pandemic, Version 3 (28 April 2020).
As the COVID -[ADDRESS_3867] igator in consultat ion with the study 
team  and the m edical team  as needed, while maintaining patient safet y and confident iality as the 
priori ty.
Procedural  changes due to COVID -19 may include the fo llowing:
Inform ed consent procedure: If necessary, informed consent fro m a potenti al or current tri al 
participant m aybe obtained via electronic informed consent capabilit ies, or an electronic 
face-to-face consent interview when these individuals are unable to travel to the site.
During the COVID -19 public healt h emergency, remote visits may be conducted by [CONTACT_648] (eg, 
collection of AEs and safet y mo nitoring), video conferencing (Telehealt h with the physician or 
Telemedicine or other plat form acceptable to the physician and pat ient) or site staff visit ing the 
participant’s residence. Local visits and Telemedicine must comp ly wi th national and local 
laws and regulations. The ty pe of al ternative visi t must be recorded on the eCRF. The 
investigator may  use thei r judgement to determine the appropriateness of a remote visit as an 
alternat ive visit in advance (for example, if no significant issues arise that may  necessitate a 
hands -on physical exam).
“Remote visits” via virtual communicat ions may be perform ed as a safet y check on the 
patient’s well -being.
For hom e heal thcare visi ts, collect ion of clinical laboratory  samples (bl oodspecimen 
collect ion or other diagnost ic tests) may be performed by [CONTACT_093], qualified site staff or 
qualified ho me healt hcare provider who can visit the study participant’s residence. These may 
be obtained the day  before a scheduled visit (see Appendix A).
ECG procedures: For home healt hcare visits, ECGs may be performed by a qualified health 
care professio nal who is authorized/cert ified to perfo rm such tests routinely .
Patient visi ts at screening, Weeks [ADDRESS_3868] be done with the patient 
present at the investigative site. Other visits may be conducted at the clinic or by [CONTACT_4166] (or a hybrid of Telehe alth/Telemedi cine wi th home healt hcare) to extend 
flexibilit y to pati ents during COVID -19 public healt h emergency . Hom e heal thcare visit s will 
be documented in the study records and eCRF. As per the investigator’s judgment, if there are 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 68of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALno concerns raised by [CONTACT_4167] -directed physical , vital signs measurements will not be 
requi red to be co llected at the Week14 visit during the COVID- 19 pandemic. QMG, MGC and 
the physician examinat ion porti on of  MGII m ay be omitted if performing a remote visit. 
For possi ble dosing visit s at hom e, the invest igator or qualified site staff must evaluate the 
patient ei ther rem otely  or at the pati ent’s residence pri or to dose administration. A patient 
shoul d have previ ously  received 4 doses of study  drug at the clinic site unl ess otherwi se 
approved by [CONTACT_456]. Safet y parameters for dosing decisio ns (Table 8.d) mu st be evaluated 
as in a regular in -clinic visit. Dose administ ration must be performed by a qualified healt hcare 
provi der.
Safety labs (eg, complete blood count, chemistry , liver funct ion tests) may be obtained at a 
clinic local to the patient’s ho me with sponsor approval.
Deviat ions from  the protocol -specified proce dures will be recorded as related to COVID -19.
The assessment of forced vital capacit y for the QMG test may be omitted for 
COVID -
19-related reasons.
Patients who discont inued fro m screening due to COVID -19–
related factors but were 
otherwi se qualified to pa rticipate in the trial may  be rescreened if the sponsor’s clinician 
agrees.
Missed or delayed clinic visits or subject withdrawals due to COVID -[ADDRESS_3869] be recorded on 
the eCRF.
Withdrawal: If a patient chooses to withdraw from study participat ion due to pe rsonal  concerns 
related to the COVID -19 pandemic (other than a COVID -19–
related AE), this should be 
specified as the reason for patient withdrawal in the eCRF.
10.0 ADVERSE EVENTS
10.1 Definitions
10.1.1 Pretreatment Event Definition
A pretreatment event (PTE) is any untoward m edical  occurrence in a patient who has signed 
inform ed consent to participate in a study  but before administration of any  study  medicati on; it 
does not necessarily  have to have a causal relat ionship wit h study  parti cipat ion.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3870]; 
the untoward medical occurrence does not necessarily have a causal relat ionship with this 
treatm ent.
An AE can therefore be any unfavorable and unint ended sign (including an abnorm al laboratory  
finding), symptom, or disease temporally  associated wi th the use of a m edicinal  (invest igational) 
product whether or not it is related to the medicinal product.
An untoward finding generally may:
Indicate a new diagnosis or unexpect ed worsening of a preexist ing condit ion. (Intermittent 
events for preexist ing condit ions or underlying disease should not be considered PTEs or 
AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Be considered unfavorable by [CONTACT_4168].
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (includi ng 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as a PTE(s) or an AE(s).
Laboratory  values and ECG findings:
Changes in l aboratory  values or ECG param eters maybe considered AEs if they are judged to 
be clinically  significant, i e, if som e acti on or intervent ion is required or if the investigator 
judges the change to be beyo nd the range of normal physio logic fluctuation. A lab oratory  retest 
and/or continued mo nitoring of an abnormal value are not considered an intervent ion. In 
addition, repeated or addit ional noninvasive testing for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as an AE.
Preexist ing condit ions:
A preexist ing c ondition (present at the time of signing of informed con sent) i s consi dered a 
concurrent medical history condit ion and should NOT be recorded as a PTE or AE. A baseline 
evaluat ion (eg, laboratory test, ECG, x -ray) should NOT be recorded as a PTE unless rel ated to 
a study  procedure. However, if the patient experiences a worsening or complicat ion of such a 
concurrent medical history  condi tion, the worsening or complicat ion should be recorded 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 70of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALappropriately  as a PTE (worsening or complicat ion occurs before star t of study medicat ion) or 
an AE (worsening or complicat ion occurs after start of study medicat ion). Investigators should 
ensure that the event term recorded captures the change in the condit ion, eg, “worsening of…”.
If a patient has a preexist ing epi[INVESTIGATOR_4068] (eg, asthma, epi[INVESTIGATOR_002]), any occurrence of an 
epi[INVESTIGATOR_4069]/AE if the epi[INVESTIGATOR_4070], serious, 
or severe in nature; that is, invest igators should ensure that the AE term recorded captures the 
change from baseline in the condit ion, eg “worsening of…”.
If a patient has a degenerat ive concurrent condit ion (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion shoul d only  be captured as a PTE/AE if occurring to a greater 
extent than that which would be expected. Again, investigators should ensure that the AE term 
recorded captures the change in the condit ion, eg, “worsening o f…”.
Worsening of AEs:
If the pat ient experiences a worsening or complicatio n of a PTE after the first administration of 
study  medicat ion or a worsening or complicat ion of an AE after any change in study 
medicat ion, the worsening or complicat ion should be recorded as a new AE. Investigators 
shoul d ensure that the AE term recorded captures the change in the condit ion, eg, “worsenin g 
of…”.
Changes in severit y of AEs:
If the patient exper iences a change in the severit y of an AE that is not associated with a change 
in study  medicati on, the event shoul d be captured once with the maximum severit y recorded.
Prepl anned surgeries or procedu res:
Prepl anned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled before signing of informed 
consent are not considered AEs. However, if a preplanned procedure is performed early (eg, as 
an emergency) because of worsening of the preexisting condit ion, the worsening o f the 
condi tion shoul d be captured appr opriately  as an AE. Com plicat ions result ing from any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the pat ient’s medical condit ion 
shoul d not be recorded as AEs but should be documented in the patient’s source documents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a stud y patient, at a dose above that which is assigned to that individual pat ient 
according to the study  protocol . 
All cases of overdose (with or without associated AEs) are to be documented on the Overdose 
page of the eCRF to capture this important safet y info rmation consistent ly in t he database. AEs 
associ ated wi th an overdose will be documented on the AE CRF(s) according to Section 10.5.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 71of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALSAEs of overdose should be reported according to the procedure outlined in Sect ion 10.2.
If an overdose does occur, close monitoring and supportive tr eatment as medically required.
10.1.[ADDRESS_3871] medical occurrence that at any  dose:
Results in death.
Is life -threatening (refers to an AE in which the patient was at risk of death at the time of the 
event. It does not refer to an eve nt which hypothetically might have caused death if it were 
more severe).
Requi res inpat ienthospi [INVESTIGATOR_4071].
Results in persistent or significant disabilit y or incapaci ty.
Is a congenital ano maly/birth defect.
Is a m edically important event that satisfies any  of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the pati ent to danger, even though the event is not immediately  
life-threatening or fatal  or does not result in hos pi[INVESTIGATOR_3094].
Includes any event or synonym described in the [COMPANY_005] Medically  Significant AE List 
(Table 10.a).
Table 10.
a [COMPANY_005] Medically Significant Adverse Event List
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_4072]/ventricular fibrillation/ventricular 
tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by a 
medicinal productToxic epi[INVESTIGATOR_194]/Stevens -Johnson 
syndrome Neuroleptic malignant syndrome/malignant hyperthermia
Spontaneous abortion/stillbirth and fetal death
Note: Some clinical centers may only be able to provide certain rescue therapi [INVESTIGATOR_014] (eg, IVIg) via 
inpat ient hospi [INVESTIGATOR_3094]. Therefore, the hospi[INVESTIGATOR_4073] n itself (in an otherwise clinically 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 72of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALstable patient) specifically  for access and administrati on of  rescue therapy  does not count 
autom atically as an SAE, unless there are other ci rcumstances that fulfill SAE criteria.
AEs that fulfill [ADDRESS_3872] ive 27 November 2017 [47]. Use of the CTCAE criteria scale is aligned with the 
internat ional consensus guidance for the management of MG [48] which is supported by [CONTACT_4169] (aan/Guidelines/home/Gui delineDetail/823 Accessed 21 Aug 
2019) and the My asthenia Gravis Foundat ion of America 
(myastheniagravisnews/2018/02/01/panel -of-myasthenia -gravis -experts -propose -guidelines -for-
t
reatm ent-and-care/ Accessed 21 Aug 2019). Especially at lower grades of toxic ity, laboratory  
param eters are similar between the CTCAE and WHO toxicit y criteria; note in this study  the 
thresho ld for holding study  drug is at a l ow grade (see Table 8.d), therefore either scale could be 
applicable. The CTCAE criteria, however, also allo ws for more precise grading of severit y of AEs 
reported with bio logics such as infect ions and infusion related reactions (hypersensit ivity and 
anaphylaxi s) as co mpared to the WHO toxicit y grading scale where criterion for these are lacking. 
In addit ion, the CTCAE criteria has very thorough criteria for Neuro and Neuromuscular AEs 
which again is quite sparse in the WHO criteria. For these reasons, rather th an try to use 2 separate 
scales, the CTCAE criteria will be used in this study.
Clarificat ion should be made between an SAE and an AE that is considered severe in intensit y 
(Grade 3 or 4) because the terms serious and severe are NOT synonymous. The general term 
severe is often used to describe the intensit y (severity ) of a specific event; the event itself, however, 
may be of relat ively minor medical significance (such as a Grade 3 headache). This is NOT the 
same as serious , which is based on patient/event o utcome or action criteria described above and is 
usually associated with events that pose a threat to a patient’s life or abilit y to funct ion. A severe 
AE (Grade 3 or 4) does not necessarily need to be considered serious. For example, a white blood 
cell co unt of 1000/mm3to less than 2000/mm3is considered Grade 3 (severe) but may not be 
considered serious. Seriousness (not intensit y) serves as a gui de for defining regul atory  reporting 
obligat ions.
10.2 Procedures for Recording and Reporting AEs and SAEs
All AEs spontaneously reported by  [CONTACT_4170] m study  
personnel or revealed by [CONTACT_4171], physical examinat ion, or other diagnostic procedures will be 
recorded on the appropriate page of the eCRF (see Section 10.3 for the period of observat ion). Any 
clinically relevant deterioration in laboratory assessments or other clinical finding is considered an 
AE. When possible, signs and symptoms indicating a commo n underlying patho logy shoul d be 
noted as a single comprehen sive event.
Regardless of causalit y, SAEs must be reported (see Section
 10.3 for the period of observat ion) by 
[CONTACT_4172] 24 hours 
of beco ming aware of the event. This will be done by [CONTACT_4173] (EDC) 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 73of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALSAE report. If transmissio n of an EDC SAE report is not feasible within 24 hours, then a facsimile 
of the co mpleted [COMPANY_005] paper -based SAE form should be sent (please see fax numbers below). In 
case of fax, site personnel need to confirm successful transmissio n of all pages and include an 
email address on the fax cover sheet so that an acknowledgment of recei pt can be returned via 
e-mail wit hin [ADDRESS_3873] listed as 
follows:
SAE Reporting Contact [CONTACT_4174]- free fax #: 1-800- 963-[ADDRESS_3874] of World fax#: +1 -[PHONE_066]
Email: [EMAIL_039]
If informat ion not available at the time of the first report becomes available at a later date, then the 
investigator will transmit a fo llow-up EDC SAE report (or a paper -based SAE form if an EDC 
SAE report is not feasi ble) or provide other documentation immediately wit hin 24 hours of receipt. 
Copi [INVESTIGATOR_4074] (eg, ECGs, l aboratory  tests, di scharge 
summary, postmortem results) should be sent to the addressee, if requested.
All SAEs shou ld be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
Planned hospi[INVESTIGATOR_4075]; eg, surgery  was perform ed earlier or l ater than planned.
For both serious and nonserious AEs, the invest igator m ust determine both the severit y (toxi city 
grade) of the event and the relat ionship of the event to study drug administration. 
Severit y (toxicit y grade) for each AE, including any lab abnormalit y, will be determined using the 
NCI CTCAE, versio n 4.03, effect ive 27 November 2017 [47]. 
Relationship of the event to study  drug administratio n (ie, its causali ty) will be determined by  [CONTACT_4175] y es (rel ated) or no (unrelated) to this quest ion: Is there a reasonable 
possibilit y that the AE is associated with the study  drug?
10.3 Monitoring of AEs and Period of Observation
AEs, both nonserious and serious, will be mo nitored throughout the study  as fo llows: 
AEs will be reported fro m the signing of informed consent through the SFP and recorded in the 
eCRF. AEs ongoi ng at the Week 16 visit of the SFP should be monitored through the LFP until 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 74of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALthey are reso lved, return to baseline, or are clearly determined to be due to a patient’s stable or 
chronic condit ion or intercurrent illness(es). Study -drug related AEs/SAEs with onset after the 
SFP will be co llected through the LFP.
SAEs will be reported to the [COMPANY_005] Global Pharmacovigilance department or designee from 
the signing of informed consent through the SFP and recorded in the eCRF. After this period, 
during the LFP, on ly related SAEs must be reported to the [COMPANY_005] Global Pharmacovigilance 
departm ent or desi gnee. SAEs shoul d be m onitored until they  are resolved or are clearly 
determined to be due to a patient’s stable or chronic condit ion or intercurrent illness(es).
10.[ADDRESS_3875] be fo llowed for the final 
pregnancy outcome.
If a female partner of a male patient becomes pre gnant during the male pat ient’s participat ion in 
this study , the sponsor m ust also be contact[CONTACT_4176] a com pleted pregnancy  
form to the [COMPANY_005] Global Pharmacovigilance department or designee. Every  effort shoul d be 
made to fo llow the pregn ancy for the final pregnancy  outcom e.
10.5 Procedures for Reporting Including Overdose
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF to capture this important safet y informat ion consistent ly in the dat abase. AEs 
associ ated wi th an overdose will be documented on the AE eCRF. SAEs of overdose should be 
reported according to the procedure outlined in Section 10.2.
10.[ADDRESS_3876] ions 
(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory  authori ties, inve stigators, and IRBs and 
IECs, as applicable, in accordance with nat ional regulat ions in the countries where the study  is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the sponsor or 
sponsor’s designee, S[LOCATION_003]Rs will be su bmitted to the regulatory  authori ties as expedi ted reports 
within [ADDRESS_3877]’s administration or in the over all conduct of the study . The 
investigat ional site also will forward a copy  of all expedited reports to his or her IRB or IEC in 
accordance with nat ional regulat ions. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3878] (DSMB) should be convened. Applicable 
regul ation and guidance (including the guidance set forth by [CONTACT_4177]: Establis hment and Operation of Clinical Trial Data 
Moni toring Committees, fda.gov/downloads/Regulatory Informat ion/Guidances/ucm127073.pdf, 
Accessed 24 July 2019) are used to evaluate each trial in terms of potential confounding factors 
that complicate evaluation o f the study safet y and/or efficacy data, and potential ris ks of the study 
design or treatment to study  parti cipants.
A DSMB is not indicated at this time for this study given that [COMPANY_005]’s standards and processes, 
which include cont inuous review and evaluati on of safet y data reported from all part icipating sites 
through the conduct of the study , are appropri ate for the ongoing m onitoring of pat ient safet y and 
data integrit y (see Sect ion 6.2). However, the decisio n to convene a DSMB could be made at any  
time during the conduct of Study  TAK -079-1005.
Though a formal DSMB will not be formed, internal reviews of available safet y information will 
be conducte d. Key  safety data will be reviewed and evaluated by  [CONTACT_4178](s). The sponsor representatives will make decisio ns 
regarding dosing and/or scheduling, which will be discussed with invest igators for de cision for 
alignment.
12.0 DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_4076] o f procedures for data handling will be documented in the data management plan. 
If selected for coding, AEs, medical history , and concurrent condit ions will be coded using the 
MedDRA. Drugs will be coded using the World Health Organizat ion (WHO) Drug Dict ionary.
12.[ADDRESS_3879] complete eCRFs in Englis h.
After complet ion of the entry  process, com puter l ogic checks will be run to ident ify items such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_1748] (or designee) and will be answered by  [CONTACT_4179].
Any change of, m odificat ion of, or addit ion to the data on the eCRFs should be made by [CONTACT_4180]. Corrections to eCRFs are recorded in an audit trail that 
captures the old informat ion, the new information, ident ificat ion ofthe person making the 
correcti on, the date the correction w as made, and the reason for the change.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3880] retain 
full responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by [CONTACT_4181]. The sponsor (or designee) will be permitted to review the pat ient’s medical and 
hospi [INVESTIGATOR_4077]. The co mpleted eCRFs are 
the sole property  of the sponsor and should not be made available in any form to third parties , 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
12.[ADDRESS_3881] igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing patients, medical records, temporary med ia such as thermal -sensit ive paper, source 
worksheets, all original signed and dated ICFs, patient authorizat ion forms regarding the use of 
personal healt h informat ion (if separate from the ICFs), electronic copi[INVESTIGATOR_4078], and d etailed records of drug disposit ion to enable evaluat ions or audits from regulatory 
authori ties and the sponsor (or designees). Any  source docum entati on printed on degradable 
thermal-sensit ive paper should be photocopi[INVESTIGATOR_4079]’s chart to ensure long -term legibili ty. Furtherm ore, ICH E6 Section 4.9.5 requires the 
investigator to retain essent ial documents specified in ICH E6 (Secti on 8) until at least [ADDRESS_3882] igator and sponsor.
Refer to the clinical study  site agreement for the sponsor’s requirements for record retention. The 
investigator should contact [CONTACT_4182] m the sponsor before disposing of any 
such documents.
13.[ADDRESS_3883] ives.
13.1.1 Analysis Sets
Full analysis set : all enrolled patients. In efficacy analyses, only pat ients with both baseline and at 
least 1 valid postbaseline value will be included. 
Safety analysis set : patients who have received at least 1 dose of study  drug. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 77of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALPK analysis set : pati ents who have received at least [ADDRESS_3884] 1 measur able 
TAK -079 serum  concentrati on.
Pharmacodynamic analysis set : pati ents who have a baseline and at least 1 postbaseline sample 
assessment. 
Immunogenicity analysis set : patients fro m the safet y populat ion who have a baseline and at least 
[ADDRESS_3885] ics will be summarized descript ively. Variables to be 
analyzed include sex, age, race, medical history , prior m edicat ions/therapi[INVESTIGATOR_014], ECG findings, and 
other parameters as appropriate. For continuous variables, descriptive statist ics (number, mean, 
standard deviat ion, median, minimum, and maximum) will be provided. For categorical variables, 
patient counts and percentages w ill be provided. Categories for missing data will be presented as 
needed.
13.1.3 Efficacy Analysis
Efficacy is not the primary endpoint for this study . Secondary  efficacy  measures will  include:
Score change fro m baseline for the fo llowing:
–MG-ADL score
–QMG score
–MGC score
Change from baseline in ant i-AChR antibody  or anti -MuSK ant ibody  levels.
Percentage of patients meet ing minimal clinically important difference criteria in the 
respective MG clinical impairment scales (MG -
ADL, QMG, MGC).
Exploratory  efficacy measures will include: 
Score change fro m baseline in the MGII score.
Durati on of  a clinically meaningful effect on MG disease severit y (in all the clinical disease 
impairment scales: MG -ADL, QMG, MGC, MGII). 
Percentage of patients me eting minimal clinically important difference criteria in the MGII 
scale. 
Frequency and proportion of pat ients requi ring rescue therapy
Efficacy endpo ints will be summarized by [CONTACT_4183]. 
Where appropriate, ef ficacy endpo ints may be analyzed wit h the fo llowing methods:
Binary endpo ints will be analyzed using a Fisher’s exact test.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 78of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALChange from baseline endpo ints measured repeatedly  over time will  be analyzed using a 
mixed -model repeated -measures analysis, which includes treatment, visit, and 
(treatment ×visit) interaction terms as the factors, with baseline values as covariates. 
All tests of treatment effects will be conducted at a 2 -sided α l evel of 0.05, and 95% CIs for the 
differences in proportions and leas t squares means will be provided. No inferent ial hypothesis was 
tested in these endpo ints, so CIs and p- values are not adjusted for mult iplicit y.
All efficacy analyses will be performed using the full analysis set.
13.1.[ADDRESS_3886] 
dose, and half -life may be reported. A populat ion PK m odel may be devel oped. If  devel oped, the 
popul ation PK model will be reported separately. PK/pharmacodynamic analyses of selected 
pharmacodynamic and/or efficacy measures may be conducted as data permit. Any population 
PK/pharmacodynamic analysis if conducted will be reported separately.
13.1.5 Immunogenicity Analyses 
TAK -079 immunogenicit y status (ADA incidence) will be analyzed and summarized using 
descript ive statistics, as applicable, and using the immunogenicit y analysis set. The effect of 
immunogenicit y on PK, pharm acodynamics, safety , and efficacy may be explored. 
Immunogenicit y analyses will be based on available data from pat ients with a baseline assessment 
and at least 1 postbaseline immunogenicit y assessment. 
13.1.6 Safety Analysis
Safety will be evaluated by [CONTACT_4118], severit y and ty pes of AEs, and by [CONTACT_4184] m 
baseline in pat ients’ vital signs, weight, and clinical laboratory results using the safet y analysis set. 
Exposure to study  drug and reasons for discont inuation will be tabulated. 
TEAEs that occur after administration of the fi rst dose of study  drug and through the end of the 
SFP peri od will be tabulated. 
AEs will be tabulated according to the MedDRA, and data will be summarized using Preferred 
Term  and primary  System  Organ Class. All safety  analyses will  be perform ed using the safet y 
analysis population.
In thi s study , Grade [ADDRESS_3887] 12 safet y
-evaluable pat ients and then every 12 safet y-evaluable patients. If the stoppi[INVESTIGATOR_4080] ≥3/12, and ≥5/[ADDRESS_3888] been achieved, accrual to the study will be suspended to allow for 
a blinded investigation o f the safet y profile. After consideration by  [CONTACT_2362] , which coul d 
include the safet y management team as appropriate, especially if case unblinding is necess ary, a 
decisio n will be made as to whether accrual can be resumed. The AE grading limits are based on 
the International Consensus Guidelines for the Management of Myasthenia Gravis where the aim 
is no more than grade 1 CTCAE medicat ion side effects [48]. The statist ical bounds are based on a 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 79of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALBayesian strategy  to m onitor outcom es in clinical tri als. If the stoppi[INVESTIGATOR_4081], there is 80% 
probabilit y that the true toxicit y rate i s greater than 10% with a prior beta distribut ion with 
param eters 0.2 and 1 .8 for the bino mially distributed toxicit y rate [49].
[COMPANY_005] clinicians will conduct reviews of SAEs and related clinical parameters to ensure 
consistency wit h an acceptable benefit -risk rati o throughout the study . If >[ADDRESS_3889] igation by [CONTACT_4185] y management team  as noted above; after which a decision will be 
made to whether accrual can be resumed.
13.2 Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
13.3 Determination of Sample Size
Approximately 36 pat ients are planned to be random ized to treatm ent in a ratio of 1:1:1 (TAK -[ADDRESS_3890] acebo). Thi s study is exploratory  and not powered to address any 
predefined hypothesis. 
14.[ADDRESS_3891] itution guarantee access to source documents by  [CONTACT_3210] i ts 
designee (CRO) and by  [CONTACT_4186].
In the event a monitor cannot visit the site in a timely manner due to the COVID -[ADDRESS_3892] 
may be used to ensure data qualit y and integri ty and maintain pat ient safet y. Alternative 
monitoring approaches should be used only  where all owed by  [CONTACT_4187]/IEC.
All aspects of the study and its documentation will be subject to review by [CONTACT_4188], but not limited to, the investigator’s binder, study  medicat ion, pati ent m edical  records, 
inform ed consent docum entati on, docum entati on of  patient authorization to use personal health 
inform ation (if separate fro m the ICFs), and eCRFs and associated source documents. It is 
important that the invest igator and other study personnel are available during the monitoring visit s 
and that sufficient time is devoted to the process.
14.[ADDRESS_3893] ances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 80of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALdesignee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospective ly approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the patient’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB or EC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the healt h risk to the patient, or confound interpretation of the primary study 
assessment.
The sponsor will assess any protocol deviat ion; if it is likely to affect to a significant degree the 
safet y and ri ghts of  a pati ent or the reliabilit y and robustness o f the data generated, it may be 
reported to regulatory  authori ties as a seri ous breach of GCP and the protocol.
14.[ADDRESS_3894] the si te in advance to arrange an 
auditing visit. The audit or may ask to vi sit the f acilities where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by [CONTACT_4189], including 
those of foreign governments (eg, US FDA, the United Kingdo m [[LOCATION_006]] Medicines and Healthcare 
products Regulatory  Agency  [MHRA], the Pharmaceuticals and Medical Devices Agency of 
Japan [PMDA]). If the study  site is contact[CONTACT_4190] a regulatory  body, the sponsor 
shoul d be notified immediately. The invest igator and inst itution guarantee access for qualit y 
assurance auditors to all study  docum ents as described in Sect ion 14.1.
15.[ADDRESS_3895] for the individual participants (ie, patients) 
according to the protocol, the ethical principles that have their origin in t he Declarat ion of Helsinki, 
and the ICH Harmonized Tripartite Guideline for GCP. Each invest igator will conduct the study 
according to applicable local or regional regulatory requirements and align his or her conduct in 
accordance with the responsibilit iesof the investi gator that are listed in Appendix B. The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requirements for informed consent and invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require docum entati on noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Ame rican sites unwilling to provide names and tit les of all members 
because of privacy  and conflict of interest concerns should instead provide a Federalwide 
Assurance number or comparable number assigned by  [CONTACT_4191] h and Human 
Services.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 81of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALThesponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, a copy  of the ICF, and, if 
applicable, patient recruitment materials and advertisements and other documents required by [CONTACT_4192] a central or local IRB or IEC for approval. 
The IRB’s or IEC’s written approval o f the protocol and patient informed consent must be 
obtained and submitted to the sponsor or de signee before commencement of the study , ie, before 
shipment of the sponsor -supplied drug or study -specific screening act ivity. The IRB or IEC 
approval  must ref er to the study  by [CONTACT_4193], number, and versio n date; ident ify 
versio ns of othe r documents (eg, ICF) reviewed; and state the approval date. If required by [CONTACT_4194], approval from the co mpetent regulatory authorit y will be 
obtained before commencement of the study  or impl ementati on of  a substant ial amendment. The 
sponsor will ship drug once the sponsor has confirmed the adequacy o f site regul atory  
docum entati on and, when applicable, the sponsor has received permissio n from the com petent 
authori ty to begin the study . Unt il the site receives notificat ion, no protocol  activit ies, including 
screening, may  occur.
Sites m ust adhere to all requirements stipulated by  [CONTACT_4195]. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruit ment 
materials intended for viewing by  [CONTACT_1962], local safet y reporti ng requirements, reports and 
updates regarding the ongoing review of the study  at intervals specified by [CONTACT_4196], and submissio n of the invest igator’s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these i tems must be provi ded to the sponsor (or 
designee).
Patient incent ives should not exert undue influence for participation. Payments to patients must be 
approved by  [CONTACT_4197].
15.2 Patient Information, Informed Consent, and Patient Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, patient authorizat ion form (if applicable), and patient 
inform ation sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the patient’s personal and personal health informat ionfor purposes of conducting 
the study. The ICF and the patient informat ion sheet (if applicable) further explain the nature of the 
study , its obj ectives, and potential risks and benefit s, and the date informed consent is given. The 
ICF will detail the requ irements of the participant and the fact that he or she is free to withdraw at 
any time wit hout giving a reason and wit hout prejudice to his or her further medical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and, if applicable, the patient authorization form. The ICF, patient authorizat ion form (if 
applicable), and patient information sheet (if applicable) must be approved by [CONTACT_4198].
The ICF, patient authoriza tion form (if applicable), and patient informat ion sheet (if applicable) 
must be written in a language fully co mprehensible to the prospective pat ient. It is the 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3896] igator to explain the detailed elements of the ICF, patient author ization 
form (if applicable), and patient informat ion sheet (if applicable) to the patient. Information should 
be given in both oral and wr itten form whenever possible and in the manner deemed appropriate by 
[CONTACT_4186]. If the patient is not capable of rendering adequate written informed consent, the 
patient’s legally  acceptable representative may  provide such consent for the patient in accordance 
with applicable l aws and regul ations.
The patient, or the patient’s legally acceptable representative, must be given ample opportunity to 
(1) inquire about details of the study  and (2) deci de whether to participate in the study . If the 
patient, or the patient’s legally acceptable representative, determines that he or she will participate 
in the study , then the ICF and patient authorizat ion form  (if applicable) must be signed and dated 
by [CONTACT_102], or the patient’s legally acceptable representative, at the time of consent and before 
the pati ent enters into the study . The patient or the patient’s legally  accept able representative 
shoul d be instructed to si gn using thei r legal names, not ni cknames, using a ballpo int pen wi th 
either blue or black ink. The invest igator must also sign and date the ICF and patient authorizatio n 
(if applicable) at the time of consent and before the patient enters into the study; however, the 
sponsor may allow a designee of the invest igator to sign to the extent permitted by [CONTACT_1289].
Once signed, the original ICF, patient authorizat ion form (if applicable), and pat ient informat ion 
sheet (if applicable) will be stored in the investigator’s site file. The investigator must document 
the date the patient signs the informed consent in the patient’s medical record. Copi[INVESTIGATOR_4082], the si gned patient authorizat ion form (if appl icable), and pat ient information sheet (if 
applicable) shall be given to the patient.
All revised ICFs must be reviewed and signed by [CONTACT_4199]’s legally 
acceptable representative in the same manner as the original informed consent. The date the 
revised consent was obtained should be recorded in the patient’s medical record, and the patient 
shoul d receive a copy  of the revised ICF.
15.3 Patient Confidentiality
The sponsor and designees affirm and upho ld the principle of the patien t’s right to protecti on 
against invasio n of privacy. Throughout this study , a pati ent’s source data will be linked to the 
sponsor’s clinical study  database or documentation only via a unique ident ificat ion number. As 
permitted by [CONTACT_4200], limited patient attributes, such as sex, age, or date 
of birth, and patient initials may be used to verify the pat ient and accuracy  of the pati ent’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance wit h this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, US FDA, [LOCATION_006] MHRA, Japan PMDA), the sponsor’s designated auditors, 
and the appropriate IRBs and IECs to rev iew the patient’s original medical records (source data or 
docum ents) including, but not limited to, laboratory test resul t reports, ECG reports, admissio n and 
discharge summaries for hospi[INVESTIGATOR_1684] a patient’s study  parti cipat ion, an d 
autopsy  reports. Access to a patient’s original medical records requires the specific authorizat ion 
of the pati ent as part of the informed consent process (see Section 15.2).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3897] certain 
ident ifying personal informat ion removed, eg, patient name, address, and other ident ifier fields not 
collected on the patient’s eCRF.
15.[ADDRESS_3898] igators or to regulatory  agencies, except as required by  
[CONTACT_4201]. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible webs ites) rel ated to the protocol  or study  resul ts, other 
than study  recrui tment m aterials and advert isements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by [CONTACT_3170]) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the clinical study  site agreement. In the event of any discrepancy between the 
protocol  and the clinical study  site agreement, the clinical study  site agreement will  prevail.
15.4.2 Clinical Study Registration
To ensure that i nform ation on clinical studies reaches the public in a timely manner and to comply 
with applicable laws, regulations, and guidance, [COMPANY_005] will, at a minimum, register intervent ional 
clinical studies it sponsors anywhere in the world on ClinicalTrials.gov or other publicly  
accessible websites on or before start of study , as defined by [CONTACT_4202]/standards. [COMPANY_005] 
contact [CONTACT_4203], along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing. 
As needed, [COMPANY_005] and invest igator/site contact [CONTACT_4204]. In certain situat ions/registries, [COMPANY_005] may assist 
participants or potential part icipant s in finding a clinical study  by [CONTACT_4205][INVESTIGATOR_4083] r homes by [CONTACT_4206], address, and phone number via 
email/phone or other methods preferred by  [CONTACT_4207]. Once pat ients 
receive invest igator contact [CONTACT_4203], they  may call the si te requesting enrollment into the 
study . The invest igative sites are encouraged to handle the study inquiries according to their 
established pat ient screening process. If the caller asks addit ional ques tions bey ond the topic of 
study  enrollment, they  shoul d be referred to the sponsor. 
Any invest igator who objects to [COMPANY_005] providing this informat ion to callers must provide [COMPANY_005] 
with a wri tten noti ce request ing that their informat ion not be listed on t he registry site. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3899] the results of clinical studies on ClinicalTrials.gov, and other publicly accessible 
websites (including the [COMPANY_005] corporate site) and registries, as required by [CONTACT_4208]/standards , applicable laws, and/or regulat ions. 
15.4.[ADDRESS_3900] addit ional scient ific research, which 
may be unrelated to the study  drug or the patient’s disease. The data provided to external 
researchers will not include informat ion that i dentifies pat ients personally.
15.[ADDRESS_3901] be insured in accordance with the regulat ions applicable to the site 
where the patient is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will ob tain clinical study  insurance against the risk o f injury to clinical study pat ients. 
Refer to the clinical study  site agreement regarding the sponsor’s policy on patient compensation 
and treatment for injury . If the invest igator has questions regarding thi s policy , he or she shoul d 
contact [CONTACT_4209]’s designee.
16.[ADDRESS_3902] 2016;26(1):41 -6.
2.Carr AS, Cardwell CR, McCarron PO, McConville J. A systemat ic review of populat ion based 
epi[INVESTIGATOR_4084]. BMC Neurol 2010;10:46.
3.Heldal AT, Ei de GE, Gilhus NE, Romi F. Geographical distribut ion of a seroposit ive 
myasthenia gravis popul ation. Muscle Nerve 2012;45(6):815- 9.
4.
Santos E, Coutinho E, Moreira I, Silva AM, Lopes D, Costa H, et al. Epi[INVESTIGATOR_4085]: Frequency est imates and clinical epi[INVESTIGATOR_4086]. Muscle Nerve 2016;54(3):413-21.
5.Ludwig RJ, Vanhoorelbeke K, Ley poldt F, Kaya Z, Bi eber K, McLachlan SM, et al. 
Mechanisms o f Autoantibody -Induced Pathology . Front Immuno l 2017;8:603.
6.Phillips WD, Vincent A. Pathogenesis o f myasthenia gravis: update on disease ty pes, m odels, 
and mechanisms. F1000Res 2016;5.
7.Gilhus NE. My asthenia Gravis. N Engl J Med 2016;375(26):2570-81.
8.Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory : clinical signposts 
and treatment strategies. Ther Adv Neuro l Disord 2018;11:1756285617749134.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 85of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL9.Kiessling P, Lledo -Garcia R, Watanabe S, Langdon G, Tran D, Bari M, et al. The FcRn 
inhibitor rozano lixizumab reduces human serum IgG concentration: A rando mized phase 1 
study . Sci Transl  Med 2017;9(414).
10.Howard JF , Jr., Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safet y and efficac y 
of eculizumab in anti -acetylcho line receptor antibody -positive refractory  generalised 
myasthenia gravis (REGAIN): a phase 3, randomised, double -blind, pl acebo -controlled , 
multicentre study . Lancet Neurol  2017;16(12):976-86.
11.Smithson G, Zal evsky  J, Korver W, Roepcke S, Zhao L. TAK -[ADDRESS_3903] ively mediates CD38+ cell depletion. J Immuno l 2017;198([ADDRESS_3904] ement):224.20.
12.Fujii Y, Monden Y, Hashimoto J, Nakahara K, Kawashima Y. Acetylcho line receptor antibody 
producti on by [CONTACT_4210] m arrow cells in a patient with myasthenia gravis. Neurology  
1985;35(4):577 -9.
13. Robeson KR, Kumar A, Keung B, DiCapua DB, Grodinsky E, Patwa HS, et al . Durabili ty of 
the rituximab response in acet ylcho line receptor autoantibody -positive myasthenia gravis. 
JAMA Neurol 2017;74(1):60-6.
14.Howard JF, Jr., Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Rando mized 
phase [ADDRESS_3905] efgarti gimod in generalized myasthenia gravis. Neurology  
2019;92(23):e2661- e73.
15.Fujii Y, Hashimoto J, Monden Y, Ito T, Nakahara K, Kawashima Y. Specific act ivation of 
lymphocy tes against acetylcholine receptor in the thymus in myasthenia gra vis. J Immuno l 
1986;136(3):887 -91.
16.Chapuy  CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for Delayed Red -Cell 
Engraft ment after Allogeneic Transplantation. N Engl J Med 2018;379(19):[ADDRESS_3906] -transplant autoimmune 
hemo lytic anemia: A pediatric case report. Blood 2016;128:4819.
18.Anand S, Miller D, Chipman G, Morris D, Srinivas T. Daratumumab for Severe Refractory  
Proliferat ive Glo merulo nephrit is with Monoclonal Immune Deposi ts (PGNMID). Am J 
Transplant 2017;17(suppl 3). B169.
19.Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et al. 
Second symposium on the definit ion and m anagement of anaphylaxis: summary  
report --Second National Inst itute of Al lergy and Infect ious Di sease/Food Allergy and 
Anaphylaxis Network symposium. J Allergy Clin Immuno l 2006;117(2):391 -7.
20.Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the 
diagnosis and m anagement of cy tokine releas e syndrom e. Bl ood 2014;124(2):188 -95.
21.Mankarious S, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA, et al. The half -lives of IgG 
subclasses and specific antibodies in pat ients with primary  immunodeficiency  who are 
receiving intravenously  administered i mmunoglobulin. J Lab Clin Med 1988;112(5):634 -40.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 86of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL22.Suzuki  T, Ishii -Watabe A, Tada M, Kobay ashi T, Kanayasu- Toyoda T, Kawanishi T, et al. 
Importance of neonatal FcR in regulat ing the serum half -life of therapeutic proteins containing 
the Fc dom ain of hum an IgG1: a comparat ive study o f the affinit y of mo noclonal antibodies 
and Fc -fusio n proteins to human neonatal FcR. J Immuno l 2010;184(4):1968 -76.
23.Darzal ex (daratum umab) injecti on. Prescribing Inform ation. Horsham , PA, US: Janssen 
Biotech, Inc., Revise d February  2019.
24.Regan DM, Markowitz MA. Mit igating the Ant i-CD38 Interference with Serology  Test ing. 
Advancing Transfusio n and Cellular Therapi[INVESTIGATOR_4087] #16 -02 
2016:1 -4.
25.Rituxan (ri tuximab) [package insert]. South San Franc isco, CA: Genentech, Inc., 2013.
26.Darzal ex (daratum umab) Prescribing Informat ion. Horsham, Pennsylvania: Janssen Biotech, 
Inc., 2017.
27.Ellis AK, Day  JH. Di agnosis and management of anaphylaxis. CMAJ 2003;169(4):307-11.
28.Delforge M, Ludwig H. How I manage the toxicit ies in myelo ma drugs. Blood (ASH Annual 
Meet ing Abstracts) 2017;129:2359 -67.
29.Lieberman P, Kemp SF, Oppenheimer J, Lang DM, Bernstein L, Nicklas RA, et al. The 
diagnosis and m anagement of anaphylaxis: an updated practice parameter. J Allergy Clin 
Immunol 2005;115([ADDRESS_3907] 2):S483-523.
30.Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy  G, Boum an-Thio E. Monocl onal 
antibody -induced cy tokine -release syndrome. Expert Rev Clin Immuno l 2009;5(5):499 -521.
31.RITUXAN (ri tuximab) [prescrib ing informat ion]. San Francisco, CA: Genentech, Inc., 2013.
32.Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine -release syndrome in 
patients with B -cell chronic lymphocyt ic leukemia and high lymphocyte counts after treatm ent 
with an an ti-CD20 m onocl onal antibody  (rituximab, IDEC -C2B8). Blood 
1999;94(7):2217 -24.
33.Rituxan (ri tuximab) inject ion. Prescribing Information. South San Francisco, CA, US: 
Genentech, Inc., Revised January 2019.
34.Chari  A, Mateos M, Van de Donk N, Kaufman J, M oreau P, Ori ol A, et al . Subcutaneous 
Daratum umab in Pat ients with Relapsed or Refractory  Mul tiple Myelo ma: Part 2 Safet y and 
Efficacy Update of the Open -Label, Mult icenter, Phase 1b Study  (PAVO). Bl ood 
2018;132(Suppl 1). 1995.
35.Wolfe GI, Herbelin L, Na tions SP, Foster B, Bry an WW, Barohn RJ. Myasthenia gravis 
activit ies o f daily living profile. Neurology  1999;52(7):[ADDRESS_3908]  M, Burns TM, Mg C, Mg -Qol15 Study G. MG -ADL: still a 
relevant outcom e measure. Muscle Nerve 2011;44 (5):727 -31.
37. Barnett C, Bril V, Kapral M, Kulkarni AV, Davis AM. Myasthenia Gravis Impairment Index: 
Responsiveness, meaningful change, and relat ive efficiency. Neuro logy 2017;89(23):2357 -64.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 87of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIAL38.Barnett C, Bril V, Kapral M, Kulkarni A, Davis AM. Develo pment and validat ion of the 
Myasthenia Gravis Impairment Index. Neurology  2016;87(9):879 -86.
39.Burns TM. The MG composite: an outcome measure for myasthenia gravis for use in clinical 
trials and every day pract ice. Ann N Y Acad Sci 2012;1274:[ADDRESS_3909]  M, Cutter G, Sanders DB, Burns TM, Group MGCM -QS. Psy chometric 
evaluat ion of the myasthenia gravis co mposite using Rasch analysis. Muscle Nerve 
2012;45(6):820 -5.
41.Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F, et al. Reco mmendat ions 
for myasthenia gravis clinical trials. Muscle Nerve 2012;45(6):909 -17.
42.Katzberg HD, Barnett C, Merkies IS, Bril V. Minimal clinically important difference in 
myasthenia gravis: outcomes fro m a rando mized trial. Muscle Nerve 2014;49(5):661 -5.
43.Barohn RJ, McInt ire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliabilit y testing of the 
quant itative myasthenia gravis score. Ann N Y Acad Sci 1998;841:[ADDRESS_3910] 
and concurrent validat ion of the MG -QOL15 in the practice setting. Muscle Nerve 
2010;41(2):219 -26.
45.Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, et al. International 
clinimetric evaluat ion of the MG -QOL15, result ing in slight revisio n and subsequent 
validat ion of the MG -QOL15r. Muscle Nerve 2016;54(6):1015-22.
46.Burns TM, Grouse CK, Wolfe GI, Conaway  MR, Sanders DB, Composite MG, et al. The 
MG-QOL15 for fo llowing the healt h-related qualit y of life of pat ients wit h myasthenia gravis. 
Muscle Nerve 2011;43(1):14-8.
47.Commo n Termino logy Criteria for Adverse Events (CTCAE), Version 4.03. U.S. Department  
of Heal th and Human Services National Cancer Institute. 14 June 2010.
48.Sanders DB, Wo lfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus 
guidance for m anagement of myasthenia gravis: Execut ive summary. Neuro logy 
2016;87(4):[ADDRESS_3911] ics in Medi cine 1998;17(14):1563 -80.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 88of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix ASchedule of Events
Study Proceduresa
Screen
ingTreatment Period Safety
Follow -up Period (SFP)Long -term
Follow -up Period (LFP) Period Length: 8 weeks
Week bDays 
-28 to 
-11 2 3 4 5 6 7 8 10 12 14 16 c20 d24 28 32
Window ±2 days ±2 days ±2 days
Informed consent eX
Eligibility criteria fX
Demographics X
Complete medical history, 
including prior therapyX
Complete physical examination X X X
Symptom -directed physical 
examination g X X X X X X X X X X X X X X
12-lead ECG hX X X X
Vital signs iX X X X X X X X X X X X X
Investigator predosing criteria 
assessmentX X X X X X X
Height (cm) X
Weight (kg) X X X X
Blood ty pe assessment X
Laboratory Assessments
Serum pregnancy test h X X X X
Urine pregnancy test h,j,mX X
Hematology h,k,mX X X X X X X X X X X X X X
Clinical chemistry h,k,mX X X X X
Direct/indirect Coombs test h,mX X X X
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 89of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix ASchedule of Events
Study Proceduresa
Screen
ingTreatment Period Safety
Follow -up Period (SFP)Long -term
Follow -up Period (LFP) Period Length: 8 weeks
Week bDays 
-28 to 
-11 2 3 4 5 6 7 8 10 12 14 16 c20 d24 28 32
Window ±2 days ±2 days ±2 days
T-cell interferon -γ release assay 
(TIGRA)X
Serum sample for anti -AChR or 
anti-MuSK antibodiesh,l,m X X X X X X X X X X X X X X X X X
Blood sample for immunoprofiling 
h,m X X X X X X
Blood sample for CD19 assay nX
Serum sample for circulating 
biomarkers h,m,o,p X X X X X X
Serum sample for quantitative 
IgA/IgM/IgGh,m,q X X X X X X X X X X X X X X X X X
Serum sample for TAK -079 PK h,m,pX X X X X X X X X X X X
Blood sample for 
pharmacodynamic biomarkers h,m X X X X X X
Serum sample for immunogenicity 
(eg, ADA) h,m X X X X X X X X X
Serum sample for vaccine -induced 
protective antibodies h, m X X X X X
Samples for HBV, HCV, and HIV 
assessmentX
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 90of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix ASchedule of Events
Study Proceduresa
Screen
ingTreatment Period Safety
Follow -up Period (SFP)Long -term
Follow -up Period (LFP) Period Length: 8 weeks
Week bDays 
-28 to 
-11 2 3 4 5 6 7 8 10 12 14 16 c20 d24 28 32
Window ±2 days ±2 days ±2 days
Disease Assessment tests h
MG-ADL score X X X X X X X X X X X X X
MGII score rX X X X X X X X X X X X
MGC score sX X X X X X X X X X X X
QMG score sX X X X X X X X X X X X
MG-QoL15r X X X X X X X X X X X X
PGIS X X X X X X X X X X X X
PGIC X X X
Study Therapy Administration
Premedication dosing tX X X X X X X X
TAK -079, SC uX X X X X X X X
Postdose medication vX
AE reporting w New onset AEs recorded from the signing of the ICF through the SFP; SAEs collected from the signing of the ICF through the 
SFP; unresolved AEs/SAEs as of Week 16 and study drug -related AEs/SAEs with onset after SFP collected through the LFP
Concomitant medications/ 
procedures monitoringRecorded from signing of the ICF through SFPRecorded only for concomitant 
medications/procedures related 
to underlying disease
AChR: acetylcholine receptor; ADA: antidrug antibodies; AE: adverse event; CRS: cytokine release syndrome; COVID -19: coronavirus disease 2019; ECG: 
electrocardiogram; eCRF: electronic case report form; HBV: hepatitis B virus; HCV: hepatitis C virus; ICF: informed consent form; Ig: Immunoglobulin; IRB: 
institutional review board; IVIg: intravenous immunoglobulin; LFP: long -term follow -up period; MG: myasthenia gravis; MG -ADL: Myasthenia Gravis -Activities 
of Daily  Living; MGC: Myasthe nia Gravis Composite; MGII: Myasthenia Gravis Impairment Index; MG -QoL15r; Myasthenia Gravis Quality of Life Scale; 
MuSK: muscle -specific tyrosine kinase; PGIC: Patient Global Impression of Change; PGIS: Patient Global Impression of Severity; PK: pharmac okinetic; QMG: 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 91of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix ASchedule of Events
Study Proceduresa
Screen
ingTreatment Period Safety
Follow -up Period (SFP)Long -term
Follow -up Period (LFP) Period Length: 8 weeks
Week bDays 
-28 to 
-11 2 3 4 5 6 7 8 10 12 14 16 c20 d24 28 32
Window ±2 days ±2 days ±2 days
Quantitative Myasthenia Gravis; SAE: serious adverse event; SC: subcutaneous; SFP: safety follow -up period; TEAE: treatment -emergent adverse event.
aPatients may undergo additional laboratory assessments and observations as necessary based on the principal investigator’s be st medical judgment, and as 
warranted by [CONTACT_4211]. 
bPatient visits at scr eening, Weeks [ADDRESS_3912] be done with the patient present at the investigative site. Other visits may be conducted at th e 
clinic or by [CONTACT_4212] (or a hybrid of Telehealth/Telemedicine with home healthcare) to ext end flexibility to patients during COVID -19 public 
health emergency. Home healthcare visits will be documented in the study records and eCRF.
c Patients will be unblinded after Week 16. Clinical parameters below the levels in Table 8.dfor continued dosing, including ongoing drug -related AEs, at Week 16 
should be monitored until the parameters/AEs are resolved, return to baseline, or are clearly determined to be due to a pati ent’s stable or chronic condition or 
intercurrent illness(es).
d The Week [ADDRESS_3913] be documented before initiating any screening procedures associated with the study.
fScreening period is 28 days (ie, Day -28 to Day -1). Confirmation of patient eligibility by a [COMPANY_005] project clinician or designee is required before enrollment and 
before receiving study drug. See Section 9.5for additional time allowance for extenuating circumstance s, to include b ut not be limited to, need for screening 
retesting, as granted on approval by [CONTACT_4213].
gPhysical examinations are to be symptom -and MG disease –directed with significant clinical findings noted as AEs. In LFP, needed only if ther e were ongoing 
drug- related AEs at the Week [ADDRESS_3914] 
should be conducted for delayed menses (see Section 9.5.10 )
.
hAssessments may be performed on the day before or the day of the indicated visit before dosing.
iVital signs (temperature, blood pressure, respi[INVESTIGATOR_697], and heart rate) are measured before all TAK -079 administrations and 2 hours (±10 minutes) postdose 
after the first and second TAK -079/placebo dose. In addition, vital signs should be assessed at any time it is clinically warranted. As per the investigator’s judgment , 
if there are no concerns raised by [CONTACT_4167] -directed physical, vital signs measurements will not be required to be collected at the Week14 visit during the 
COVID -[ADDRESS_3915] should be completed i f the patient's 
menstrual period is delayed, or if the IRB requests, and a negative result obtained before dosing with the study drug (see Section 9.5.10 ). Serum pregnancy testing 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 92of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix ASchedule of Events
Study Proceduresa
Screen
ingTreatment Period Safety
Follow -up Period (SFP)Long -term
Follow -up Period (LFP) Period Length: 8 weeks
Week bDays 
-28 to 
-11 2 3 4 5 6 7 8 10 12 14 16 c20 d24 28 32
Window ±2 days ±2 days ±[ADDRESS_3916] of urine pregnancy testing with prior permission from the sponsor.
kHematology and chemistry l aborato ry samples will be collected locally. Local laboratory evaluations may be done more frequently at the investigator’s d iscretion 
(eg, for acute management of TEAEs) and may be used for dosing decisions.
lClinical laboratory evaluations for disease a ssessments (anti -AChR and anti -MuSK antibodies) will be tested centrally.
mSamples collected before TAK -079 administration. 
nCD19 evaluation to be performed only in patients with prior exposure to rituximab; CD19 counts must be within the normal rang e at screening to be eligible. 
oCirculating biomarkers may include assessment of complement C3 and C4 levels. Sample is also drawn for cytokine markers. Additional samples of cytokine 
markers are to be drawn if CRS is suspected.
pAdditional PK and biomarke r sampling may be requested.
qQuantitative immunoglobulins will be tested at a central laboratory; thus, results will not be available before each weekly d ose. However, per standard medical 
practice, investigators should review the results once available and take appropriate clinical action, which may include but is not limited to withholding study drug 
and treatment with IVIg, for example, in the setting of a severe infection.
r Physician examination portion of this assessment may be omitted if performing a remote visit.
sProcedure may be omitted if performing a remote visit. The assessment of forced vital capacity for QMG test may be omitted for COVID -19-related reasons (see 
Section 9.12).
t Premedication and postdose medication before and after TAK -[ADDRESS_3917] and second 
TAK -079 dose; before discharge from the clinic, the possible signs and symptoms of anaphylac tic reactions and CRS should be reviewed with patients.
vPostdose medication should be given 2 hours (±15 minutes) after the first injection of the first dose and [ADDRESS_3918] dose of study drug in the morning.
Postdose medication may be given wi th subsequent doses if clinically indicated and under the discretion of the principal investigator (see Section 8.1.2).
w Assessments for AEs are to i nclude a sy mptomatic examination per standard medical practice.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 93of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix B Clinical Signs and Symptoms of Cytokine Release Syndrome
Organ System Symptoms
Constitutional Fever with or without rigors, malaise, fatigue, anorexia, myalgias, arthralgia, nausea, 
vomiting, headache
Skin Rash
Gastrointestinal Nausea, vomiting, diarrhea
Respi[INVESTIGATOR_4088], hy poxemia
Cardiovascular Tachycardia, widened pulse pressure, hypotension, increased cardiac output (early), 
potentially diminished cardiac output (late)
Coagulation Elevated D -dimer, hypofibrinogenemia with or without bleeding
Renal Azotemia
Hepatic Transaminitis, hyperbilirubinemia
Neurologic Headache, mental status changes, confusion, delirium, word -finding difficulty or frank 
aphasia, hallucinations, tremor, dysmetria, altered gait, seizures 
Source: Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the di agnosis and 
management of cytokine release syndrome. Blood 2014;124(2):188 -95[20].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 94of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix CGrading System for Cytokine Release Syndrome
Grade Toxicity
Grade 1 Symptoms are not life-threatening and require symptomatic treatment only, eg, fever, 
nausea, fatigue, headache, myalgias, malaise)
Grade 2 Symptoms require and respond to moderate intervention
Oxygen requirement <40%, or
Hypotension responsive to fluids or low dose of 1 vasopressor, or 
Grade 2 organ toxicity
Grade 3 Symptoms require and respond to aggressive intervention
Oxygen requirement ≥40%, or
Hypotension requiring high dose or multiple vasopressors, or
Grade 3 orga n toxicity , or 
Grade 4 transaminitis
Grade 4 Life-threatening sy mptoms
Requirements for ventilator support, or
Grade 4 organ toxicity (excluding transaminitis)
Grade 5 Death
Source: Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and 
management of cytokine release syndrome. Blood 2014;124(2):188 -95 [20].
Grades 2 to 4 refer to the Common Terminology Cri teria for Adverse Events ,version 4.03 grading.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3919] igators by  [CONTACT_4214] (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by [CONTACT_2960] a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to pe rform 
study -related duti es and funct ions, the invest igator/inst itution shoul d ensure that this 
individual or party  is qualified to perform those study -related duti es and functi ons and shoul d 
implement procedures to ensure the integrity  of the study -related duties and funct ions 
perform ed and any  data generated.
4.Ensure that study -related procedures, including study -specific (nonroutine/nonstandard panel) 
screening assessments, are NOT performed on potent ial patients before the receipt of written 
approval  from relevant governing bodies/authorit ies.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by [CONTACT_4215]/IEC that conform to 
21 CFR Pa rt 56, ICH and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to pati ents. Make at l east y early  reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9.Obtain valid informed consent from each pat ient who participates in the study , and document 
the date of consent in the patient’s medical chart. Valid informed consent is the most current 
versio n approved by [CONTACT_1201]/IEC. Each ICF should contain a patient au thorization sect ion that 
describes the uses and disclosures of a patient’s personal informat ion (including personal 
healt h informat ion) that will take place in connect ion with the study. If an ICF does not include 
such a patient authorizat ion, then the inv estigator must obtain a separate patient authorization 
form from each patient or the patient’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospi[INVESTIGATOR_1097], laboratory  resul ts, etc, and maintain these data for a minimum o f [ADDRESS_3920] igator should 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3921] and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by [CONTACT_4216] -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disp osition of  sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor. 
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3922] igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
[LOCATION_006], US, and Japan), including the fo llowing:
[COMPANY_005], its affiliates, and licensing partners.
Business partners assist ing [COMPANY_005], its affiliates, and licensing partners.
Regul atory  agencies and other health authorit ies.
IRBs and IECs.
The invest igator’s personal informat ion may be retained, processed, and transferred by [CONTACT_4217]:
Assessment of the suitabilit y of the invest igator for the study and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by [CONTACT_4218].
Self-inspect ion and internal audit within [COMPANY_005], its affiliates, an d licensing partners.
Archiving and audit of study  records.
Posting investigator site contact [CONTACT_4203], study details, and results on publicly accessible 
clinical study  registri es, databases, and websites.
The invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level o f protection as data protection laws in the invest igator’s 
own country .
The invest igator acknowledges and consents to the use of his or her personal informat ionby 
[CONTACT_4219].
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 98of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix FMG-ADL Score
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
 
 

	


 
 
MG-ADL
 - [LOCATION_002]/English 
MG-ADL_AU1.1_eng-USori.docx  MG Activities of Daily Living (MG-ADL) profile 




	


 
	


	
  
  	
	

	
 

			

	
 

		
	

	
	

	
  
  
 

 
 
 
!"	
  
  #
 
	

$		

		

	
	 
 
%&
	
  
  "
	

'
	"
	 



(	

		
)
	
*



	  +'

 
	


	#
 
			 
	
		
,
	
*



	  - 

-
 
*
".

$
 
	
/.	  	  0
 
	** 
					  
1+*
  	  0
 
	** 
					  
 




 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 99of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix GMGII Score
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
Constant or present 
most of the dayINSTR UCTIONS:
Please answer the following questions regarding your symptoms. Only consider those that you think are related to myasthenia. Check the answer that best describes your symptoms over the past [ADDRESS_3923] you experienced epi[INVESTIGATOR_4089]?  If yes, at what time do they occur (on average)?No Double 
V i s i o n                 Epi[INVESTIGATOR_4090]
2. Double vision with activities
Have you experienced double vision with activities such as reading, driving, watching TV or using a computer?  If yes, how long does it take (on average)  
before the double vision occurs?No Double 
V i s i o n                After more than 
[ADDRESS_3924] you experienced double vision? If yes, how severe has it been (at 
your worst)?No Double 
V i s i o n                Mild: it doesn’t affect my daily 
activitiesIt affects my activities 
but no need to cover 
one eyeI need to cover 
one eye to be able 
to function
4. Eyelid droopi[INVESTIGATOR_4091](s)? If yes, when does it occur (on average)? No eyelid 
d r o o p i n g                                                      Only in the 
eveningsDroopi[INVESTIGATOR_4092]
5. Eyelid droopi[INVESTIGATOR_4093]
6. Severity of eyelid droopi[INVESTIGATOR_4094](s) with activities such as reading, driving, watching TV or using a com-puter?  If yes, how long does it take (on average) before the droopi[INVESTIGATOR_4095]?
Have you experienced droopi[INVESTIGATOR_4096]? If yes, how severe has it been (at your worst)?No eyelid 
d r o o p i n g                                                           After more than 
1 hourAfter less than 1 hour, 
but not immediatelyConstant droopi[INVESTIGATOR_4097] 
d r o o p i n g                                              Mild: it doesn’t 
affect my visionIt affects my vision 
but no need to lift my 
eyelidI need to lift my eyelid 
or tilt my head to be 
able to seeMG Impairment Index (MGII)TM - Patient Questionnaire
 PROBLEMS WITH YOUR EYES:  Please ans wer regarding the past 2 weeks.ID: _______________ 
Date:______________
  0       1 2                 3
  0       1 2                 3
  0       1 2                 3
  0       1 2                 3
  0       1 2                 3
  0       1 2                 3
MGII. V1.0. English- Canada 
 
 
 
 
 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
 PROBLEMS EATING: Please answer regarding the past [ADDRESS_3925] you experienced difficulty 
swallowing? How severe has it been (at your worst)?No 
swallowing 
problemsOccasional epi[INVESTIGATOR_4098]/coughing 
with food or liquidsLiquids return 
through my nose, 
but no problems 
with solid foodDifficulty 
swallowing hard 
food, requiring a 
change in dietUnable to 
swallow or 
using a feeding 
tube
8. Chewing different types of food
Have you experienced difficulty chewing? How severe has it been (at your worst)? No difficulty 
c h e w i n g            Difficulty chewing 
hard foods (e.g. 
steak, raw carrots)Difficulty chewing soft 
foods (e.g. hard boiled 
egg)Unable to chew (eating 
only liquids or feeding 
tube)
9. Chewing tiredness/fatigue
At your worst, how long does it take to develop fatigue or tiredness in your jaw?No difficulty 
c h e w i n g            Difficulty chewing 
at the end of the 
mealDifficulty chewing from 
the beginning of the 
mealUnable to chew (eating 
only liquids or feeding 
tube)
 PROBLEMS SPEAKING AND BREATHING: Please answer regarding the past [ADDRESS_3926] you experienced epi[INVESTIGATOR_4099], hoarse or weak voice? When do they occur  on average?No voice 
c h a n g e s                                 Voice changes only 
in the eveningsVoice changes 
starting in the 
afternoonsConstant voice 
changes or present 
most of the day
11. Voice changes with prolonged conversation
How long can you talk (on    
average), before developi[INVESTIGATOR_4100], such as nasal, hoarse or weak voice? (Normal conversation, with pauses for other speakers)No voice 
c h a n g e s                                 Voice changes 
after more than 30 
minutesVoice changes after 
less than 30 minutes, 
but not immediatelyConstant voice changes 
or they start immediately 
(less than 1 minute)
12. Severity of voice changes
At your worst, how severe have your voice changes been? (Nasal, hoarse, weak voice)No voice 
c h a n g e s                                 Mild changes: my 
voice is mostly 
clearModerate changes: 
it can be hard to 
understand meSevere changes: 
it is impossible to 
understand meID: _____________
  0     1   2    3
  0     1   2    3  0     1                2                3 4
  0     1   2    3
  0     1   2    3
  0     1   2    3
MGII. V1.0.MG Impairment Index (MGII)TM - Patient Questionnaire
MGII. V1.0. English- Canada 
 
 
 
 
 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
ID: _________ ____
 PROBLEMS SPEAKING AND BREATHING (Cont.): Please answer regarding the past [ADDRESS_3927] you experienced difficulty 
pronouncing words or slurred speech? When does it occur  on 
average?No epi[INVESTIGATOR_4101] 
s l u r r e d  s p e e c h                    Slurred speech 
only in the 
eveningsSlurred speech 
starting in the 
afternoonsConstant slurring, or 
present most 
of the day
14. Speech clarity with prolonged conversation
How long can you talk (on    
average), before developi[INVESTIGATOR_4102]? (Normal conversation, with pauses for other speakers)
15. Severity of speech changes
At your worst, how severe have your speech changes been? (Slur-ring, difficulty pronouncing words)No epi[INVESTIGATOR_4101] 
s l u r r e d  s p e e c h                            Mild slurring: 
It is easy to 
understand meModerate slurring: There 
are some difficulties 
understanding meSevere slurring: 
it is impossible to 
understand meN o  e p i s o d e s  o f                          
s l u r r e d  s p e e c h                    Slurred speech 
after 30 minutesSlurred speech after 
less than 30 minutes, 
but not immediatelyConstant slurring, or 
it starts immediately  
(less than 1 minute)
16. Difficulty breathing
Have you experienced shortness of breath that is caused by[CONTACT_4220]?  (i.e. not caused by [CONTACT_4221], or other lung/heart disease) If yes, when has it occurred (at your worst)?No shortness of 
breath (except 
for strenuous 
exercise)With moderate 
effort (e.g. walking 
several blocks at my 
own pace)With minimal 
effort (e.g. getting 
dressed, walking 
inside the house)At rest or when 
lying on my
 backRequiring 
assisted
 ventilation
 GENERALIZED SYMPTOMS: Please answer regarding the past [ADDRESS_3928] you experienced overall physical tiredness caused by [CONTACT_4222]? (i.e. not by [CONTACT_4223], depression or other medical conditions) No physical 
t i r e d n e s s                                
Overall physical 
tiredness in the 
eveningsOverall physical 
tiredness starting in 
the afternoonsConstant physical 
tiredness, or present 
most of the day  0     1    2    3
  0     1    2    3
  0     1    2    3
  0     1                2              3 4
  0     1    2    3MG Impairment Index (MGII)TM - Patient Questionnaire
MGII. V1.0. English- Canada 
 
 
 
 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
ID: _________ ___
18. Arm weakness severity
Have you experienced weakness 
in your arms? If yes, how severe has it been (at your worst)?No arm 
w e a k n e s s                        Mild weakness 
(e.g. difficulty 
lifting heavy 
objects)Moderate weakness 
(e.g. difficulty lifting arms 
above the shoulders, but 
I can do it)Severe weakness 
(unable to lift arms 
above the shoulders)
19. Arm weakness with prolonged use
Have you experienced weakness in your arms after prolonged use? When does it happen (on 
average)?
20. Leg weakness severity
Have you experienced weakness in your legs? If yes, how severe has it been (at your worst)?No leg
w e a k n e s s                          Mild weakness (e.g. 
difficulty standing 
from a squat or from 
tying my shoes)Moderate weakness 
(e.g difficulty standing   
from a chair, I need to 
push up with my arms)Severe weakness 
(e.g unable to stand 
from a chair without 
assistance)No arm 
w e a k n e s s                        Weakness when 
keepi[INVESTIGATOR_4103] (e.g. washing 
or drying my hair)Weakness with  prolonged 
activities at shoulder level 
(organizing objects on a 
shelf, holding a phone to 
the ear)Weakness with 
minimal effort (e.g. 
desk work, choppi[INVESTIGATOR_4104])GENERALIZED SYMPTOMS: Please answer regarding the past [ADDRESS_3929] you experienced weakness in your legs after prolonged use? When does it happen (on 
average)?No leg
w e a k n e s s                          Weakness when 
walking more than 
10 blocks at my own 
paceWeakness when 
walking less than 10 
blocks at my own paceConstant weakness 
or with minimal effort 
(standing, walking 
inside the house)
22. Neck weakness
Have you experienced weakness in your neck? When does it happen (on average)?No neck
w e a k n e s s                          Weakness only in 
the eveningsWeakness starting in 
the afternoonsConstant weakness 
or present most of the 
day  0   1    2    3
  0    1    2     3
  0    1    2     3
  0    1    2     3
  0    1    2     3MG Impairment Index (MGII)TM - Patient Questionnaire
MGII. V1.0. English- Canada 
 
 
 
 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
MG Impairment Index (MGII) - Examination  
ID:_________________ 
Date:________________
0 1 2 3 Score
E1. Diplopia No Diplopi[INVESTIGATOR_4105] 1 
direction. Diplopia in 2 directions.Diplopia in ≥[ADDRESS_3930] with cheeks, but air escapes through lips.Unable to seal lips or provide resis-tance with cheeks.
E4. Arm EnduranceHolds arms for 180 seconds.Holds arms for 91-179 seconds.Holds arms for 30-90 seconds.Holds arms for < 30 seconds.
E5. Leg Endurance Holds leg for 90 seconds.Holds leg for 40-89 seconds.Holds leg for 16-39 seconds.Holds leg for ≤ 15 seconds.
E6. Neck EnduranceHolds head for 60 seconds.Holds head for 35-59 seconds.Holds head for 11-34 seconds.Holds head for ≤ 10 seconds.This sheet refers to the physical examination. Detailed instructions are found in the instruction 
manual. You will need a stopwatch.
MGII. V1.0. English- Canada
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 100of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix HMGC Score
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
MG composite scale 
Ptosis, upward ease >45 seconds = 0 11-45 seconds = 1 1-10 seconds = 2 Immediate = 3 
(physician examination) 
Double vision on lateral >45 seconds = 0 11-45 seconds = 1 1-10 seconds = 3 Immediate = 4 
Gaze, left or right  
(physician examination) 
Eye closure Normal = 0 Mild weakness (can Moderate weakness Severe weakness 
(physician examination) be forced open with (can be forced open (unable to keep  
effort) = 0 easily) = 1 eye closed) = 2 
Talking   Normal = 0 Intermittent slurring Constant slurring or Difficult to 
(patient history) or nasal speech = 2 nasal but can be  understand 
understood = 4 speech = 6 
Chewing Normal = 0 Fatigue with solid Fatigue with soft Gastric tube = 6 
(patient history) food = 2  food = 4 
Swallowing Normal = 0 Rare epi[INVESTIGATOR_4106] = 6 
(patient history) choking or trouble swallowing, for example 
swallowing = 2  necessitating change in 
diet = 5 
Breathing (thought to Normal = 0 Shortness of breath Shortness of breath at Ventilator  
be caused by [CONTACT_4224]) with exertion = [ADDRESS_3931] = 4  dependence = 9 
Neck flexion or  Normal = 0 Mild weakness = 1 Moderate weakness Severe weakness 
extension (weakest) (i.e., ~50% weak, ±15%) = 4 
(physician examination) = 3 
Shoulder abduction Normal = 0 Mild weakness = 2 Moderate weakness Severe weakness 
(physician examination) (i.e., ~50% weak, ±15%) = 5 
= 4 
Hip flexion Normal = 0 Mild weakness = 2 Moderate weakness Severe weakness 
(physician examination) (i.e., ~50% weak, ±15%) = 5 
= 4 
TOTAL _________ 
Note: Please note 
that “moderate weakness” for neck and limb items should be construed as weakness that equals 
roughly 50% ± 15% of expected normal strength. Any weakness milder than that would be “mild,” and any
weakness more severe than that would be classified as “severe.”
Patient ID #: ______________ 
Date: ____________________ 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 101of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix IQMG Score
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
© 1997 UT Southwestern Medical Center, Dallas  
 
QMG - [LOCATION_002]/English – Original version  
QMG_AU 2.1_eng -USori.docx   
 
 
 
Test Item  None  Mild  Moderate  Severe  Score  
Grade  0 1 2 3 Raw  Scale  
Double vision on lateral gaze  
Right or left (circle one), secs  61 11-60 1-10 Spontaneous    
Ptosis (upward gaze)  61 11-60 1-10 Spontaneous    
Facial muscles  Normal lid  
closure  Complete, weak,  
some resistance  Complete, without  
resistance  Incomplete    
Swallowing 4 oz water  
(1/2 cup)  Normal  Minimal coughing or 
throat clearing  Severe coughing/choking  
or nasal regurgitation  Cannot swallow   
(test not attempted)    
Speech after counting aloud  
from 1 to 50 (onset of  
dysarthria)  None at 50  Dysarthria at  
30-49 Dysarthria at  
10-29 Dysarthria at 9    
Right arm outstretch ed (90 
degrees sitting), seconds  240 90-239 10-89 0-9   
Left arm outstretched (90  
degrees sitting), seconds  240 90-239 10-89 0-9   
Forced Vital Capacity  
 > 80 65-79 50-64 <50   
Rt- hand grip, kg  
Men 
Women   
> 45 
> 30  
15-44 
10-29  
5-14 
5-9  
0-4 
0-4   
Lt- hand grip, kg  
Men 
Women   
> 35 
> 25  
15-34 
10-24  
5-14 
5-9  
0-4 
0-4   
Head lifted (45 degrees supi[INVESTIGATOR_050]), 
seconds  120 30-119 1-29 0   
Right leg outstretched (45  
degrees supi[INVESTIGATOR_050]), seconds  100 31-99 1-30 0   
Left leg outstretched (45  
 degrees supi[INVESTIGATOR_050]), seconds  100 31-99 1-30 0   
                                                                                         
 
                                                                                                                               TOTAL QMG SCORE :  
 
 
 
  
QMG form  
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 102of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix JMG-QoL15r
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
Patient ID #: __________ 
Date: __________
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 103of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix KPGIC
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
P GIC  Q ues ti o n na i r e
R egardi n g  your m yast he ni a  gravi s,  how  has your f unct i on i n g  chang e d 
si n ce y o u  started  taki n g  stu d y  m ed i cati o n ?  
M u ch  b ette r
M o d erate l y  b ette r
A  l i ttl e  b etter
No  c h a n g e
A  lit t le  w o r s e
M o d e r a t e l y  wo r s eone box only
M u c h  wo r s ePa t i e nt  I D : _ _ _ ______ _____
D ate: __ ______ ______ ____
version as of 9/4/2019
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 104of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix LPGIS
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
PGIS Questionnaire
How much has your myasthenia gravis affected your functioning
in the past 7 days? 
Not at allPatient ID:______________
Date:__________________
A little bit
Somewhat
Quite a bit
Very muchone box only
version as of 9/4/2019
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -079
Study No. TAK -079-1005 Page 105of 114
Protocol Incorporating Amendment No. 4 02 February 2021
CONFIDENTIALAppendix M Protocol History
Date Amendment Number Type Region
02 February 2021 Amendment 4 Substantial Global
28 September 2020 Amendment 3 Substantial Global
05 March 2020 Amendment 2 Substantial Global
18 October 2019 Amendment 1 Nonsubstantial Global
05 September 2019 Initial Protocol Not applicable Global
Protocol Amendment 3 Summary and Rationale
The primary  reason for thi s amendment was to add contingency  plans f or the coronavirus disease 
2019 (COVID -19) pandemic by [CONTACT_4225] y for study  parti cipants and inve stigators, 
while cont inuing to maintain pat ient safet y and study  integrity as per l ocal site regul ations. Other 
minor changes and clarificat ions to the protocol are summarized below.
Protocol Amendment [ADDRESS_3932] Version of the Approved Protocol
Sections Affected by [CONTACT_4112] 2.0STUDY SUMMARY Statistical Considerations: Updated 
text in the synopsis for the primary 
endpoint analysis to be consistent 
with the body of the protocol.To harmonize the analysis of the 
safety data between the synopsis and 
body of the protocol.
Section 2.0STUDY SUMMARY 
Section 5.2.3 Exploratory Endpoints Amended the wording for the 
exploratory endpoint of 
pharmacokinetics (PK) from "PK of 
TAK -079 in combination with the 
background therapy. PK parameters 
include but are not limited to Cmax, 
AUC, and t max(time of first 
occurrence of C max) to read: "Serum 
concentration -time profile of 
TAK -079 PK parameters will 
include, but are not limited to C trough
over time."Clarify  PK endpoint.
Added exploratory endpoint: Change 
in serum immunoglobulin levels.The reduction in immunoglobulin 
levels is an important 
pharmacodynamic indicator of 
TAK -[ADDRESS_3933].
Added antidrug antibody (ADA) as 
an immunogenicity assessment and 
removed ADA as a biomarker.To clarify that ADA is an 
immunogenic ity assessment and not 
a biomarker of disease activity.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3934] Version of the Approved Protocol
Sections Affected by [CONTACT_4112] 2.0STUDY SUMMARY
Section 7.2Exclusion Criteria Exclusion Criterion #4: Revised to 
exclu de patients if there is an 
expectation that any rescue therapy 
may be needed between screening 
and dosing.To clarify that a patient’s underlying 
MG should be stable enough that the 
need for rescue therapy is not 
expected before dosing. 
Section 2.0STUDY SUMMARY
Section 13.1.3 Efficacy Analysis Statistical Considerations:
Changed "Secondary Efficacy 
Endpoints" to read: "Efficacy 
Endpoint Analyses."
Revised text to specify how different 
types of secondary  efficacy 
endpoints (binary vs continuous) 
will be analyzed.To clarify statistical analyses.
Section 13.1.[ADDRESS_3935].
Section 5.1.3 Exploratory Objectives Rem oved "in combination with 
background therapy" from the 
exploratory objectives of the PK and 
pharmacodynamics of TAK -079.To clarify that the PK and
pharmacodynamics of TAK -[ADDRESS_3936] 
been recently obtained in the absence 
of recently administered study drug. 
For other doses, the window is 
expanded to allow obtaining labs the 
day before (rather than restricted to 
24hours before the study visit) for 
flexibility in obtaining lab oratory  
results, especially in light of 
operatio nal complexities due to 
coronavirus disease 2019 
(COVID -19).
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3937] Version of the Approved Protocol
Sections Affected by [CONTACT_4112] 8.1.2 Postdose Medication The d ose of methylprednisone was 
corrected from <20 mg to read ≤[ADDRESS_3938] typographical error.
Section 8.2Excluded Concomitant 
Medications and Procedures, Table
8.bExcluded Concomitant 
Medications Added footnote b to the categories of 
intravenous immunoglobulin, 
plasmapheresis/plasma exchange, 
and subcutaneous immunoglobulin: 
"Patients for whom any therapy 
(besides the allowed standard 
background therapi[INVESTIGATOR_4040]) is 
reasonably expected between 
screening and dosing are excluded 
from study participation."To align with text in Exclusion 
Criterio n No 4.
Corrected exclusion criteria for 
dosing of rituximab, belimumab, 
eculizumab, or any monoclonal 
antibody for immuno modulation 
restricted from ≤6 months "before 
the screening visit" to read "before 
the first dosing."To align with text in Exclusion 
Criterio n No 6. 
Section 8.4.1 Assessment and Criteria 
for Terminating Patient Dosing, Table 
8.dSummary of Subsequent Dos ing 
Criteria Safety Parameter: Total lymphocyte 
count:
Continue Dosing: Corrected 
"≥500/mm3" to read: " ≥500/mm3or 
≥90% of the baseline level."
Dose Hold: Corrected "<500/mm3" 
to read:" <500/mm3and <90% of the 
baseline level."Allows for minor fluctuatio ns in the 
cell counts for patients on 
background therapy who may also 
have low baseline values. This 
criterion is based on emerging 
information from ongoing clinical 
studies with TAK -079.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3939] Version of the Approved Protocol
Sections Affected by [CONTACT_4226] c from 
"Laborato ry grading is based on 
CTCAE v4.0 3" to read: "Laboratory 
and infection grading are based on 
CTCAE v4.03.
Added footnote c to: row labeled 
"Platelets" for Thrombocytopenia 
≤Grade 2c and Thrombocytopenia 
≤Grade 3c; row labeled 
"Hypersensitivity (allergic reaction 
or anaphy laxis)e" for ≤Grade 2c, and 
row labeled "Systemic infection" for 
Grade 2cand ≥Grade 3c
Rem oved footnote f from Systemic 
infection Grade 2cand ≥Grade 3c.To clarify that all laboratory and 
infection grades listed in the table are 
based on Common Terminology 
Criteria for Adverse Events
(CTCAE) v4.03 criteria.
Section 8.5.1 Pregnancy, Lactations, 
and Contraception Changed Section heading to include 
"Contraception" and added Table 8.e
(methods of contraception for female 
patients) and Table 8.f(methods of 
contraception for male patients) to 
match with contraception method 
recommendations provided in the 
informed consent form.Text added in response to a request 
from a health authority.
Section [IP_ADDRESS] Management 
Recommendations for 
Hypersensitivity Reactions First sentence: Change ISR to IRR. Correct typo.
Add "Signs and symptoms of 
systemic hy persensitivity  reactions 
include rash, urticaria, fever, and/or 
bronchospasms."To describe the clinical presentation 
of an infusion reaction. 
Rem ove examples of Grade 1, Grade 
2, and Grade 3 hypersensitivity 
reactions.
Add text in parenthesis after Grade 3 
or greater: "(including any diagnosis 
of anaphy laxis according to 
Sampson [24])."To avoi d confusion with definition 
of CTCAE v4.03 grades and criteria 
for diagnosis of anaphylaxis. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3940] Version of the Approved Protocol
Sections Affected by [CONTACT_4227] 8.dSummary of Subsequent 
Dosing CriteriaTable 8.d: Revised wording:
Hypersensitivity (IRR, allergic 
reaction, or anaphylaxis (See Section 
8.6.1 ).NOTE: IRR, allergic reaction, 
and anaphylaxis are each classified 
according to CTCAE v4.03. 
Anaphy laxis is diagnosed according 
to Sampson et al [19].
Continue Dosing: ≤Grade 2 
Dose Discontinuation: ≥Grade 3 or 
any signs o r symptoms of an 
anaphy lactic reaction [19].
CRS (See Section 8.6.2 )
NOTE: CRS is classified in 
accordance with Lee et al [20].
Continue Dosing: Grade 1 with 
symptomatic treatment allowed in 
accordance with Lee et al [20].
Dose Discontinuation: ≥Grade 2.
Rem ove Table footnotes e and f as 
information is redundant with 
information provided in table.Make dosing criteria for 
hypersensitivity and CRS in table
consistent with text in Section 8.6.1
and Section 8.6.2
Section 9.12 COVID -19 Related 
Procedural Changes Added new section (Section 9.12) 
and text regard ing contingency plans 
for the COVID -[ADDRESS_3941] 
of the COVID -19 pandemic to 
ensure the rights, safety, and 
well-being of patients, the safety of 
clinical trial staff, maintain 
compliance with Good Clinical 
Practice, maintain study integrity, 
and patient privacy.
Section [IP_ADDRESS] Timing of Pregnancy 
TestingChanged timing of pregnancy testing 
before i nitial study dosing at baseline 
from "within 24 hours before the 
start of study drug" to read: "Either 
Day 1 prio r to initial study dosing, or 
1 day  before study dosing."To clarify the timing of pregnancy 
testing at baseline.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3942] Version of the Approved Protocol
Sections Affected by [CONTACT_4112] 9.6End of Safety Follow -up 
Period Assessments, Table 9.cEnd of 
Safety Follow -Up Period Clinical 
Parameters Table 9.c: Revised criteria for 
neutrophils, platelets, total 
lymphocy te count, and Hgb as 
follows:
End-of-Study Criteria: ≥LLN or 
≥study baseline levels, or abnormal 
levels that are not directly relat ed to 
dosing of investigational product.
Continuation to Long -term 
Follow -up:<LLN and < study 
baseline levels that are directly 
related to dosing of investigational 
product.To clarify the end -of-study  criteria 
and long -term follow -up parameters 
by [CONTACT_4228].
TAK -079-related hy persensitivity 
reaction (IRR, allergic reaction, or 
anaphy laxis) (See Section 8.6.1 )
End-of-Study Criteria: Clinical 
symptoms related to hypersensitivity 
reaction resolved.
Continuation to Long -term 
Follow -up: Clinical symptoms 
related to hypersensitivity reaction 
ongoing.
TAK -079- related CRS (See Section 
8.6.2 )
End-of-Study Criteria: Clinical 
symptoms related to CRS reaction 
resolved. 
Continuation to Long -term 
Follow -up:Clinical symptoms 
related to CRS reaction ongoing.
Revised criteria for systemic 
infection as follows:
Continuation to Long -term 
Follow -up:Any ≥Grade 2b
systemic infection that is not 
resolved.
Footnote a: added "see Section 8.6.2 
for details" for definitions of 
CTCAE grades.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3943] Version of the Approved Protocol
Sections Affected by [CONTACT_4112] 10.1.3 SAE Definition Added: Note: Some clinical centers 
may only  be able to provide certain 
rescue therapi[INVESTIGATOR_014] (eg, IVIg) via 
inpatient hospi[INVESTIGATOR_059]. Therefore, 
the hospi[INVESTIGATOR_4107] (in an 
otherwise clinically stable patient) 
specifically for access and 
administration of rescue therapy 
does not count automatically as an 
SAE, unless there are other 
circumstances that fulfill SAE
criteria.Added clarification that inpatient 
stay for rescue therapy does not 
automatically count as a serious 
adverse event (SAE).
Section 13.1.1 Analysis Sets The definition of the PK analysis set 
has been clarified to read “Patients 
who have received at least [ADDRESS_3944] 1 measurable TAK -079 
serum concentration.”Clarification.
Section 13.1.5 Immunogenicity 
Analy sesAdded "pharmacodynamics" to the 
statement that reads: The effect of 
immunogenicity on PK, 
pharmacodynamics, safety, and 
efficacy may be explored.Correction.
Section 14.1 Study -Site Monitoring 
Visits Added 2nd paragraph of text 
regarding contingency plans for 
Study -Site Monitoring Visits 
conducted during the COVI D-19 
pandemic.Text added per Sponsor's COVID -19 
guidelines.
Appendix ASchedule of Events Rem oved serum sample collection 
for immunogenicity (eg, ADA) at 
Weeks 3, 5, and 7.Serum samples do not need to be 
collected every week.
Reordered all footnotes due to the
addition of 4 footnotes (b, h, r, and 
s).N/A
Added footnote b to table row 
labeled "Week" to allow for remote 
visits at certain time points.Added per COVID -19 guidelines to 
allow flexibility for remote visits.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3945] Version of the Approved Protocol
Sections Affected by [CONTACT_4229] A continued... Added footnote letter h to table rows 
labeled: 12- lead ECG; serum 
pregnancy test; urine pregnancy test; 
hematology; clinical chemistry; 
direct/indirect Coombs test; serum 
sample for anti -AChR or anti -MuSK 
antibodies; blood sample for 
immunoprofiling; serum sample for 
circulating biomarkers; serum 
sample for quantitative 
IgA/IgM/IgG; serum sample for 
TAK -079 PK; serum sample for 
immunogenicity (eg, ADA); serum 
sample for vaccine -induced 
protective antibodies; 
pharmacodynamic biomarkers; and 
Disease assessment tests.To ind icate that assessments may be 
performed on the day before or the 
day of the indicated visit before 
dosing.
Added text to table footnote i to state 
that vital signs measurements will 
not be required at the Week 14 visit 
during the COVID -19 pandemic 
visit as long as there are no concerns 
raised by  [CONTACT_4230] -directed 
physical.Added per COVID -19 guidelines to 
allow flexibility for remote visits.
Added text to footnote j and added 
footnote “j” designator to table row 
labeled urine pregnancy test to 
indica te that serum pregnancy 
testing may be used in place of urine 
pregnancy testing with prior 
permission from the sponsor.To clarify that the intent of the 
protocol is not to exclude use of 
more accurate serum pregnancy tests 
if this is logistically feasible for a 
site.
Added footnote letter m to table rows 
labeled: urine pregnancy test, 
hematology; clinical chemistry; 
direct/indirect Coombs test, and 
serum sample for vaccine -induced 
protective antibodies.To ensure that samples are collected 
before TAK -079 administration
Added footnote r to table row labeled 
Myasthenia Gravis Impairment 
Index (MGII) score to indicate that 
the Physician examination portion of 
the MGII score may be omitted if 
performing a remote visit.Added per COVID -19 guidelines to 
allow flexibility for remote visits.
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3946] Version of the Approved Protocol
Sections Affected by [CONTACT_4231] s to table rows 
labeled Myasthenia Gravis 
Composite (MGC) and Quantitative 
Myasthenia Gravis (QMG) scores to 
indicate that the MGC and QMG 
may be omitted if performing a 
remote visit.Added per COVID -19 guidelines to 
allow flexibility for remote visits.
Appendix IQMG Score Updated the version of the QMG 
form from v2.0 to v2.1.Minor version update to t he QMG 
form, which includes a vertical 
border in the column header 
separating “Raw” and “Scale” 
scores. 
Rationale for Amendment [ADDRESS_3947] ive 
vaccines. 
3.Updated Exclusio n Criterion 12 to cl arify  the intent not to exclude a minor, benign, resolved, 
localized herpes simplex infection not requiring systemic therapy . 
4.Updated Exclusio n Cri terion 13f to change “lower limit of normal” to “5 g/L.” As a result of 
this edit, subjects are excluded if the IgG is less than 5 g/L (500 mg/dL) at screening.
5.Updated Exclusio n Criterion [ADDRESS_3948] been fully cured of the disease. Addit ionally , more stringent cri teria 
are used to exclude subjects with hepat itis B infectio n. 
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
TAK -[ADDRESS_3949] Informat ion.
8.Descriptors for circulat ing bio marker samples and quant itative IgA/IgM/IgG samples have 
been changed fro m blood to serum in the schedule of events.
9.Updated the versio n number of the QMG scoring assessment tool (to Version 2.0; previously 
Versi on 1.0) which fixes a ty pographical error in the definit ion of severe forced vital capacit y 
(FVC) (in Version 2 FVC is <50; in Versio n 1 FVC was ≤50).
10.Serum  samples for hepat itis B, hepat itis C, and HIV have been added to the Section 9.[ADDRESS_3950] acebo 
formulation were changed to be the same as for the active drug (both no w refrigerated at 5°C, 
whereas previously the placebo was to be stored frozen at -20°C). This avo ids the need for an 
unblinded site pharmacist. Therefore, all site personnel, including the site pharmacist, are to be 
blinded as to treatment assignments.
Addit
ionally , a protocol  subsect ion is added to provide informat ion regarding potential 
interference wi th serol ogical testing.
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarifi cation and administrative purposes only. 
Changes in Amendment [ADDRESS_3951] ion 8.5.3 to provide clarificat ion regarding potential 
interference wi th serol ogical testing
Property of [COMPANY_005]: For non-commercial use only and subject to the applicable Terms of Use
  ELECTRONIC SIGNATURES
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GIIG䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢶䢢䣶䣱䢢䣃䢢䣒䣪䣣䣵䣧䢢䢴䢮䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣒䣮䣣䣥䣧䣤䣱䢯䣅䣱䣰䣶䣴䣱䣮䣮䣧䣦䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣕䣣䣨䣧䣶䣻䢮䢢䣖䣱䣮䣧䣴䣣䣤䣫䣮䣫䣶䣻䢮䢢䣣䣰䣦
䣇䣨䣨䣫䣥䣣䣥䣻䢢䣱䣨䢢䣖䣃䣍䢯䢲䢹䢻䢢䣫䣰䢢䣒䣣䣶䣫䣧䣰䣶䣵䢢䣹䣫䣶䣪䢢䣉䣧䣰䣧䣴䣣䣮䣫䣼䣧䣦䢢䣏䣻䣣䣵䣶䣧䣰䣫䣣䢢䣉䣴䣣䣸䣫䣵䢰
&OLQLFDO$SSURYDO )HE87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO )HE87&
%LRVWDWLVWLFV$SSURYDO )HE87&[INVESTIGATOR_4108]
PI
3URSHUW\RI7DNHGD)RUQRQFRPPHUFLDOXVHRQO\DQGVXEMHFWWRWKHDSSOLFDEOH7HUPVRI8VH7HUPate ate 
H7 HHH:mm ‘UH:mmUP
H87&87&

)HEE